Jazz Pharmaceuticals (JAZZ) 10-K 24 Feb 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Feb. 18, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Registrant Name	Jazz Pharmaceuticals plc
Entity Central Index Key	1232524
Trading Symbol	jazz
Entity Filer Category	Large Accelerated Filer
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		60,657,182
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	Yes
Entity Public Float			$8,420,403,204

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$684,042	$636,504
Accounts receivable, net of allowances of $3,483 and $3,680 at December 31, 2014 and 2013, respectively	186,371	124,805
Inventories	30,037	28,669
Prepaid expenses	12,800	7,183
Deferred tax assets, net	48,440	33,613
Other current assets	21,322	33,843
Assets held for sale	32,833	0
Total current assets	1,015,845	864,617
Property and equipment, net	58,363	14,246
Intangible assets, net	1,437,435	812,396
Goodwill	702,713	450,456
Deferred tax assets, net, non-current	75,494	74,597
Deferred financing costs	33,174	14,605
Other non-current assets	15,931	7,304
Total assets	3,338,955	2,238,221
Current liabilities:
Accounts payable	25,126	21,005
Accrued liabilities	164,091	119,718
Current portion of long-term debt	9,428	5,572
Income taxes payable	7,588	336
Contingent consideration	0	50,000
Deferred tax liability, net	9,430	6,259
Deferred revenue	1,138	1,138
Total current liabilities	216,801	204,028
Deferred revenue, non-current	4,499	5,718
Long-term debt, less current portion	1,333,000	544,404
Deferred tax liability, net, non-current	375,054	168,497
Other non-current liabilities	38,393	20,040
Commitments and contingencies (Note 11)
Shareholders’ equity:
Ordinary shares, nominal value $0.0001 per share; 300,000 shares authorized; 60,643 and 57,854 shares issued and outstanding at December 31, 2014 and 2013, respectively	6	6
Non-voting euro deferred shares, €0.01 par value per share; 4,000 shares authorized, issued and outstanding at both December 31, 2014 and 2013	55	55
Capital redemption reserve	471	471
Additional paid-in capital	1,458,005	1,220,317
Accumulated other comprehensive income (loss)	-122,097	56,153
Retained earnings	34,704	18,532
Total Jazz Pharmaceuticals plc shareholders’ equity	1,371,144	1,295,534
Noncontrolling interests	64	0
Total shareholders’ equity	1,371,208	1,295,534
Total liabilities and shareholders’ equity	$3,338,955	$2,238,221

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical)	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified	USD ($)	EUR (€)	USD ($)	EUR (€)
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$3,483		$3,680
Nonvoting Euro Deferred shares, par value (in euros per share)		€ 0.01		€ 0.01
Nonvoting Euro Deferred shares, number of shares authorized	4,000,000	4,000,000	4,000,000	4,000,000
Nonvoting Euro Deferred shares, number of shares issued	4,000,000	4,000,000	4,000,000	4,000,000
Nonvoting Euro Deferred shares, number of shares outstanding	4,000,000	4,000,000	4,000,000	4,000,000
Ordinary shares, nominal value (in dollars per share)	$0.00		$0.00
Ordinary shares, number of shares authorized	300,000,000	300,000,000	300,000,000	300,000,000
Ordinary shares, number of shares issued	60,643,000	60,643,000	57,854,000	57,854,000
Ordinary shares, number of shares outstanding	60,643,000	60,643,000	57,854,000	57,854,000

Consolidated_Statements_of_Inc

Consolidated Statements of Income (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues:
Product sales, net	$1,162,716	$865,398	$580,527
Royalties and contract revenues	10,159	7,025	5,452
Total revenues	1,172,875	872,423	585,979
Operating expenses:
Cost of product sales (excluding amortization of acquired developed technologies and intangible asset impairment)	117,418	102,146	78,425
Selling, general and administrative	406,114	304,303	223,882
Research and development	85,181	41,632	20,477
Acquired in-process research and development	202,626	4,988	0
Intangible asset amortization	126,584	79,042	65,351
Asset impairment charges	39,365
Impairment charges	39,365	0	0
Total operating expenses	977,288	532,111	388,135
Income from operations	195,587	340,312	197,844
Interest expense, net	-52,713	-26,916	-16,869
Foreign currency gain (loss)	8,683	-1,697	-3,620
Loss on extinguishment and modification of debt	0	-3,749	0
Income from continuing operations before income tax provision (benefit)	151,557	307,950	177,355
Income tax provision (benefit)	94,231	91,638	-83,794
Income from continuing operations	57,326	216,312	261,149
Income from discontinued operations, net of taxes	0	0	27,437
Net income	57,326	216,312	288,586
Net loss attributable to noncontrolling interests, net of tax	-1,061	0	0
Net income attributable to Jazz Pharmaceuticals plc	$58,387	$216,312	$288,586
Basic:
Income from continuing operations (in dollars per share)	$0.98	$3.71	$4.61
Income from discontinued operations (in dollars per share)	$0	$0	$0.48
Net income (in dollars per share)	$0.98	$3.71	$5.09
Diluted:
Income from continuing operations (in dollars per share)	$0.93	$3.51	$4.34
Income from discontinued operations (in dollars per share)	$0	$0	$0.45
Net income (in dollars per share)	$0.93	$3.51	$4.79
Weighted-average ordinary shares used in calculating net income per ordinary share attributable to Jazz Pharmaceuticals plc:
Basic (in shares)	59,746	58,298	56,643
Diluted (in shares)	62,614	61,569	60,195

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net income	$57,326	$216,312	$288,586
Other comprehensive income (loss):
Foreign currency translation adjustments	-178,264	25,107	31,046
Available-for-sale securities:
Net unrealized gain on available-for-sale securities, net of income taxes	0	0	8
Reclassification adjustments for gains included in earnings, net of income taxes	0	0	23
Other comprehensive income (loss)	-178,264	25,107	31,077
Total comprehensive income (loss)	-120,938	241,419	319,663
Comprehensive loss attributable to noncontrolling interests, net of tax	-1,075	0	0
Comprehensive income (loss) attributable to Jazz Pharmaceuticals plc	-119,863	241,419	319,663
Continuing Operations [Member]
Available-for-sale securities:
Comprehensive income (loss) attributable to Jazz Pharmaceuticals plc	-119,863	241,419	292,226
Discontinued Operations [Member]
Available-for-sale securities:
Comprehensive income (loss) attributable to Jazz Pharmaceuticals plc	$0	$0	$27,437

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Ordinary Shares [Member]	Non-voting Euro Deferred [Member]	Capital Redemption Reserve [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings (Accumulated Deficit) [Member]	Total Jazz Pharmaceuticals plc Shareholders' Equity [Member]	Noncontrolling Interest [Member]
In Thousands, except Share data, unless otherwise specified
Balance, beginning of period at Dec. 31, 2011	$192,788	$4	$0	$0	$542,697	($31)	($349,882)	$192,788	$0
Balance, shares, beginning of period at Dec. 31, 2011		42,468,000	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Merger with Azur Pharma	576,464	2	55	471	575,936			576,464
Merger with Azur Pharma, shares		12,360,000	4,000,000
Issuance costs related to Azur Merger	-241				-241			-241
Shares issued under directors deferred compensation plan	0				0			0
Shares issued under directors deferred compensation plan, shares		45,000
Issuance of ordinary shares in conjunction with exercise of share options	14,212				14,212			14,212
Issuance of ordinary shares in conjunction with exercise of share options, shares		1,951,000
Issuance of ordinary shares under employee stock purchase plan	3,707				3,707			3,707
Issuance of ordinary shares under employee stock purchase plan, shares		151,000
Shares withheld for payment of employee's withholding tax liability	-25,299				-25,299			-25,299
Issuance of ordinary shares in conjunction with exercise of warrants	7,084				7,084			7,084
Issuance of ordinary shares in conjunction with exercise of warrants, shares		1,039,000
Share-based compensation	23,129				23,129			23,129
Excess tax benefits from employee share options	9,785				9,785			9,785
Other comprehensive income (loss)	31,077					31,077		31,077
Net income	288,586						288,586	288,586
Balance, end of period at Dec. 31, 2012	1,121,292	6	55	471	1,151,010	31,046	-61,296	1,121,292	0
Balance, shares, end of period at Dec. 31, 2012		58,014,000	4,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of ordinary shares in conjunction with exercise of share options	20,895				20,895			20,895
Issuance of ordinary shares in conjunction with exercise of share options, shares		904,000
Issuance of ordinary shares under employee stock purchase plan	5,410				5,410			5,410
Issuance of ordinary shares under employee stock purchase plan, shares		147,000
Issuance of ordinary shares in conjunction with vesting of restricted stock units, shares		146,000
Shares withheld for payment of employee's withholding tax liability	-5,590				-5,590			-5,590
Issuance of ordinary shares in conjunction with exercise of warrants	4,398				4,398			4,398
Issuance of ordinary shares in conjunction with exercise of warrants, shares		471,000
Share-based compensation	44,367				44,367			44,367
Excess tax benefits from employee share options	-173				-173			-173
Shares repurchased	-136,484						-136,484	-136,484
Stock repurchased, shares		-1,828,000
Other comprehensive income (loss)	25,107					25,107		25,107
Net income	216,312						216,312	216,312
Balance, end of period at Dec. 31, 2013	1,295,534	6	55	471	1,220,317	56,153	18,532	1,295,534	0
Balance, shares, end of period at Dec. 31, 2013		57,854,000	4,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Noncontrolling interest on Gentium Acquisition	136,578								136,578
Acquisition of noncontrolling interest	-136,969				-1,530			-1,530	-135,439
Issuance of exchangeable senior notes	126,863				126,863			126,863
Shares issued under directors deferred compensation plan, shares		17,000
Issuance of ordinary shares in conjunction with exercise of share options	43,043				43,043			43,043
Issuance of ordinary shares in conjunction with exercise of share options, shares		1,185,000
Issuance of ordinary shares under employee stock purchase plan	7,197				7,197			7,197
Issuance of ordinary shares under employee stock purchase plan, shares		117,000
Issuance of ordinary shares in conjunction with vesting of restricted stock units, shares		222,000
Shares withheld for payment of employee's withholding tax liability	-18,030				-18,030			-18,030
Issuance of ordinary shares in conjunction with exercise of warrants	8,247				8,247			8,247
Issuance of ordinary shares in conjunction with exercise of warrants, shares		1,552,000
Share-based compensation	70,057				70,057			70,057
Excess tax benefits from employee share options	1,841				1,841			1,841
Shares repurchased	-42,215	0					-42,215	-42,215
Stock repurchased, shares		-304,000
Other comprehensive income (loss)	-178,264					-178,250		-178,250	-14
Net income	57,326						58,387	58,387	-1,061
Balance, end of period at Dec. 31, 2014	$1,371,208	$6	$55	$471	$1,458,005	($122,097)	$34,704	$1,371,144	$64
Balance, shares, end of period at Dec. 31, 2014		60,643,000	4,000,000

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating activities
Net income	$57,326	$216,312	$288,586
Adjustments to reconcile net income to net cash provided by operating activities:
Amortization of intangible assets	126,584	79,042	72,922
Share-based compensation	69,638	44,551	23,006
Impairment charges	39,365	0	0
Depreciation	7,097	3,048	1,307
Acquired in-process research and development	202,626	4,988	0
Loss on disposal of property and equipment	24	46	163
Excess tax benefit from share-based compensation	-1,841	173	-9,785
Acquisition accounting inventory fair value step-up adjustments	10,477	3,826	19,939
Change in fair value of contingent consideration	0	15,200	-300
Deferred income taxes	-43,423	-10,097	-113,862
Gain on sale of business	0	0	-35,244
Provision for losses on accounts receivable and inventory	2,493	2,446	4,654
Loss on extinguishment and modification of debt	0	3,749	0
Other non-cash transactions	1,739	6,278	3,523
Changes in assets and liabilities:
Accounts receivable	-55,041	-48,846	-4,724
Inventories	-7,630	-8,516	1,697
Prepaid expenses and other current assets	11,936	-13,871	-13,091
Other long-term assets	-8,891	-4,306	-3,491
Accounts payable	-37,966	5,089	-7,286
Accrued liabilities	20,997	14,717	-11,428
Income taxes payable	8,634	-38,984	39,340
Deferred revenue	-1,203	-1,061	-1,205
Contingent consideration	-14,900	0	0
Other non-current liabilities	17,724	14,820	2,351
Liability under government settlement	0	0	-7,320
Net cash provided by operating activities	405,765	288,604	249,752
Investing activities
Acquisitions, net of cash acquired	-828,676	0	-542,531
Acquisition of in-process research and development	-202,626	-4,988	0
Purchases of property and equipment	-36,347	-9,976	-5,976
Purchases of marketable securities	0	0	-37,443
Proceeds from Divestiture of Businesses	0	0	93,922
Proceeds from sale of marketable securities	0	0	81,246
Proceeds from maturities of marketable securities	0	0	31,988
Acquisition of intangible assets	0	-1,300	0
Purchase of product rights	0	0	-16,500
Net cash used in investing activities	-1,067,649	-16,264	-395,294
Financing activities
Net proceeds from issuance of debt	1,194,385	553,425	450,916
Proceeds from employee equity incentive and purchase plans and exercise of warrants	58,487	30,703	25,003
Share repurchases	-42,215	-136,484	0
Acquisition of noncontrolling interests	-136,969	0	0
Payment of contingent consideration	-35,100	0	0
Payment of employee withholding taxes related to share-based awards	-18,030	-5,590	-25,299
Excess tax benefit from share-based compensation	1,841	-173	9,785
Repayments of long-term debt	-9,524	-465,910	-11,875
Repayments under revolving credit facility	-300,000	0	0
Net cash provided by (used in) financing activities	712,875	-24,029	448,530
Effect of exchange rates on cash and cash equivalents	-3,453	997	2,132
Net increase in cash and cash equivalents	47,538	249,308	305,120
Cash and cash equivalents, at beginning of period	636,504	387,196	82,076
Cash and cash equivalents, at end of period	684,042	636,504	387,196
Supplemental disclosure of cash flow information:
Cash paid for interest	31,978	18,278	14,192
Cash paid for income taxes	108,189	137,616	9,143
Non-cash investing activities:
Acquisition consideration for Azur Merger	$0	$0	$576,464

Organization_and_Description_o

Organization and Description of Business	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	Organization and Description of Business
	Jazz Pharmaceuticals plc, a public limited company formed under the laws of Ireland, is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. We have a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. In these areas, we market Xyrem® (sodium oxybate) oral solution and Erwinaze® (asparaginase Erwinia chrysanthemi) in the United States, and market Erwinase® and Defitelio® (defibrotide) in Europe and other countries outside the United States. Our strategy is to create shareholder value by:
	•	Growing sales of the existing products in our portfolio, including by identifying new growth opportunities;
	•	Acquiring additional differentiated products that are on the market or product candidates that are in late-stage development; and
	•	Pursuing focused development of a pipeline of post-discovery differentiated product candidates.
	On January 18, 2012, the businesses of Jazz Pharmaceuticals, Inc. and Azur Pharma Public Limited Company, or Azur Pharma, were combined in a merger transaction, or the Azur Merger, accounted for as a reverse acquisition under the acquisition method of accounting for business combinations, with Jazz Pharmaceuticals, Inc. treated as the acquiring company for accounting purposes. As part of the Azur Merger, a wholly-owned subsidiary of Azur Pharma merged with and into Jazz Pharmaceuticals, Inc., with Jazz Pharmaceuticals, Inc. surviving the Azur Merger as a wholly-owned subsidiary of Jazz Pharmaceuticals plc. Prior to the Azur Merger, Azur Pharma changed its name to Jazz Pharmaceuticals plc.
	On June 12, 2012, we completed the acquisition of EUSA Pharma Inc., or EUSA Pharma, which we refer to as the EUSA Acquisition.
	On January 23, 2014, pursuant to a tender offer, we became the indirect majority shareholder of Gentium S.p.A., or Gentium, thereby acquiring control of Gentium on that date. In February 2014, we completed a subsequent offering period of the tender offer, resulting in total purchases pursuant to the tender offer of approximately 98% of the fully diluted voting securities of Gentium. As of December 31, 2014, we had acquired a further 1.8% interest in Gentium, resulting in an aggregate acquisition cost to us of $994.1 million, comprising cash payments of $1,011.2 million, offset by proceeds from the exercise of Gentium share options of $17.1 million. Please see Note 3 for additional information regarding our acquisition of Gentium, which we refer to as the Gentium Acquisition.
	Unless otherwise indicated or the context otherwise requires, references to “Jazz Pharmaceuticals,” “the registrant,” “we,” “us,” and “our” refer to Jazz Pharmaceuticals plc and its consolidated subsidiaries, including its predecessor, Jazz Pharmaceuticals, Inc., except that all such references prior to the effective time of the Azur Merger on January 18, 2012, are references to Jazz Pharmaceuticals, Inc. and its consolidated subsidiaries. All references to “ordinary shares” refer to Jazz Pharmaceuticals plc’s ordinary shares.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies
	Basis of Presentation
	The consolidated financial statements include the accounts of Jazz Pharmaceuticals plc and our subsidiaries and intercompany transactions and balances have been eliminated. We record noncontrolling interests in our consolidated financial statements which represent the ownership interest of minority shareholders in the equity of Gentium. The results of operations of the acquired Azur Pharma, EUSA Pharma and Gentium businesses, along with the estimated fair values of the assets acquired and liabilities assumed in each transaction, are included in our consolidated financial statements since the effective dates of the Azur Merger, the EUSA Acquisition and the Gentium Acquisition, respectively.
	Reclassifications
	Certain prior period amounts presented in these consolidated financial statements and the accompanying footnotes have been reclassified to conform to the current period presentation. Upfront license fees, previously classified as research and development expense in 2013, have been reclassified to acquired in-process research and development, or IPR&D, in the consolidated statements of income and reclassified from operating activities to investing activities in the consolidated statements of cash flows to conform to the current period presentation. Inventories of $1.4 million, previously classified as raw materials as of December 31, 2013, have been reclassified to work-in-process to conform to the current period presentation.
	Significant Risks and Uncertainties
	Our financial results are significantly influenced by sales of Xyrem. In 2014, net product sales of Xyrem were $778.6 million, which represented 67.0% of total net product sales. Our ability to maintain or increase sales of Xyrem in its approved indications is subject to a number of risks and uncertainties, including the potential introduction of generic competition, changed or increased regulatory restrictions and continued acceptance of Xyrem as safe and effective by physicians and patients. Five abbreviated new drug applications, or ANDAs, have been filed with the U.S. Food and Drug Administration, or FDA, by third parties seeking to market generic versions of Xyrem, including the most recent in the fourth quarter of 2014. We have initiated lawsuits against all five third parties, and the litigation proceedings are ongoing. We cannot predict the timing or outcome of these proceedings. Although no trial date has been set in any of the ANDA suits, we anticipate that trial on some of the patents in the case against the first ANDA filer, Roxane Laboratories, Inc., or Roxane, could occur as early as the third quarter of 2015. In addition, certain of the ANDA filers have sought to challenge the validity of our patents covering the distribution system for Xyrem by filing petitions for covered business method, or CBM, post-grant patent review and/or inter partes review, or IPR, by the Patent Trial and Appeal Board, or PTAB, of the U.S. Patent and Trademark Office, or USPTO. The PTAB has issued decisions denying institution of CBM review for all of the CBM petitions and has not yet determined whether to institute proceedings with respect to the petitions for IPR. We cannot predict whether PTAB will institute any of the petitioned IPR proceedings, whether additional post-grant patent review challenges will be filed, the outcome of any IPR or other proceeding if instituted, or the impact any IPR or other proceeding might have on ongoing ANDA litigation proceedings. We expect that the approval of an ANDA that results in the launch of a generic version of Xyrem, or the approval and launch of other sodium oxybate products that compete with Xyrem, would have a material adverse effect on our business, financial condition, results of operations and growth prospects.
	In addition, we are continuing our efforts on various regulatory matters, including updating documents that we have submitted to the FDA on our risk management and controlled distribution system for Xyrem, which we refer to as the Xyrem Risk Management Program. We are engaged in ongoing communications with respect to our risk evaluation and mitigation strategies, or REMS, documents for Xyrem, but have not reached agreement with the FDA on certain significant terms. In late 2013, the FDA notified us that it would exercise its claimed authority to modify our REMS and that it would finalize the REMS as modified by the FDA unless we initiated dispute resolution procedures with respect to the modification of the Xyrem deemed REMS.  Among other things, we disagree with the FDA’s position in the late 2013 notice that, as part of the current REMS process, the Xyrem deemed REMS should be modified to enable the distribution of Xyrem through more than one pharmacy, or potentially through retail pharmacies and wholesalers, as well as with certain modifications proposed by the FDA that would, in the FDA’s view, be sufficient to ensure that the REMS includes only those elements necessary to ensure that the benefits of Xyrem outweigh its risks, and that would, in the FDA’s view, reduce the burden on the healthcare system. Given these circumstances, we initiated dispute resolution procedures with the FDA at the end of February 2014. We received the FDA’s denial of our initial dispute resolution submission in the second quarter of 2014, and our dispute is currently subject to further supervisory review at the next administrative level of the FDA. We have received interim responses from the FDA, but the FDA has not yet communicated a decision on our further appeal to us. We expect to receive the FDA’s decision in the first quarter of 2015. We cannot predict whether, or on what terms, we will reach agreement with the FDA on final REMS documents for Xyrem, the outcome or timing of the current dispute resolution procedure, whether we will initiate additional dispute resolution proceedings with the FDA or other legal proceedings prior to finalizing the REMS documents, or the outcome or timing of any such proceedings. We expect that final REMS documents for Xyrem will include modifications to, and/or requirements that are not currently implemented in, the Xyrem Risk Management Program. Any such modifications or additional requirements could potentially make it more difficult or expensive for us to distribute Xyrem, make it easier for future generic competitors, and/or negatively affect sales of Xyrem.
	We also expect to face pressure to license or share our Xyrem Risk Management Program, which is the subject of multiple issued patents, or elements of it, with generic competitors. In January 2014, the FDA held an initial meeting with us and the then-current Xyrem ANDA applicants to facilitate the development of a single shared system REMS for Xyrem (sodium oxybate). The parties have had numerous interactions with respect to a single shared system REMS since the initial meeting, and we expect the interactions to continue. In addition, if we do not develop a single shared system REMS or license or share our REMS with a generic competitor within a time frame or on terms that the FDA considers acceptable, the FDA may assert that its waiver authority permits it to allow the generic competitor to market a generic drug with a REMS that does not include the same elements that are in our deemed REMS or, when Xyrem REMS documents are approved, with a separate REMS that includes different, but comparable, elements to assure safe use. Similarly, it is possible that, consistent with the position that the FDA articulated in its December 2012 response denying a Citizen Petition we filed in July 2012, the FDA could approve an ANDA with a risk management plan that is separate from our Xyrem deemed REMS, rather than with a final REMS or a shared REMS for both the generic and Xyrem. We cannot predict the outcome or impact on our business of any future action that we may take with respect to the development of a single shared system REMS for Xyrem (sodium oxybate), licensing or sharing our REMS, or the FDA’s response to a certification that a third party had been unable to obtain a license.
	Sales of our second largest product, Erwinaze, continue to grow. In 2014, net product sales of Erwinaze/Erwinase were $199.7 million, which represented 17.2% of net product sales in 2014. We seek to maintain and increase sales of Erwinaze, as well as to make Erwinaze more widely available, through ongoing research and development activities. However, our ability to successfully and sustainably maintain or grow sales of Erwinaze is subject to a number of risks and uncertainties, including the limited population of patients with acute lymphoblastic leukemia, or ALL, and the incidence of hypersensitivity reactions to E. coli-derived asparaginase within that population, our ability to obtain clinical data on the use of Erwinaze in young adults age 18 to 39 with ALL who are hypersensitive to E. coli-derived asparaginase, as well as our need to apply for and receive marketing authorizations, through the European Union’s, or EU’s, mutual recognition procedure or otherwise, in certain additional countries so we can launch promotional efforts in those countries. Another significant challenge to our ability to maintain current sales levels and to increase sales is our need to avoid supply interruptions of Erwinaze due to capacity constraints, production delays, quality challenges or other manufacturing difficulties. We have limited inventory of Erwinaze, which puts us at significant risk of not being able to meet product demand. The current manufacturing capacity for Erwinaze is nearly completely absorbed by demand for the product. As a consequence of constrained manufacturing capacity, we have had an extremely limited ability to build an excess level of product inventory that could be used to absorb disruptions to supply resulting from any quality or other issues. If we continue to be subject to capacity constraints or experience quality or other manufacturing challenges in the future, we may be unable to build a desired excess level of product inventory, and our ability to supply the market may be compromised. Although we are taking steps to improve the Erwinaze manufacturing process, if our ongoing efforts are not successful, we could experience additional Erwinaze supply interruptions in the future, which could have a material adverse effect on our sales of and revenues from Erwinaze and limit our potential future maintenance and growth of the market for this product. In addition, while we continue to work with the manufacturer of Erwinaze to evaluate potential steps to expand production capacity to increase the supply of Erwinaze over the longer term to address worldwide demand, our ability to maintain or increase sales of Erwinaze may be limited by our ability to obtain a sufficient supply of the product.
	In furtherance of our growth strategy, we have made a significant investment in Defitelio. We added the product to our portfolio as a result of the Gentium Acquisition and secured worldwide rights to the product by acquiring rights to defibrotide in the Americas in August 2014. Our ability to realize the anticipated benefits from this investment is subject to a number of risks and uncertainties, including our ability to successfully maintain or grow sales of Defitelio in Europe, or obtain marketing approval in other countries, including the United States, so that we can launch promotional efforts in those countries. During 2014, Defitelio was launched in a number of European countries. We expect to continue to launch Defitelio in additional European countries on a rolling basis in 2015. A key challenge to our success in maintaining or growing sales of Defitelio in Europe is our ability to obtain appropriate pricing and reimbursement approvals in those European countries where Defitelio is not yet launched. If we experience delays or unforeseen difficulties in obtaining favorable pricing and reimbursement approvals, planned launches in the affected countries would be delayed, or, if we are unable to ultimately obtain favorable pricing and reimbursement approvals in countries that represent significant markets, especially where a country’s reimbursed price influences other countries, our growth prospects in Europe could be negatively affected.
	We are also engaged in activities related to the potential approval of defibrotide in the United States. We initiated a rolling submission of a new drug application, or NDA, to the FDA for defibrotide for the treatment of severe hepatic veno-occlusive disease, or VOD, in December 2014 and expect to complete the submission in mid-2015. We do not expect to be required to complete any additional clinical trials prior to completion of the NDA submission. However, we may be unable to acquire and remediate key information to be included in the data package for the NDA in a timely manner or our analysis of such information may not support submission, which would delay or preclude the completion of our NDA submission, and we may be unable to otherwise obtain regulatory approval of defibrotide in the United States in a timely manner, if at all. We also face other challenges that could impact the anticipated value of Defitelio/defibrotide, including the limited size of the population of patients who undergo hematopoietic stem cell transplantation, or HSCT, therapy and develop severe VOD, the need to establish U.S. pricing and reimbursement support for the product in the event we are able to obtain U.S. marketing approval for defibrotide, the possibility that we may be required to conduct time-consuming and costly clinical trials as a condition of any U.S. marketing approval for the product, the lack of experience of U.S. physicians in diagnosing and treating VOD, and challenges to our ability to develop the product for indications in addition to the treatment of severe VOD. If sales of Defitelio/defibrotide do not reach the levels we expect, our anticipated revenue from the product would be negatively affected, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
	In addition to risks specifically related to Xyrem, Erwinaze and Defitelio/defibrotide, we are subject to other challenges and risks specific to our business, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including: the challenges of protecting and enhancing our intellectual property rights; delays or problems in the supply or manufacture of our products, particularly with respect to certain products as to which we maintain limited inventories, including products for which our supply demands are growing, and our dependence on single source suppliers to continue to meet our ongoing commercial demand or our requirements for clinical trial supplies; the need to obtain and maintain appropriate pricing and reimbursement for our products in an increasingly challenging environment due to, among other things, the attention being paid to healthcare cost containment and other austerity measures in the United States and worldwide, including the need to obtain and maintain reimbursement for Xyrem in the United States in an environment in which we are subject to increasingly restrictive conditions for reimbursement required by third party payors; and the challenges of compliance with the requirements of the FDA, the U.S. Drug Enforcement Administration, or DEA, and non-U.S. regulatory agencies, including with respect to product labeling, requirements for distribution, obtaining sufficient DEA quotas where needed, marketing and promotional activities, adverse event reporting and product recalls or withdrawals.
	Other risks and uncertainties related to our ability to execute on our strategy include: the challenges of achieving and maintaining commercial success of our products, such as obtaining sustained acceptance of our products by patients, physicians and payors; the risks associated with business combination or product or product candidate acquisition transactions, such as the challenges inherent in the integration of acquired businesses with our historic business, the increase in geographic dispersion among our centers of operation, taking on the operation of a manufacturing plant as a result of the Gentium Acquisition, and the risks that we may acquire unanticipated liabilities along with acquired businesses or otherwise fail to realize the anticipated benefits (commercial or otherwise) from such transactions; the difficulty and uncertainty of pharmaceutical product development, including the timing thereof, and the uncertainty of clinical success, such as the risk that results from preclinical studies and/or early clinical trials may not be predictive of results obtained in later and larger clinical trials planned or anticipated to be conducted for our product candidates; the inherent uncertainty associated with the regulatory approval process, especially as we continue to undertake increased activities and make growing investment in our product pipeline development projects; our ability to identify and acquire, in-license or develop additional products or product candidates to grow our business; and possible restrictions on our ability and flexibility to pursue certain future opportunities as a result of our substantial outstanding debt obligations, which increased significantly in 2014.
	Business Acquisitions
	Our consolidated financial statements include the results of operations of an acquired business from the date of acquisition. We account for acquired businesses using the acquisition method of accounting. The acquisition method of accounting for acquired businesses requires, among other things, that assets acquired, liabilities assumed and any noncontrolling interests in the acquired business be recognized at their estimated fair values as of the acquisition date, with limited exceptions, and that the fair value of acquired IPR&D be recorded on the balance sheet. Also, transaction costs are expensed as incurred. Any excess of the acquisition consideration over the assigned values of the net assets acquired is recorded as goodwill. Contingent consideration is included within the acquisition cost and is recognized at its fair value on the acquisition date. A liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved and changes in fair value are recognized in earnings.
	Concentrations of Risk
	Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents and marketable securities. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities and issuers of investments to the extent recorded on the balance sheet.
	We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the United States, and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on our financial position, liquidity or results of operations. As of December 31, 2014, five customers accounted for 86% of gross accounts receivable including Express Scripts Specialty Distribution Services, Inc. and its affiliate CuraScript, Inc., or Express Scripts, which accounted for 66% of gross accounts receivable and IDIS Limited, which accounted for 11% of gross accounts receivable. As of December 31, 2013, five customers accounted for 85% of gross accounts receivable including Express Scripts which accounted for 69% of gross accounts receivable and Accredo Health Group, Inc. which accounted for 9% of gross accounts receivable.
	We depend on single source suppliers and manufacturers for each of our products, product candidates and their active pharmaceutical ingredients.
	Cash Equivalents and Marketable Securities
	We consider all highly liquid investments, readily convertible to cash, that mature within three months or less from date of purchase to be cash equivalents.
	Marketable securities are investments in debt securities with maturities of less than one year from the balance sheet date, or securities with maturities of greater than one year that are specifically identified to fund current operations. Collectively, cash equivalents and marketable securities are considered available-for-sale and are recorded at fair value. Unrealized gains and losses, net of tax, are recorded in accumulated other comprehensive income (loss) in shareholders’ equity. We use the specific-identification method for calculating realized gains and losses on securities sold. Realized gains and losses and declines in value judged to be other than temporary on marketable securities are included in interest expense, net in the consolidated statements of income. Realized gains and losses on sales of marketable securities have not been significant.
	Inventories
	Inventories are valued at the lower of cost or market. Cost is determined using the first-in, first-out method for all inventories. Our policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected requirements. The estimate of excess quantities is subjective and primarily dependent on our estimates of future demand for a particular product. If our estimate of future demand changes, we consider the impact on the reserve for excess inventory and adjust the reserve as required. Increases in the reserve are recorded as charges in cost of product sales. For product candidates that have not been approved by the FDA, inventory used in clinical trials is expensed at the time of production and recorded as research and development expense. For products that have been approved by the FDA, inventory used in clinical trials is expensed at the time the inventory is packaged for the clinical trial. Prior to receiving FDA approval, costs related to purchases of the active pharmaceutical ingredient and the manufacturing of the product candidate are recorded as research and development expense. All direct manufacturing costs incurred after approval are capitalized into inventory. The fair value of inventories acquired included no step-up in the value of inventories and $0.2 million step-up in the value of inventories as of December 31, 2014 and 2013, respectively.
	Property and Equipment
	Property and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from three to 10 years. Leasehold improvements are amortized over the shorter of the noncancelable term of our operating leases or their economic useful lives. Maintenance and repairs are expensed as incurred.
	Goodwill
	Goodwill represents the excess of the acquisition consideration over the fair value of assets acquired and liabilities assumed. We have determined that we operate in a single segment and have a single reporting unit associated with the development and commercialization of pharmaceutical products. The annual test for goodwill impairment is a two-step process. The first step is a comparison of the fair value of the reporting unit with its carrying amount, including goodwill. If this step indicates impairment, then, in the second step, the loss is measured as the excess of recorded goodwill over its implied fair value. Implied fair value is the excess of the fair value of the reporting unit over the fair value of all identified assets and liabilities. We test goodwill for impairment annually in October and when events or changes in circumstances indicate that the carrying value may not be recoverable.
	Acquired In-Process Research and Development
	The initial costs of rights to IPR&D projects acquired in an asset acquisition are expensed as IPR&D unless the project has an alternative future use. The fair value of IPR&D projects acquired in a business combination are capitalized and accounted for as indefinite-lived intangible assets until the underlying project receives regulatory approval, at which point the intangible asset will be accounted for as a finite-lived intangible asset, or discontinued, at which point the intangible asset will be written off. Development costs incurred after an acquisition are expensed as incurred.
	Intangible Assets
	Intangible assets with finite useful lives consist primarily of purchased developed technology and are amortized on a straight-line basis over their estimated useful lives, which range from two to 16 years. The estimated useful lives associated with finite-lived intangible assets are consistent with the estimated lives of the associated products and may be modified when circumstances warrant. Such assets are reviewed for impairment when events or circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset and its eventual disposition are less than its carrying amount. The amount of any impairment is measured as the difference between the carrying amount and the fair value of the impaired asset.
	Revenue Recognition
	Revenues are recognized when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed and determinable and collection is reasonably assured.
	Product Sales, Net
	Product sales revenue is recognized when title has transferred to the customer and the customer has assumed the risks and rewards of ownership, which is typically on delivery to the customer or, in the case of products that are subject to consignment agreements, when the customer removes product from our consigned inventory location for shipment directly to a patient.
	Revenue from sales transactions where the buyer has the right to return the product is recognized at the time of sale only if (i) the seller’s price to the buyer is substantially fixed or determinable at the date of sale, (ii) the buyer has paid the seller, or the buyer is obligated to pay the seller and the obligation is not contingent on resale of the product, (iii) the buyer’s obligation to the seller would not be changed in the event of theft or physical destruction or damage of the product, (iv) the buyer acquiring the product for resale has economic substance apart from that provided by the seller, (v) the seller does not have significant obligations for future performance to directly bring about resale of the product by the buyer, and (vi) the amount of future returns can be reasonably estimated.
	Revenues from sales of products are recorded net of estimated allowances for returns, specialty distributor fees, wholesaler fees, prompt payment discounts, government rebates, government chargebacks, coupon programs and rebates under managed care plans. Provisions for returns, specialty distributor fees, wholesaler fees, government rebates, coupon programs and rebates under managed care plans are included within current liabilities in our consolidated balance sheets. Provisions for government chargebacks and prompt payment discounts are generally shown as a reduction in accounts receivable. Calculating certain of these items involves estimates and judgments based on sales or invoice data, contractual terms, historical utilization rates, new information regarding changes in these programs’ regulations and guidelines that would impact the amount of the actual rebates, our expectations regarding future utilization rates for these programs and channel inventory data. Adjustments to estimates for these allowances have not been material.
	Royalties and Contract Revenues
	We receive royalties from third parties based on sales of our products under licensing and distribution arrangements. For those arrangements where royalties are reasonably estimable, we recognize revenues based on estimates of royalties earned during the applicable period, and adjust for differences between the estimated and actual royalties in the following quarter. Historically, these adjustments have not been significant.
	Our contract revenues consist of fees and milestone payments. Non-refundable fees where we have no continuing performance obligations are recognized as revenues when there is persuasive evidence of an arrangement and collection is reasonably assured. In situations where we have continuing performance obligations, non-refundable fees are deferred and are recognized ratably over our projected performance period. We recognize at-risk milestone payments, which are typically related to regulatory, commercial or other achievements by us or our licensees and distributors, as revenues when the milestone is accomplished and collection is reasonably assured. Sales-based milestone payments are typically payments made to us that are triggered when aggregate net sales of a product by a collaborator for a specified period (for example, an annual period) reach an agreed upon threshold amount. We recognize sales-based milestone payments from a collaborator when the event which triggers the obligation of payment has occurred, there is no further obligation on our part in connection with the payment, and collection is reasonably assured. Refundable fees are deferred and recognized as revenues upon the later of when they become nonrefundable or when our performance obligations are completed.
	Cost of Product Sales
	Cost of product sales includes third party manufacturing and distribution costs, the cost of drug substance, royalties due to third parties on product sales, product liability and cargo insurance, FDA user fees, freight, shipping, handling and storage costs and salaries and related costs of employees involved with production. Cost of product sales in 2014 and 2013 included $10.5 million and $3.8 million, respectively, of inventory costs associated with the fair value step-up in acquired inventory. Excluded from cost of product sales, as shown on the consolidated statements of income, is amortization of acquired developed technology of $122.6 million, $78.8 million and $65.1 million in 2014, 2013 and 2012, respectively.
	Research and Development
	Research and development expenses consist primarily of personnel expenses, costs related to clinical studies and outside services, and other research and development costs. Personnel expenses relate primarily to salaries, benefits and share-based compensation. Clinical study and outside services costs relate primarily to services performed by clinical research organizations, clinical studies performed at clinical sites, materials and supplies, and other third-party fees. Other research and development expenses primarily include overhead allocations consisting of various support and facilities-related costs. Research and development costs are expensed as incurred. For product candidates that have not been approved by the FDA, inventory used in clinical trials is expensed at the time of production and recorded as research and development expense. For products that have been approved by the FDA, inventory used in clinical trials is expensed at the time the inventory is packaged for the trial.
	Advertising Expenses
	We expense the costs of advertising, including promotional expenses, as incurred. Advertising expenses for 2014, 2013 and 2012 were $1.0 million, $1.0 million and $0.7 million, respectively.
	Income Taxes
	We use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amount and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more-likely-than-not that some portion or all of a deferred tax asset will not be realized. We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. A recognized tax position is then measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon settlement. Interest and penalties related to uncertain tax positions are included in the income tax provision (benefit) and classified with the related liability on the consolidated balance sheets.
	Foreign Currency
	Our functional and reporting currency is the U.S. dollar. The assets and liabilities of our subsidiaries that have a functional currency other than the U.S. dollar are translated into U.S. dollars at the exchange rate prevailing at the balance sheet date with the results of operations of subsidiaries translated at the average exchange rate for the reporting period. The cumulative foreign currency translation adjustment is recorded as a component of accumulated other comprehensive income (loss) in shareholders’ equity.
	Transactions in foreign currencies are translated into the functional currency of the relevant subsidiary at the rate of exchange prevailing at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the relevant functional currency at exchange rates prevailing at the balance sheet date or on settlement. Resulting gains and losses are recorded in foreign currency gain (loss) in our consolidated statements of income.
	Financing Costs
	Deferred financing costs are reported at cost, less accumulated amortization and the related amortization expense is included in interest expense, net in our consolidated statements of income. The carrying amount of debt includes any related unamortized original issue discount.
	Contingencies
	From time to time, we may become involved in claims and other legal matters arising in the ordinary course of business. We record accruals for loss contingencies to the extent that we conclude that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. Legal fees and other expenses related to litigation are expensed as incurred and included in selling, general and administrative expenses.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.
	Net Income per Ordinary Share
	Basic net income per ordinary share attributable to Jazz Pharmaceuticals plc is based on the weighted-average number of ordinary shares outstanding. Diluted net income per ordinary share attributable to Jazz Pharmaceuticals plc is based on the weighted-average number of ordinary shares outstanding and potentially dilutive ordinary shares outstanding.
	Basic and diluted net income per ordinary share attributable to Jazz Pharmaceuticals plc were computed as follows (in thousands, except per share amounts):
		Year Ended December 31,
		2014				2013			2012
Numerator:
Income from continuing operations	$	57,326			$	216,312		$	261,149
Loss from continuing operations attributable to noncontrolling interests, net of tax	(1,061		)		—			—
Income from continuing operations attributable to Jazz Pharmaceuticals plc	58,387				216,312			261,149
Income from discontinued operations	—				—			27,437
Net income attributable to Jazz Pharmaceuticals plc	$	58,387			$	216,312		$	288,586
Denominator:
Weighted-average ordinary shares used in calculating net income per ordinary share attributable to Jazz Pharmaceuticals plc - basic	59,746				58,298			56,643
Dilutive effect of employee equity incentive and purchase plans	2,402				1,772			1,536
Dilutive effect of warrants	466				1,499			2,016
Weighted-average ordinary shares used in calculating net income per ordinary share attributable to Jazz Pharmaceuticals plc - diluted	62,614				61,569			60,195
Net income per ordinary share attributable to Jazz Pharmaceuticals plc:
Basic:
Income from continuing operations	$	0.98			$	3.71		$	4.61
Income from discontinued operations	—				—			0.48
Net income attributable to Jazz Pharmaceuticals plc	$	0.98			$	3.71		$	5.09
Diluted:
Income from continuing operations	$	0.93			$	3.51		$	4.34
Income from discontinued operations	—				—			0.45
Net income attributable to Jazz Pharmaceuticals plc	$	0.93			$	3.51		$	4.79
Potentially dilutive ordinary shares from our employee equity incentive and purchase plans, warrants and exchangeable senior notes are determined by applying the treasury stock method to the assumed exercise of share options and warrants, the assumed vesting of outstanding restricted stock units, or RSUs, the assumed issuance of ordinary shares under our employee stock purchase plan, or ESPP, and the assumed issuance of ordinary shares upon exchange of our exchangeable senior notes. The approximately 2.9 million ordinary shares issuable upon exchange of our exchangeable senior notes had no effect on diluted net income per ordinary share attributable to Jazz Pharmaceuticals plc because the average price of our ordinary shares for the year ended December 31, 2014 did not exceed the effective exchange price of $199.77 per ordinary share. For additional information relating to our exchangeable senior notes, see Note 9.
The following table represents the weighted-average ordinary shares that were excluded from the computation of diluted net income per ordinary share attributable to Jazz Pharmaceuticals plc for the periods presented because including them would have an anti-dilutive effect (in thousands):
	Year Ended December 31,
	2014			2013			2012
Options to purchase ordinary shares and RSUs	819			1,584			1,506
1.875% exchangeable senior notes due 2021	1,112			—			—
Share-Based Compensation
We account for compensation cost for all share-based awards at fair value on the date of grant. The fair value is recognized as expense over the service period, net of estimated forfeitures, using the straight-line method. The estimation of share-based awards that will ultimately vest requires judgment, and, to the extent actual results or updated estimates differ from current estimates, such amounts will be recorded as a cumulative adjustment in the period estimates are revised. We primarily consider historical experience when estimating expected forfeitures.
Recent Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, No. 2014-09, “Revenue from Contracts with Customers”, or ASU No. 2014-09, which states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this, an entity will need to identify the contract with a customer; identify the separate performance obligations in the contract; determine the transaction price; allocate the transaction price to the separate performance obligations in the contract; and recognize revenue when (or as) the entity satisfies each performance obligation. ASU No. 2014-09 will be effective for us beginning January 1, 2017 and can be adopted on a full retrospective basis or on a modified retrospective basis. We are currently assessing our approach to the adoption of this standard and the impact on our results of operations and financial position.
In April 2014, the FASB issued ASU No. 2014-08, “Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity”, or ASU 2014-08. Under ASU 2014-08, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Additionally, ASU 2014-08 requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. ASU 2014-08 is effective for fiscal and interim periods beginning on or after December 15, 2014, with early adoption permitted. We early adopted ASU 2014-08 in 2014. Please see Note 18 for additional information.

Business_Combination_and_Asset

Business Combination and Asset Acquisitions	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Business Combination and Asset Acquisitions	Business Combination and Asset Acquisitions
	Gentium Acquisition
	On December 19, 2013, we entered into a definitive agreement with Gentium, or the Gentium tender offer agreement, pursuant to which we made a cash tender offer of $57.00 per share for all outstanding Gentium ordinary shares and American Depositary Shares, or ADSs. As of the expiration of the initial offering period on January 22, 2014, 12,244,156 Gentium ordinary shares and ADSs were properly tendered and not withdrawn in the tender offer. These ordinary shares and ADSs represented approximately 79% of Gentium’s issued and outstanding ordinary shares and ADSs and 69% of the fully diluted number of ordinary shares and ADSs (in each case without duplication for ordinary shares underlying ADSs). All properly tendered ordinary shares and ADSs as of such date were accepted for payment, which was made in accordance with the terms of the tender offer.
	Upon payment for the properly tendered ordinary shares and ADSs on January 23, 2014, we became the indirect majority shareholder of Gentium and acquired control of Gentium. Following the expiration of the initial offering period, and in accordance with the terms of the Gentium tender offer agreement, we commenced a subsequent offering period to acquire all remaining untendered ordinary shares and ADSs. The subsequent offering period expired on February 20, 2014. In total, pursuant to the tender offer agreement, we purchased approximately 98% of Gentium’s fully diluted ordinary shares and ADSs. Later in 2014, we acquired additional Gentium ordinary shares, representing a further 1.8% interest in Gentium, for aggregate cash consideration of $17.8 million. As of December 31, 2014, the aggregate acquisition cost of the Gentium ordinary shares and ADSs was $994.1 million, comprising cash payments of $1,011.2 million, offset by proceeds from the exercise of Gentium share options of $17.1 million. $857.1 million of the acquisition consideration is attributable to the 12,244,156 Gentium ordinary shares and ADSs purchased on the closing date of the Gentium Acquisition, 1,345,023 ADSs committed to tender in accordance with the guaranteed delivery procedures contemplated by the tender offer and options to acquire 1,666,608 ordinary shares of Gentium subject to support agreements requiring that such options be exercised and the underlying ordinary shares be tendered in a subsequent offering period. These ADSs and ordinary shares represented in the aggregate approximately 86% of the fully diluted number of ordinary shares and ADSs of Gentium.  The remaining $137.0 million of the acquisition cost is attributable to the acquisition of an additional 12% of the fully diluted Gentium ordinary shares and ADSs during the subsequent offering period of the tender offer and the acquisition of an additional 1.8% interest in Gentium later in 2014, which are accounted for as an acquisition of noncontrolling interests.
	We believe the Gentium Acquisition provided us with an opportunity to diversify our development and commercial portfolio and complement our clinical experience in hematology/oncology and our expertise in reaching targeted physicians who treat serious medical conditions.
	The Gentium Acquisition was accounted for using the acquisition method of accounting under which assets and liabilities of Gentium were recorded at their respective estimated fair values as of the closing date of the Gentium Acquisition and added to the assets and liabilities of Jazz Pharmaceuticals plc, including an amount for goodwill representing the difference between the acquisition consideration and the estimated fair value of the identifiable net assets. The results of operations of Gentium and the estimated fair values of the assets acquired and liabilities assumed have been included in our consolidated financial statements since the closing of the Gentium Acquisition on January 23, 2014.
	In 2014, we incurred $11.9 million in acquisition-related costs related to the Gentium Acquisition, which primarily consisted of banking, legal, accounting and valuation-related expenses. In addition, we incurred $5.4 million related to change in control obligations associated with the Gentium Acquisition. These expenses were recorded in selling, general and administrative expense in the accompanying consolidated statements of income. In 2014, our consolidated statements of income included revenues of $78.2 million from the acquired Gentium business, as measured from the closing date of the Gentium Acquisition. The portion of total expenses and net income associated with the acquired Gentium business was not separately identifiable due to the integration of Gentium operations with our historic operations.
	The acquisition consideration (not including the acquisition cost of $119.2 million to acquire the 12% noncontrolling interests in the subsequent offering period of the tender offer and the acquisition cost of $17.8 million to acquire the 1.8% noncontrolling interests later in 2014) was comprised of (in thousands):
	Cash consideration for shares acquired in initial tender offer period	$	697,917
	Liability for shares committed under guaranteed delivery procedures	76,666
	Liability for options committed for exercise	82,503
	Total acquisition consideration	$	857,086
	The fair values of assets acquired and liabilities assumed at the closing date of the Gentium Acquisition, and the fair value of the noncontrolling interests in Gentium at the dates they were acquired, are summarized below (in thousands):
	Cash and cash equivalents	$	28,410
	Short-term deposit	5,418
	Accounts receivable (1)	13,855
	Inventories	13,525
	Prepaid and other current assets	1,383
	Intangible assets	960,350
	Goodwill	308,642
	Deferred tax assets	22,999
	Property, plant and equipment	10,201
	Other long-term assets	431
	Accounts payable	(11,778		)
	Accrued expenses	(51,477		)
	Income taxes payable	(502		)
	Other long-term liabilities	(654		)
	Debt (current and long-term)	(2,351		)
	Deferred tax liabilities	(304,788		)
	Noncontrolling interests	(136,578		)
	Total acquisition consideration	$	857,086
	___________________
	-1	The estimated fair value of trade receivables acquired was $13.9 million and the gross contractual amount was $14.9 million, of which we expect that $1.0 million will be uncollectible.
	The intangible assets as of the closing date of the Gentium Acquisition included (in thousands):
	Finite-lived intangible assets:
	Currently marketed product:
	Defibrotide VOD (Non Americas)	$	719,500
	Manufacturing contracts	14,500
	Tradename	350
	Total finite-lived intangible assets	734,350
	IPR&D:
	Defibrotide VOD Prophylaxis	168,000
	Defibrotide VOD (Americas)	58,000
	Total IPR&D	226,000
	Total intangible assets	$	960,350
	The fair value of the currently marketed product was determined using the income approach. The income approach explicitly recognizes that the fair value of an asset is premised upon the expected receipt of future economic benefits such as earnings and cash inflows based on current sales projections and estimated costs for each product line. Indications of value were developed by discounting these benefits to their present worth at a discount rate that reflects the current return requirements of the market. The fair value of the currently marketed product was capitalized as of the closing date of the Gentium Acquisition and subsequently will be amortized over the estimated remaining life of the product of approximately 16 years.
	Gentium produces active pharmaceutical ingredients, or APIs, including the defibrotide compound, urokinase, sodium heparin and sulglicotide. Other than defibrotide, these APIs are subsequently used to make the finished forms of various drugs and are distributed via supply contracts. The fair value of these supply contracts was determined using the income approach based on the expected cash flows from the projected net earnings of each API. The fair value of the API supply contracts was capitalized as of the closing date of the Gentium Acquisition and subsequently will be amortized over four years which approximates the remaining contractual term and reasonably expected renewal periods.
	The fair value of IPR&D was determined using the income approach, including the application of probability factors related to the likelihood of success of the respective products reaching final development and commercialization. This approach also took into consideration information and certain program-related documents and forecasts prepared by management. The fair value of IPR&D was capitalized as of the closing date of the Gentium Acquisition and is subsequently accounted for as an indefinite-lived intangible asset until completion or abandonment of the associated research and development efforts. Accordingly, during the development period after the closing of the Gentium Acquisition, these assets will not be amortized into earnings; instead, these assets will be subject to periodic impairment testing. Upon successful completion of the development process for an acquired IPR&D project, determination as to the useful life of the asset will be made. The asset would then be considered a finite-lived intangible asset and amortization of the asset into earnings would begin over the remaining estimated useful life of the asset.
	The excess of the total acquisition consideration over the fair value amounts assigned to the assets acquired and the liabilities assumed represents the goodwill amount resulting from the Gentium Acquisition. We believe that the factors that contributed to goodwill included the Gentium workforce, which will complement our clinical experience in hematology/oncology and our expertise in reaching targeted physicians who treat serious medical conditions, and the deferred tax consequences of intangible assets recorded for financial statement purposes. We do not expect any portion of this goodwill to be deductible for tax purposes.
	The noncontrolling interests at the closing date of the Gentium Acquisition comprised 2,007,452 of Gentium’s issued and outstanding ordinary shares and ADSs and options to acquire 484,097 ordinary shares of Gentium that were not subject to support agreements. The fair value of the noncontrolling interests was estimated using Gentium’s closing market price quoted on The NASDAQ Global Market on January 22, 2014.
	Pro Forma Financial Information (Unaudited)
	The following unaudited supplemental pro forma information presents our combined historical results of operations with adjustments to reflect one-time charges and amortization of fair value adjustments in the appropriate pro forma periods as if the Gentium Acquisition had been completed on January 1, 2013. These adjustments include:
	•	An increase in amortization expense related to the fair value of acquired identifiable intangible assets of $2.7 million in 2014 and $48.9 million in 2013.
	•	The exclusion of acquisition-related expenses of $43.0 million in 2014 and $4.8 million in 2013.
	•	An increase in interest expense of $1.3 million in 2014 and $22.5 million in 2013, incurred on additional borrowings made to fund the Gentium Acquisition as if the borrowings had occurred on January 1, 2013.
	•	The exclusion of other non-recurring expenses of $40.7 million in 2014 and the inclusion of $18.6 million in 2013 primarily related to Gentium transaction bonus costs, the fair value step-up to acquired inventory, costs of change in control obligations and share-based compensation incurred from the acceleration of stock option vesting upon the closing date of the Gentium Acquisition.
	The unaudited pro forma results do not assume any operating efficiencies as a result of the consolidation of operations and are as follows (in thousands, except per share data):
		Year Ended
		December 31,
		2014			2013
	Revenues	$	1,176,178		$	925,185
	Net income attributable to Jazz Pharmaceuticals plc	$	82,802		$	181,318
	Net income per ordinary share attributable to Jazz Pharmaceuticals plc - basic	$	1.39		$	3.11
	Net income per ordinary share attributable to Jazz Pharmaceuticals plc - diluted	$	1.32		$	2.94
Acquisition of Rights to Defibrotide in the Americas
As a result of the Gentium Acquisition, we acquired defibrotide, which is marketed under the name Defitelio in Europe. In 2013, the European Commission granted marketing authorization under exceptional circumstances for Defitelio for the treatment of severe VOD in adults and children undergoing HSCT therapy. In March 2014, we commenced the launch of Defitelio on a rolling basis in Europe. At the time of the Gentium Acquisition, Gentium had licensed to Sigma-Tau Pharmaceuticals, Inc., or Sigma-Tau, the rights to defibrotide for the treatment and prevention of VOD in North America, Central America and South America. In July 2014, we entered into a definitive agreement to acquire the rights to defibrotide in the Americas from Sigma-Tau. Pursuant to the agreement, upon the closing of the transaction in August 2014, we paid Sigma-Tau an upfront payment of $75.0 million. This transaction was accounted for as a purchase of IPR&D assets with no alternative future use. Accordingly, the $75.0 million upfront payment was charged to acquired IPR&D expense upon closing of the transaction. Sigma-Tau is also eligible to receive milestone payments of $25.0 million upon the acceptance for filing by the FDA of the first NDA for defibrotide for VOD and up to an additional $150.0 million based on the timing of potential FDA approval of defibrotide for VOD. We funded the upfront payment with cash on hand.
Acquisition of Rights to JZP-110 (formerly known as ADX-N05)
On January 13, 2014, we entered into a definitive agreement with Aerial BioPharma, LLC, or Aerial, under which we acquired certain assets related to JZP-110, a novel compound in clinical development for the treatment of excessive daytime sleepiness in patients with narcolepsy. Under the agreement, and in exchange for an upfront initial payment from us totaling $125.0 million, we acquired worldwide development, manufacturing and commercial rights to JZP-110, other than in certain jurisdictions in Asia where SK Biopharmaceuticals Co., Ltd, or SK, retains rights. Aerial and SK are eligible to receive milestone payments, in an aggregate amount of up $270.0 million, based on development, regulatory and sales milestones and tiered royalties from high single digits to mid-teens based on potential future sales. This acquisition was accounted for as a purchase of IPR&D assets with no alternative future use. Accordingly, the $125.0 million upfront payment was charged to acquired IPR&D expense in the year ended December 31, 2014. The assignment of the JZP-110 rights from Aerial to us triggered a milestone payment of $2.0 million to SK, which was also charged to acquired IPR&D expense in the year ended December 31, 2014.

Fair_Value_Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement
	Cash and cash equivalents consisted of the following (in thousands):
		31-Dec-14
		Amortized		Gross		Gross		Estimated		Cash and Cash Equivalents
		Cost		Unrealized		Unrealized		Fair Value
				Gains		Losses
	Cash	$	338,262	$	—	$	—	$	338,262	$	338,262
	Time deposits	345,780		—		—		345,780		345,780
	Totals	$	684,042	$	—	$	—	$	684,042	$	684,042
		31-Dec-13
		Amortized		Gross		Gross		Estimated		Cash and
		Cost		Unrealized		Unrealized		Fair Value		Cash
				Gains		Losses				Equivalents
	Cash	$	495,990	$	—	$	—	$	495,990	$	495,990
	Time deposits	140,514		—		—		140,514		140,514
	Totals	$	636,504	$	—	$	—	$	636,504	$	636,504
	Cash equivalents are considered available-for-sale securities. We use the specific-identification method for calculating realized gains and losses on securities sold and include them in interest expense, net in the consolidated statements of income.
	The following table summarizes, by major security type, our available-for-sale securities and liabilities that were measured at fair value on a recurring basis and were categorized using the fair value hierarchy (in thousands):
		31-Dec-14				31-Dec-13
		Significant		Total		Significant		Total
		Other		Estimated		Other		Estimated
		Observable		Fair Value		Observable		Fair Value
		Inputs				Inputs
		(Level 2)				(Level 2)
	Assets:
	Available-for-sale securities
	Time deposits	$	345,780	$	345,780	$	140,514	$	140,514
	Liabilities:
	Contingent consideration	$	—	$	—	$	50,000	$	50,000
	As of December 31, 2014, our available-for-sale securities included time deposits which were measured at fair value using Level 2 inputs and their carrying values were approximately equal to their fair values. Level 2 inputs, obtained from various third party data providers, represent quoted prices for similar assets in active markets, or these inputs were derived from observable market data, or if not directly observable, were derived from or corroborated by other observable market data. There were no transfers between the different levels of the fair value hierarchy in 2014 or in 2013.
	In connection with the EUSA Acquisition in 2012, we agreed to make a contingent payment of $50.0 million in cash if Erwinaze achieved net sales in the United States of $124.5 million or greater in 2013. This net sales milestone was achieved in the fourth quarter of 2013, and as a result we made the contingent payment in the first quarter of 2014.
	As of December 31, 2014, the estimated fair value of the $895.4 million principal amount of our term loans was $881.9 million and the carrying amount was $890.5 million. The fair value was determined using quotes from the administrative agent of our credit facility that are based on the bid/ask prices of our term loans (Level 2). As of December 31, 2014, the estimated fair value of our exchangeable senior notes was $653.8 million. The fair value of the exchangeable senior notes was estimated using quoted market prices obtained from brokers (Level 2). The fair value of other borrowings approximates book value based on the borrowing rates currently available for variable rate loans (Level 2).
	As of December 31, 2014, assets measured at fair value on a non-recurring basis subsequent to initial recognition included assets classified as held for sale on the consolidated balance sheet. These assets are associated with certain products we acquired as part of the EUSA Acquisition that we expect to sell in the first half of 2015. See Note 18 for additional information. The carrying amount of $32.8 million for assets held for sale is equal to estimated fair value,which is based on the sales price agreed less costs to sell, and represents a Level 3 input.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventories	Inventories
	Inventories consisted of the following (in thousands):
		December 31,
		2014		2013
	Raw materials	$	3,570	$	3,506
	Work in process	9,870		10,301
	Finished goods	16,597		14,862
	Total inventories	$	30,037	$	28,669
	Inventories included no step-up in fair value and $0.2 million in acquisition accounting inventory fair value step-ups as of December 31, 2014 and 2013, respectively.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment
	Property and equipment consisted of the following (in thousands):
		December 31,
		2014			2013
	Construction-in-progress	$	37,145		$	4,388
	Computer software	10,634			7,960
	Leasehold improvements	7,931			4,587
	Computer equipment	7,670			5,610
	Machinery and equipment	6,408			417
	Furniture and fixtures	2,220			1,897
	Land and buildings	1,547			—
	Subtotal	73,555			24,859
	Less accumulated depreciation and amortization	(15,192		)	(10,613		)
	Property and equipment, net	$	58,363		$	14,246

Accrued_Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued Liabilities
	Accrued liabilities consisted of the following (in thousands):
		December 31,
		2014		2013
	Rebates and other sales deductions	$	51,899	$	38,772
	Employee compensation and benefits	46,143		31,829
	Sales returns reserve	14,039		21,110
	Accrued interest	10,327		4,150
	Royalties	7,964		6,082
	Accrued construction-in-progress	4,931		450
	Professional fees	3,295		5,225
	Other	25,493		12,100
	Total accrued liabilities	$	164,091	$	119,718

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets
	The gross carrying amount of goodwill was as follows (in thousands):
	Balance at December 31, 2013	$	450,456
	Goodwill arising from the Gentium Acquisition	308,642
	Goodwill allocated to assets held for sale (1)	(1,686		)
	Foreign exchange	(54,699		)
	Balance at December 31, 2014	$	702,713
	_________________________
	-1	In December 2014, we entered into a definitive agreement to sell certain products and related assets. See Note 18 for information regarding assets held for sale.
	The gross carrying amounts and net book values of our intangible assets were as follows (in thousands):
		December 31, 2014									December 31, 2013
		Remaining		Gross		Accumulated			Net Book		Gross		Accumulated			Net Book
		Weighted-		Carrying		Amortization			Value		Carrying		Amortization			Value
		Average Useful		Amount							Amount
		Life
		(In years)
	Acquired developed technologies	12.9		$	1,450,606	$	(259,889	)	$	1,190,717	$	957,089	$	(179,225	)	$	777,864
	Manufacturing contracts	3.1		13,012		(3,060		)	9,952		—		—			—
	Trademarks	0.1		2,914		(2,896		)	18		2,600		(2,327		)	273
	Total finite-lived intangible assets			1,466,532		(265,845		)	1,200,687		959,689		(181,552		)	778,137
	Acquired IPR&D assets			236,748		—			236,748		34,259		—			34,259
	Total intangible assets			$	1,703,280	$	(265,845	)	$	1,437,435	$	993,948	$	(181,552	)	$	812,396
	The increase in the gross carrying amount of intangible assets as of December 31, 2014 compared to December 31, 2013 reflected the acquisition of the Gentium intangible assets as described in Note 3, offset by the negative impact of foreign currency exchange which was primarily due to the strengthening of the U.S. dollar against the Euro, the impairment charge discussed below and the reclassification of certain intangible assets to assets held for sale as described in Note 18.
	The assumptions and estimates used to determine future cash flows and remaining useful lives of our intangible and other long-lived assets are complex and subjective. They can be affected by various factors, including external factors, such as industry and economic trends, and internal factors such as changes in our business strategy and our forecasts for specific product lines.
	In the second quarter of 2014, we recorded an impairment charge of $32.8 million on acquired developed technologies related to certain products we acquired as part of the EUSA Acquisition in June 2012. We report sales of these products under “Other” products. The impairment charge resulted from the reorganization of our operations in Europe to focus on our hematology/oncology therapeutic area following the Gentium Acquisition.  In the fourth quarter of 2014, we entered into a definitive agreement to sell these products and the related business, and reclassified intangible assets associated with these products with a net book value of $27.5 million as assets held for sale. See Note 18 for information regarding assets held for sale.
	Based on finite-lived intangible assets recorded as of December 31, 2014, and assuming the underlying assets will not be further impaired and that we will not change the expected lives of the assets, future amortization expenses were estimated as follows (in thousands):
	Year Ending December 31,	Estimated Amortization Expense
	2015	$	102,508
	2016	99,167
	2017	99,167
	2018	95,313
	2019	95,071
	Thereafter	709,461
	Total	$	1,200,687
	In 2012, we sold the women’s health business, a component of the acquired Azur Pharma business. Intangible assets related to the women’s health business had a net book value of $41.4 million. Please see Note 20 for information regarding discontinued operations.

Debt

Debt	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt	Debt
	The following table summarizes the carrying amount of our indebtedness (in thousands):
		December 31,
		2014			2013
	1.875% exchangeable senior notes due 2021	$	575,000		$	—
	Unamortized discount on 1.875% exchangeable senior notes due 2021	(124,735		)	—
	1.875% exchangeable senior notes due 2021, net	450,265			—
	Term loans	890,479			549,976
	Other borrowings	1,684			—
	Total debt	1,342,428			549,976
	Less current portion	9,428			5,572
	Total long-term debt	$	1,333,000		$	544,404
	Exchangeable Senior Notes
	In August 2014, we completed a private placement of $575.0 million principal amount of 1.875% exchangeable senior notes due 2021, or the 2021 Notes, resulting in net proceeds to us, after debt issuance costs, of $558.9 million. Interest on the 2021 Notes is payable semi-annually in cash in arrears on February 15 and August 15 of each year, beginning on February 15, 2015, at a rate of 1.875% per year. In certain circumstances, we may be required to pay additional amounts as a result of any applicable tax withholding or deductions required in respect of payments on the 2021 Notes. The 2021 Notes mature on August 15, 2021, unless earlier exchanged, repurchased or redeemed.
	The holders of the 2021 Notes have the ability to require us to repurchase all or a portion of their 2021 Notes for cash in the event Jazz Pharmaceuticals plc undergoes certain fundamental changes. Prior to August 15, 2021, we may redeem the 2021 Notes, in whole but not in part, subject to compliance with certain conditions, if we have, or on the next interest payment date would, become obligated to pay to the holder of any 2021 Note additional amounts as a result of certain tax-related events. We also may redeem the 2021 Notes on or after August 20, 2018, in whole or in part, if the last reported sale price per ordinary share has been at least 130% of the exchange price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide the notice of redemption.
	The 2021 Notes are exchangeable at an initial exchange rate of 5.0057 ordinary shares per $1,000 principal amount of 2021 Notes, which is equivalent to an initial exchange price of approximately $199.77 per ordinary share. Upon exchange, the 2021 Notes may be settled in cash, ordinary shares or a combination of cash and ordinary shares, at our election. Our intent and policy is to settle the principal amount of the 2021 Notes in cash upon exchange. The exchange rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain make-whole fundamental changes occurring prior to the maturity date of the 2021 Notes or upon our issuance of a notice of redemption, we will in certain circumstances increase the exchange rate for holders of the 2021 Notes who elect to exchange their 2021 Notes in connection with that make-whole fundamental change or during the related redemption period. Prior to February 15, 2021, the 2021 Notes will be exchangeable only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date.
	The 2021 Notes were issued by Jazz Investments I Limited, or the Issuer, a 100%-owned finance subsidiary of Jazz Pharmaceuticals plc. The Issuer’s obligations under the 2021 Notes are fully and unconditionally guaranteed on a senior unsecured basis by Jazz Pharmaceuticals plc. No subsidiary of Jazz Pharmaceuticals plc guaranteed the 2021 Notes. Subject to certain local law restrictions on payment of dividends, among other things, and potential negative tax consequences, we are not aware of any significant restrictions on the ability of Jazz Pharmaceuticals plc to obtain funds from the Issuer or Jazz Pharmaceuticals plc’s other subsidiaries by dividend or loan, or any legal or economic restrictions on the ability of the Issuer or Jazz Pharmaceuticals plc’s other subsidiaries to transfer funds to Jazz Pharmaceuticals plc in the form of cash dividends, loans or advances. There is no assurance that in the future such restrictions will not be adopted.
	In accounting for the issuance of the 2021 Notes, we separated the 2021 Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the estimated fair value of a similar liability that does not have an associated exchange feature. The carrying amount of the equity component representing the exchange option was determined by deducting the fair value of the liability component from the face value of the 2021 Notes as a whole. The excess of the principal amount of the liability component over its carrying amount will be amortized to interest expense over the expected life of the 2021 Notes using the effective interest method with an effective interest rate of 6.4% per annum. We have determined the expected life of the 2021 Notes to be equal to the original seven-year term. The equity component is not remeasured as long as it continues to meet the conditions for equity classification. As of December 31, 2014, the “if-converted value” did not exceed the principal amount of the 2021 Notes.
	We allocated the total issuance costs incurred of $16.1 million to the liability and equity components based on their relative values. Issuance costs attributable to the liability component will be amortized to expense over the term of the 2021 Notes, and issuance costs attributable to the equity component were included with the equity component in our shareholders’ equity.
	For the year ended December 31, 2014, we recognized $9.9 million in interest expense related to the contractual coupon rate and amortization of the debt discount on the 2021 Notes.
	As of December 31, 2014, the carrying value of the equity component related to the 2021 Notes, net of equity issuance costs, was $126.9 million.
	Amendment of Credit Facility and Term Loan Refinancing
	In June 2012, Jazz Pharmaceuticals plc, as guarantor, and certain of its wholly owned subsidiaries, as borrowers, entered into a credit agreement that provided for $475.0 million principal amount of term loans and a $100.0 million revolving credit facility. On June 13, 2013, we amended the credit agreement to provide for $557.2 million principal amount of term loans and a $200.0 million revolving credit facility that replaced the $100.0 million revolving credit facility. We used a portion of the proceeds from the term loans to refinance in full the $457.2 million principal amount of term loans outstanding under the credit agreement prior to the amendment. As a result of the June 2013 amendment, interest rate margins on the term loans and the revolving loans were reduced by 150 basis points.
	On January 23, 2014, we entered into a second amendment to the credit agreement to provide for (i) a tranche of incremental term loans in the aggregate principal amount of $350.0 million, (ii) a tranche of term loans that refinanced the $554.4 million principal amount of term loans previously outstanding under the amended credit agreement, or the prior term loans, in their entirety, and (iii) a $425.0 million revolving credit facility that replaced the $200.0 million revolving credit facility. We used the proceeds from the incremental term loans and $300.0 million of loans under the revolving credit facility, together with cash on hand, to purchase the Gentium ordinary shares and ADSs properly tendered and accepted for payment on the January 22, 2014 expiration of the initial tender offer period relating to the Gentium Acquisition. The January 2014 amendment also reduced the interest rate margins on the terms loans by 25 basis points. In August 2014, we used a portion of the net proceeds from the issuance of the 2021 Notes to repay all outstanding borrowings under the revolving credit facility.
	The term loans under the credit agreement mature on June 12, 2018 and the revolving credit facility terminates, and any loans outstanding thereunder become due and payable, on June 12, 2017.
	The term loans under the credit agreement, as amended in January 2014, bear interest, at our option, at a rate equal to either the LIBOR, plus an applicable margin of 2.50% per annum (subject to a 0.75% LIBOR floor), or the prime lending rate, plus an applicable margin equal to 1.50% per annum (subject to a 1.75% prime rate floor). Borrowings under the current revolving credit facility bear interest, at our option, at a rate equal to either the LIBOR, plus an applicable margin of 2.50% per annum, or the prime lending rate, plus an applicable margin equal to 1.50% per annum, subject to reduction by 0.25% or 0.50% based upon our secured leverage ratio. The revolving credit facility has a commitment fee payable on the undrawn amount ranging from 0.25% to 0.50% per annum based upon our secured leverage ratio.
	The borrowers’ obligations under the credit agreement and any hedging or cash management obligations entered into with a lender or an affiliate of a lender are guaranteed on a senior secured basis by Jazz Pharmaceuticals plc and certain of its subsidiaries (including the Issuer) and are secured by substantially all of Jazz Pharmaceuticals plc’s, the borrowers’ and the subsidiary guarantors’ assets.
	We may make voluntary prepayments of principal at any time without payment of a premium. We are required to make mandatory prepayments of the term loans (without payment of a premium) with (1) net cash proceeds from certain non-ordinary course asset sales (subject to reinvestment rights and other exceptions), (2) net cash proceeds from issuances of debt (other than certain permitted debt), (3) 50% of our excess cash flow as defined in the current credit agreement (subject to decrease to 25% if our total leverage ratio is equal to or less than 2.25 to 1.00 and greater than 1.25 to 1.00 or 0% if our total leverage ratio is equal to or less than 1.25 to 1.00), and (4) casualty proceeds and condemnation awards (subject to reinvestment rights and other exceptions).
	Principal repayments of the term loans, which are due quarterly, began in March 2014 and are equal to 1.0% per annum of the original principal amount of $904.4 million, with any remaining balance payable on the final maturity date.
	The credit agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to Jazz Pharmaceuticals plc and its restricted subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness and dividends and other distributions. The credit agreement also contains a financial covenant that requires Jazz Pharmaceuticals plc and its restricted subsidiaries to maintain a maximum secured leverage ratio. We were, as of December 31, 2014, and are currently in compliance with this financial covenant.
	The refinancing of the term loans involved multiple lenders who were considered members of a loan syndicate. In determining whether the refinancing was to be accounted for as a debt extinguishment or modification, we considered whether the lenders remained the same or changed and whether the change in debt terms was substantial. The debt terms would be considered substantially different if the present value of the cash inflows and outflows of the new term loans, including all principal increases and lender fees on the refinancing date, was at least 10% different from the present value of the remaining cash inflows and outflows of the original term loans, or the 10% Test. We performed a separate 10% Test for each individual lender participating in the loan syndication. For existing lenders who participated in the new term loans as part of the new loan syndicate, the refinancing was accounted for as a modification as the change in debt terms was determined to not be substantial using the 10% Test.
	Deferred financing costs of $21.7 million and an original issue discount of $6.1 million were associated with modified and new debt and will be amortized to interest expense using the interest method over the life of the term loans. As of December 31, 2014, the interest rate on the term loans was 3.25% and the effective interest rate was 4.1%.
	As the borrowing capacity relating to each creditor under the revolving credit facility was greater than that under the original revolving credit facility, deferred financing costs totaling $5.4 million were associated with the new arrangement and are being amortized to interest expense on a straight-line basis over the life of the facility. As of December 31, 2014, there were no borrowings outstanding under the revolving credit facility.
	Scheduled maturities with respect to our long-term debt are as follows (in thousands):
	Year Ending December 31,	Scheduled Long-Term Debt Maturities
	2015	$	9,428
	2016	9,433
	2017	9,438
	2018	868,479
	2019	114
	Thereafter	575,150
	Total	$	1,472,042

Deferred_Revenue

Deferred Revenue	12 Months Ended
	Dec. 31, 2014
Other Liabilities [Abstract]
Deferred Revenue	Deferred Revenue
	We have an agreement with UCB Pharma Limited, or UCB, under which UCB has the right to market Xyrem for certain indications in various countries outside of the United States. We recognized contract revenues of $1.1 million during each of 2014, 2013, and 2012 relating to two upfront payments received from UCB in 2006 totaling $15.0 million. As of December 31, 2014, $5.6 million was recorded as deferred revenues related to this agreement, of which $1.1 million is a current liability. The deferred revenue balance is being recognized ratably through 2019.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies
	Indemnification
	In the normal course of business, we enter into agreements that contain a variety of representations and warranties and provide for general indemnification, including indemnification associated with product liability or infringement of intellectual property rights. Our exposure under these agreements is unknown because it involves future claims that may be made but have not yet been made against us. To date, we have not paid any claims or been required to defend any action related to these indemnification obligations.
	We have agreed to indemnify our officers, directors and certain other employees for losses and costs incurred in connection with certain events or occurrences, including advancing money to cover certain costs, subject to certain limitations. The maximum potential amount of future payments we could be required to make under the indemnification obligations is unlimited; however, we maintain insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we believe the fair value of these indemnification obligations is not significant. Accordingly, we have not recognized any liabilities relating to these obligations as of December 31, 2014 and December 31, 2013. No assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations.
	Lease and Other Commitments
	We have noncancelable operating leases for our office buildings and we are obligated to make payments under noncancelable operating leases for automobiles used by our sales force.
	Lease expense under our operating leases was as follows (in thousands):
		Year Ended December 31,
		2014		2013		2012
	Lease expense	$	10,678	$	9,114	$	5,303
	Future minimum lease payments under our noncancelable operating leases at December 31, 2014, were as follows (in thousands):
	Year ending December 31,	Lease
		Payments
	2015	$	10,165
	2016	7,852
	2017	4,915
	2018	1,443
	2019	671
	Thereafter	—
	Total	$	25,046
	In January 2015, we entered into an agreement to lease approximately 100,000 square feet of office space in Palo Alto, California. We expect to occupy this office space by the end of 2017. This lease has a term of 12 years from commencement and we have an option to extend the term of the lease twice for a period of five years each. As a result, we are obligated to make lease payments over the initial term of the lease totaling approximately $96 million in addition to estimated operating expenses totaling $25 million. We also have an option to terminate this lease 10 years from commencement, with no less than one year prior written notice and the payment of a termination fee. The costs associated with this lease are not included in the above table.
	As of December 31, 2014, we had $34.6 million of noncancelable purchase commitments due within one year, primarily related to agreements with third party manufacturers.
	Legal Proceedings
	We are involved in several legal proceedings, including the following matters:
	Xyrem ANDA Matters: On October 18, 2010, we received a notice of Paragraph IV Patent Certification, or Paragraph IV Certification, from Roxane that it had submitted an ANDA to the FDA requesting approval to market a generic version of Xyrem (sodium oxybate) oral solution. Roxane’s initial notice alleged that all five patents then listed for Xyrem in the FDA’s publication “Approved Drug Products with Therapeutic Equivalence Evaluations,” or Orange Book, on the date of the notice are invalid, unenforceable or not infringed by Roxane’s proposed generic product. On November 22, 2010, we filed a lawsuit against Roxane in response to Roxane’s initial notice in the U.S. District Court for the District of New Jersey, or the District Court, seeking a permanent injunction to prevent Roxane from introducing a generic version of Xyrem that would infringe our patents. In accordance with the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Act, as a result of our having filed a timely lawsuit against Roxane, FDA approval of Roxane’s ANDA was stayed for 30 months, or until April 18, 2013. That stay has expired. Additional patents covering Xyrem were issued between December 2010 and December 2012, and, after receiving Paragraph IV Certification notices from Roxane, we filed additional lawsuits against Roxane on February 4, 2011, May 2, 2011, October 26, 2012 and December 5, 2012 to include these additional patents in the litigation. All of the lawsuits filed against Roxane between 2010 and 2012 have been consolidated by the District Court into a single case, or the Roxane consolidated case, alleging that 10 of our patents covering Xyrem are or will be infringed by Roxane’s ANDA and seeking a permanent injunction to prevent Roxane from launching a generic version of Xyrem that would infringe these patents.
	In December 2013, the District Court permitted Roxane to amend its answer in the Roxane consolidated case to allege additional equitable defenses, and the parties were given additional time for discovery on those new defenses. In addition, in March 2014, the District Court granted our motion to bifurcate and stay the portion of the Roxane consolidated case regarding patents related to the distribution system for Xyrem. Although no trial date has been scheduled, based on the District Court’s current schedule, we anticipate that trial on the patents in the Roxane consolidated case that are not subject to the stay could occur as early as the third quarter of 2015. We do not have any estimate of a possible trial date for trial on the patents in the Roxane consolidated case that are currently subject to the stay. The actual timing of events in this litigation may be significantly earlier or later than we currently anticipate, and we cannot predict the specific timing or outcome of events in this litigation.
	On April 1, 2014 and January 15, 2015, we received additional notices of Paragraph IV Certification from Roxane regarding newly issued patents for Xyrem listed in the Orange Book. On February 20, 2015, we filed a new lawsuit against Roxane in the District Court, alleging that three of our patents covering Xyrem are infringed or will be infringed by Roxane’s ANDA and seeking a permanent injunction to prevent Roxane from introducing a generic version of Xyrem that would infringe these patents. We cannot predict the timing or outcome of events in this matter or its impact on the Roxane consolidated case.
	On December 10, 2012, December 12, 2012 and August 8, 2013, we received notices of Paragraph IV Certification from Amneal Pharmaceuticals, LLC, or Amneal, that it had submitted an ANDA to the FDA requesting approval to market a generic version of Xyrem. On January 18, 2013 and September 12, 2013, we filed lawsuits against Amneal in the District Court, alleging that nine of our patents covering Xyrem are infringed or will be infringed by Amneal’s ANDA and seeking a permanent injunction to prevent Amneal from introducing a generic version of Xyrem that would infringe these patents. These lawsuits against Amneal were consolidated by the District Court on November 6, 2013.
	On November 21, 2013 and November 24, 2013, we received notices of Paragraph IV Certification from Par Pharmaceutical, Inc., or Par, that it had submitted an ANDA to the FDA requesting approval to market a generic version of Xyrem. On December 27, 2013, we filed a lawsuit against Par in the District Court, alleging that 13 of our patents covering Xyrem are infringed or will be infringed by Par’s ANDA and seeking a permanent injunction to prevent Par from introducing a generic version of Xyrem that would infringe these patents.
	In April 2014, Amneal asked the District Court to consolidate its case with the Par case, stating that both cases would proceed on the schedule for the Par case. The District Court granted this request in May 2014. The order consolidating the cases provides that Amneal’s 30-month stay period will be extended to coincide with the date of Par’s 30-month stay period. As a result, FDA’s approval of both Amneal’s and Par’s ANDAs is stayed until the earlier of (i) May 20, 2016, or (ii) a District Court decision finding that the identified patents are invalid, unenforceable or not infringed. We cannot predict the timing or outcome of events in the Amneal/Par consolidated case or their impact on other ongoing proceedings with Amneal or Par.
	On April 7, 2014 and January 19, 2015, we received additional notices of Paragraph IV Certification from Amneal regarding newly issued patents for Xyrem listed in the Orange Book. On May 20, 2014 and February 6, 2015, we filed additional lawsuits against Amneal in the District Court, alleging that four of our patents covering Xyrem are infringed or will be infringed by Amneal’s ANDA and seeking a permanent injunction to prevent Amneal from introducing a generic version of Xyrem that would infringe these patents. These additional lawsuits have not been consolidated with the Amneal/Par consolidated case. We cannot predict the timing or outcome of events in these matters or their impact on other ongoing proceedings with Amneal.
	On July 3, 2014, August 6, 2014 and November 25, 2014, we received additional notices of Paragraph IV Certification from Par regarding newly issued patents for Xyrem listed in the Orange Book. We filed additional lawsuits against Par in the District Court on August 15, 2014, October 2, 2014 and January 8, 2015, alleging that three of our patents covering Xyrem are infringed or will be infringed by Par’s ANDA and seeking a permanent injunction to prevent Par from introducing a generic version of Xyrem that would infringe these patents. These additional lawsuits have not been consolidated with the Amneal/Par consolidated case. We cannot predict the timing or outcome of events in these matters or their impact on other ongoing proceedings with Par.
	On June 4, 2014, we received a notice of Paragraph IV Certification from Ranbaxy Laboratories Limited, or Ranbaxy, that it had submitted an ANDA to the FDA requesting approval to market a generic version of Xyrem. On June 6, 2014, we received a notice of an amended Paragraph IV Certification from Ranbaxy. On July 15, 2014, we filed a lawsuit against Ranbaxy in the District Court, alleging that 14 of our patents covering Xyrem are infringed or will be infringed by Ranbaxy’s ANDA and seeking a permanent injunction to prevent Ranbaxy from introducing a generic version of Xyrem that will infringe these patents. On August 20, 2014 and December 1, 2014, we received additional notices of Paragraph IV Certification from Ranbaxy regarding newly issued patents for Xyrem listed in the Orange Book. On October 2, 2014 and January 9, 2015, we filed additional lawsuits against Ranbaxy in the District Court, alleging that two of our patents covering Xyrem are infringed or will be infringed by Ranbaxy’s ANDA and seeking a permanent injunction to prevent Ranbaxy from introducing a generic version of Xyrem that would infringe these patents. We cannot predict the timing or outcome of events in these matters or their impact on other ongoing proceedings with Ranbaxy.
	On October 30, 2014, we received a notice of Paragraph IV Certification from Watson Laboratories, Inc., or Watson, that it has submitted an ANDA to the FDA requesting approval to market a generic version of Xyrem. On December 11, 2014, we filed a lawsuit against Watson in the District Court, alleging that 15 of our patents covering Xyrem are or will be infringed by Watson’s ANDA and seeking a permanent injunction to prevent Watson from introducing a generic version of Xyrem that would infringe these patents. We cannot predict the timing or outcome of events in this litigation.
	In January 2015, Amneal, Ranbaxy and Watson proposed the consolidation of their respective cases and a consolidated schedule to the District Court. Under the proposed consolidated schedule, the District Court would hold a Markman hearing no earlier than January 2016. Par is currently seeking its own proposed schedule. Under Par’s proposed schedule, the District Court would hold a Markman hearing in the Par case no earlier than September 2015. We cannot predict the timing or outcome of events in these proceedings, including what cases, if any, the District Court will consolidate and what cases, if any, the District Court will permit to go forward separately.
	Between June and August 2014, petitions seeking covered business method, or CBM, post-grant patent review by the Patent Trial and Appeal Board, or PTAB, of the U.S. Patent and Trademark Office, or USPTO, were filed by certain of the ANDA filers with respect to the validity of six of our patents related to the distribution system for Xyrem. In the fall of 2014, we filed preliminary responses to the petitions in which, among other things, we asserted that the challenged patents should not be subject to CBM review. In early 2015, the PTAB issued decisions denying institution of CBM review for all of these petitions.
	In January 2015, petitions for IPR were filed by certain of the ANDA filers with respect to the validity of six of our patents related to the distribution system for Xyrem. The PTAB has not yet determined whether to institute proceedings with respect to these petitions for IPR. We cannot predict whether PTAB will institute any of the petitioned IPR proceedings, whether additional post-grant patent review challenges will be filed, the outcome of any IPR or other proceeding if instituted, or the impact any IPR or other proceeding might have on ongoing ANDA litigation proceedings.
	FazaClo ANDA Matters: Azur Pharma received notices of Paragraph IV Certifications from three generics manufacturers, Barr Laboratories, Inc., or Barr, Novel Laboratories, Inc., or Novel, and Mylan Pharmaceuticals, Inc., or Mylan, indicating that ANDAs had been filed with the FDA requesting approval to market generic versions of FazaClo® (clozapine, USP) LD orally disintegrating clozapine tablets. Azur Pharma and CIMA Labs Inc., or CIMA, a subsidiary of Teva Pharmaceutical Industries Limited, or Teva, our licensor and the entity whose drug-delivery technology is incorporated into FazaClo LD, filed a lawsuit in response to each certification claiming infringement based on such certification against Barr on August 21, 2008, against Novel on November 25, 2008 and against Mylan on July 23, 2010. Each case was filed in the U.S. District Court for the District of Delaware, or the Delaware Court. On July 6, 2011, CIMA, Azur Pharma and Teva, which had acquired Barr, entered into an agreement settling the patent litigation and Azur Pharma granted a sublicense to an affiliate of Teva of Azur Pharma’s rights to have manufactured, market and sell a generic version of both FazaClo LD and FazaClo HD, as well as an option for supply of authorized generic product. The sublicense for FazaClo LD commenced in July 2012, and the sublicense for FazaClo HD will commence in May 2015. Teva exercised its option for supply of an authorized generic product for FazaClo LD and launched the authorized generic product at the end of August 2012. Teva has also exercised its option for supply of an authorized generic product for FazaClo HD. The Novel and Mylan matters had been stayed pending reexamination of the patents in the lawsuits. In September 2013 and January 2014, reexamination certificates were issued for the two patents-in-suit, and the patentability of the claims of the patents confirmed. The Delaware Court lifted the stay of litigation in the two cases in March 2014. On December 19, 2014, we and CIMA entered into an agreement with Novel settling the patent litigation against Novel and we granted Novel a sublicense to manufacture, market and sell a generic version of FazaClo LD and, if applicable, FazaClo HD. The sublicense will commence on May 1, 2017, or earlier upon the occurrence of certain events. Trial in the Mylan case is currently set for the third quarter of 2015, but we cannot predict the specific timing or outcome of this litigation.
	Cutler Matter: On October 19, 2011, Dr. Neal Cutler, one of the original owners of FazaClo, filed a complaint against Azur Pharma and one of its subsidiaries, as well as Avanir Pharmaceuticals, Inc., or Avanir, in the California Superior Court in the County of Los Angeles, or the Superior Court. The complaint alleges that Azur Pharma and its subsidiary breached certain contractual obligations. Azur Pharma acquired rights to FazaClo from Avanir in 2007. The complaint alleges that as part of the acquisition of FazaClo, Azur Pharma’s subsidiary agreed to assume certain contingent payment obligations to Dr. Cutler. The complaint further alleges that certain contingent payments are due because revenue thresholds have been achieved, entitling Dr. Cutler to a $10.5 million and an additional $25.0 million contingent payment, plus unspecified punitive damages and attorneys’ fees. In March 2012, the Superior Court granted our petition to compel arbitration of the dispute in New York and stayed the Superior Court litigation. In July 2012, the arbitrator dismissed the arbitration on the grounds that the parties’ dispute falls outside of the scope of the arbitration clause in the applicable contract. That ruling was affirmed by the California Court of Appeal in January 2014, and the case was remanded to Superior Court for discovery and trial. Trial has been scheduled for October 2015. We cannot predict the specific timing or outcome of this litigation.
	Shareholder Litigation Matter: In January 2014, we became aware of a purported class action lawsuit filed in the U.S. District Court for the Southern District of New York in connection with the Gentium Acquisition.  The lawsuit named Gentium, each of the Gentium’s directors, us and our Italian subsidiary as defendants. The lawsuit alleged, among other things, that Gentium’s directors breached their fiduciary duties to Gentium’s shareholders in connection with the Gentium tender offer agreement that Gentium entered into with us and our Italian subsidiary valuing Gentium ordinary shares and ADSs at $57.00 per share, and that we and our Italian subsidiary violated Sections 14(e) and 20(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, by allegedly overseeing Gentium’s preparation of an allegedly false and misleading Section 14D-9 Solicitation/Recommendation Statement. On November 19, 2014, the plaintiff dismissed us and our Italian subsidiary from the lawsuit. On January 22, 2015, the entire lawsuit was dismissed with prejudice by the court.
	From time to time we are involved in legal proceedings arising in the ordinary course of business. We believe there is no other litigation pending that could have, individually or in the aggregate, a material adverse effect on our results of operations or financial condition.
	Other Contingencies
	We have not previously submitted pricing data for two radiopharmaceutical products, ProstaScint® (capromab pendetide) and Quadramet® (samarium sm 153 lexidronam injection), for Medicaid and the Public Health Service’s 340B drug pricing discount program.  We engaged in interactions with the Centers for Medicare and Medicaid Services, or CMS, and a trade group, the Council on Radionuclides and Radiopharmaceuticals, or CORAR, regarding the reporting of Medicaid pricing data and paying Medicaid rebates for radiopharmaceutical products.  For ProstaScint, we plan to begin making any required reports when CMS issues guidance on any requirements and reporting methodologies.  We sold Quadramet to a third party in December 2013, but have retained any liabilities related to sales of the product during prior periods.  In addition to the discussions with CMS as part of CORAR, we have had separate discussions with CMS directly regarding Quadramet.  We are currently unable to predict whether price reporting and rebates will be required for ProstaScint and Quadramet and, if so, for what period they will be required.  The initiation of any reporting of Medicaid pricing data for ProstaScint and Quadramet could result in retroactive 340B ceiling price liability for these two products as well as prospective 340B ceiling price obligations for ProstaScint. We are currently unable to reasonably estimate an amount or range of a potential contingent loss. Any material liability resulting from radiopharmaceutical price reporting would negatively impact our financial results.

Shareholders_Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Shareholders' Equity	Shareholders’ Equity
	Share Repurchase Program
	In May 2013, our board of directors authorized a share repurchase program pursuant to which we may repurchase a number of ordinary shares having an aggregate repurchase price of up to $200 million, exclusive of any brokerage commissions. The authorization became effective immediately and has no set expiration date. Under this authorization, we may repurchase our ordinary shares through open market purchases, privately negotiated purchases or a combination of these transactions. The timing and amount of repurchases will depend on a variety of factors, including the price of our ordinary shares, alternative investment opportunities, restrictions under our credit agreement, corporate and regulatory requirements and market conditions. Share repurchases may be suspended or discontinued at any time without prior notice. We initiated purchases under this program in May 2013. In 2014, we spent a total of $42.2 million to repurchase 0.3 million of our ordinary shares under the share repurchase program at an average total purchase price, including brokerage commissions, of $138.64 per share. All ordinary shares repurchased were canceled. As of December 31, 2014, the remaining amount authorized under the share repurchase program was $21.3 million.
	Authorized But Unissued Ordinary Shares
	We had reserved the following shares of authorized but unissued ordinary shares (in thousands):
		December 31, 2014
	2011 Equity Incentive Plan	10,143
	2007 Equity Incentive Plan	962
	2007 Employee Stock Purchase Plan	587
	Amended and Restated 2007 Non-Employee Directors Stock Option Plan	419
	Amended and Restated Directors Deferred Compensation Plan	178
	Total	12,289

Comprehensive_Income_Loss

Comprehensive Income (Loss)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Comprehensive Income (Loss)	Comprehensive Income (Loss)
	Comprehensive income (loss) includes net income and all changes in shareholders’ equity during a period, except for those changes resulting from investments by shareholders or distributions to shareholders.
	Accumulated Other Comprehensive Income (Loss)
	The components of accumulated other comprehensive income (loss) attributable to Jazz Pharmaceuticals plc at December 31, 2014 and December 31, 2013 were as follows (in thousands):
		Foreign Currency Translation Adjustments			Total Accumulated Other Comprehensive Income (Loss)
	Balance at December 31, 2013	$	56,153		$	56,153
	Other comprehensive loss	(178,250		)	(178,250		)
	Balance at December 31, 2014	$	(122,097	)	$	(122,097	)
	In 2014, other comprehensive loss included foreign currency translation adjustments which were primarily due to the strengthening of the U.S. dollar against the Euro.

ShareBased_Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	Share-Based Compensation
	2011 Equity Incentive Plan
	In connection with the Azur Merger, Jazz Pharmaceuticals, Inc.’s board of directors adopted the 2011 Equity Incentive Plan, or the 2011 Plan, in October 2011 and its stockholders approved the 2011 Plan at the special meeting of the stockholders held in December 2011 in connection with the Azur Merger. The 2011 Plan became effective immediately before the consummation of the Azur Merger and was assumed and adopted by us upon the consummation of the Azur Merger. The terms of the 2011 Plan provide for the grant of stock options, stock appreciation rights, restricted stock awards, RSUs, other stock awards, and performance awards that may be settled in cash, shares, or other property. All of the grants under the 2011 Plan were granted to employees and vest ratably over service periods of four years and expire no more than 10 years after the date of grant. As of December 31, 2014, a total of 13,549,336 of our ordinary shares had been authorized for issuance under the 2011 Plan. In addition, the share reserve under the 2011 Plan will automatically increase on January 1 of each year through January 1, 2022, by the least of (a) 4.5% of the total number of ordinary shares outstanding on December 31 of the preceding calendar year, (b) 5,000,000 shares, or (c) such lesser number of ordinary shares as determined by our board of directors. On January 1, 2015, the share reserve under the 2011 Plan automatically increased by 2,728,927 ordinary shares pursuant to this provision.
	2007 Equity Incentive Plan
	The 2007 Equity Incentive Plan, or the 2007 Plan, which was initially adopted by the Jazz Pharmaceuticals, Inc. board of directors and approved by the Jazz Pharmaceuticals, Inc. stockholders in connection with its initial public offering, was continued and assumed by us upon consummation of the Azur Merger. The 2007 Plan provided for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, RSUs, stock appreciation rights, performance stock awards and other forms of equity compensation to employees, including officers, non-employee directors and consultants. Prior to the consummation of the Azur Merger, all of the grants under the 2007 Plan were granted to employees and vest ratably over service periods of three to five years and expire no more than 10 years after the date of grant. Effective as of the closing of the Azur Merger on January 18, 2012, the number of shares reserved for issuance under the 2007 Plan was set to 1,000,000 ordinary shares. The share reserve under the 2007 Plan will not automatically increase. Since the Azur Merger, all of the new grants under the 2007 Plan were granted to non-employee directors and vest ratably over service periods of one to three years and expire no more than 10 years after the date of grant.
	2007 Employee Stock Purchase Plan
	In 2007, Jazz Pharmaceuticals, Inc.’s employees became eligible to participate in the Employee Stock Purchase Plan, or ESPP. The ESPP was amended and restated by Jazz Pharmaceuticals, Inc.’s board of directors in October 2011 and approved by its stockholders in December 2011. The amended and restated ESPP became effective immediately prior to the effective time of the Azur Merger and was assumed by us upon the consummation of the Azur Merger. The amended and restated ESPP allows our eligible employee participants (including employees of any of a parent or subsidiary company if our board of directors designates such company as eligible to participate) to purchase our ordinary shares at a discount of 15% through payroll deductions. The ESPP consists of a fixed offering period of 24 months with four purchase periods within each offering period. The number of shares available for issuance under our ESPP during any six-month purchase period is 175,000 shares. As of December 31, 2014, a total of 2,660,000 of our ordinary shares had been authorized for issuance under the ESPP. The share reserve under the ESPP will automatically increase on January 1 of each year through January 1, 2022, by the least of (a) 1.5% of the total number of ordinary shares outstanding on December 31 of the preceding calendar year, (b) 1,000,000 shares, or (c) such lesser number of ordinary shares as determined by our board of directors. Our compensation committee determined not to automatically increase the share reserve under the ESPP on January 1, 2015.
	Amended and Restated 2007 Non-Employee Directors Stock Option Plan
	The Amended and Restated 2007 Non-Employee Directors Stock Option Plan, or the 2007 Directors Option Plan, which was initially adopted by the Jazz Pharmaceuticals, Inc. board of directors and approved by the Jazz Pharmaceuticals, Inc. stockholders in connection with its initial public offering, was continued and assumed by us upon the consummation of the Azur Merger. Until October 2011, the 2007 Directors Option Plan provided for the automatic grant of nonstatutory stock options to purchase shares of Jazz Pharmaceuticals, Inc.’s common stock to its non-employee directors initially at the time any individual first became a non-employee director, which vest over three years, and then annually over their period of service on its board of directors, which vest over one year. On October 24, 2011, Jazz Pharmaceuticals, Inc.’s board of directors amended the 2007 Directors Option Plan to eliminate all future initial and annual automatic grants so that future automatic grants would not be made that would be subject to the excise tax imposed by Section 4985 of the Internal Revenue Code of 1986, as amended, or the Internal Revenue Code, in connection with the Azur Merger. Accordingly, all future stock option grants under the 2007 Directors Option Plan will be at the discretion of our board of directors. Since the Azur Merger, all of the new grants under the 2007 Directors Option Plan were granted to non-employee directors and vest ratably over service periods of one to three years and expire no more than 10 years after the date of grant. In addition, the 2007 Directors Option Plan provides the source of shares to fund distributions made prior to August 15, 2010 under the Directors Deferred Compensation Plan described below. As of December 31, 2014, a total of 837,713 of our ordinary shares had been authorized for issuance under the 2007 Directors Option Plan. The number of shares reserved for issuance under the 2007 Directors Plan automatically increases on each January 1, from January 1, 2008 through (and including) January 1, 2017, by the excess of (a) the number of shares subject to options granted, over (b) the number of shares added back to the share reserve, in each case, during the preceding calendar year under the 2007 Directors Plan; provided, that, for any year, the automatic increase may not exceed 200,000 shares and the board of directors may approve a lesser, or no, automatic increase. On January 1, 2015, the share reserve under the 2007 Directors Option Plan automatically increased by 32,075 ordinary shares pursuant to this provision.
	Amended and Restated Directors Deferred Compensation Plan
	In May 2007, the Jazz Pharmaceuticals, Inc. board of directors adopted the Directors Deferred Compensation Plan, or the Directors Deferred Plan, which was amended in December 2008 and was then amended and restated in August 2010, and which was continued and assumed by us upon consummation of the Azur Merger. The Directors Deferred Plan allows each non-employee director to elect to defer receipt of all or a portion of his or her annual retainer fees to a future date or dates. Amounts deferred under the Directors Deferred Plan are credited as shares of Jazz Pharmaceuticals, Inc.’s common stock (or our ordinary shares following the Azur Merger) to a phantom stock account, the number of which are based on the amount of the retainer fees deferred divided by the market value of Jazz Pharmaceuticals, Inc.’s common stock (or our ordinary shares following the Azur Merger) on the first trading day of the first open window period following the date the retainer fees are deemed earned. On the 10th business day following the day of separation from the board of directors or the occurrence of a change in control, or as soon thereafter as practical once the non-employee director has provided the necessary information for electronic deposit of the deferred shares, each non-employee director will receive (or commence receiving, depending upon whether the director has elected to receive distributions from his or her phantom stock account in a lump sum or in installments over time) a distribution of his or her phantom stock account, in our ordinary shares (i) reserved under the 2007 Directors Option Plan prior to August 15, 2010 and (ii) from a new reserve of 200,000 shares set up under the Directors Deferred Plan on August 15, 2010. Although we continue to maintain the Directors Deferred Plan, since the consummation of the Azur Merger we have not permitted and will not permit the non-employee directors to defer any annual retainer fees under the Directors Deferred Plan. We recorded no expense in 2014, 2013 and 2012 related to retainer fees earned and deferred. As of December 31, 2014, 14,499 of our ordinary shares that were unissued related to retainer fees that were deferred under the Directors Deferred Plan.
	Share-Based Compensation
	The table below shows, for all share option grants, the weighted-average assumptions used in the Black-Scholes option pricing model and the resulting weighted-average grant date fair value of share options granted in each of the past three years:
		Year Ended December 31,
		2014				2013				2012
	Grant date fair value	$	60.29			$	29.09			$	25.28
	Volatility	45		%		58		%		64		%
	Expected term (years)	4.3				4.4				4.6
	Range of risk-free rates	1.1-1.4%				0.5-1.4%				0.5-1.1%
	Expected dividend yield	—		%		—		%		—		%
	Since 2012, we rely on a blend of the historical and implied volatilities of our own ordinary shares to determine expected volatility for share option grants because our trading history exceeds the expected term of the share options. In addition, we use a single volatility estimate for each share option grant. The weighted-average volatility is determined by calculating the weighted average of volatilities for all share options granted in a given year.
	The expected term of share option grants represents the weighted-average period the awards are expected to remain outstanding and our estimates were based on historical exercise data. The risk-free interest rate assumption was based on zero coupon U.S. Treasury instruments whose term was consistent with the expected term of our share option grants. The expected dividend yield assumption was based on our history and expectation of dividend payouts.
	Share-based compensation expense in continuing operations related to share options, RSUs and grants under our ESPP was as follows (in thousands):
		Year Ended December 31,
		2014				2013				2012
	Selling, general and administrative	$	55,083			$	35,674			$	18,950
	Research and development	12,179				6,673				2,640
	Cost of product sales	2,376				2,204				1,416
	Total share-based compensation expense, pre-tax	69,638				44,551				23,006
	Tax benefit from share-based compensation expense	(20,795		)		(13,822		)		(7,499		)
	Total share-based compensation expense, net of tax	$	48,843			$	30,729			$	15,507
	We realized tax benefits related to share option exercises of $11.8 million, $6.7 million and $18.3 million in 2014, 2013 and 2012, respectively.
	Share Options
	The following table summarizes information as of December 31, 2014 and activity during 2014 related to our share option plans:
		Shares			Weighted-				Weighted-		Aggregate
		Subject to			Average				Average		Intrinsic
		Outstanding			Exercise				Remaining		Value
		Options			Price				Contractual		(In thousands)
		(In thousands)							Term (Years)
	Outstanding at January 1, 2014	4,306			$	42.54
	Options granted	1,000			160.4
	Options exercised	(1,185	)		36.33
	Options forfeited	(251	)		75.08
	Options expired	—			—
	Outstanding at December 31, 2014	3,870			72.77				7.6		$	354,050
	Vested and expected to vest at December 31, 2014	3,632			70.29				7.5		341,118
	Exercisable at December 31, 2014	1,639			36.61				6.5		208,339
	Aggregate intrinsic value shown in the table above is equal to the difference between the exercise price of the underlying share options and the fair value of our ordinary shares for share options that were in the money. The aggregate intrinsic value changes based on the fair market value of our ordinary shares. The aggregate intrinsic value of share options exercised was $138.2 million, $46.0 million and $106.5 million, during 2014, 2013 and 2012, respectively. We issued new ordinary shares upon exercise of share options.
	As of December 31, 2014, total compensation cost not yet recognized related to unvested share options was $68.8 million, which is expected to be recognized over a weighted-average period of 2.3 years.
	As of December 31, 2014, total compensation cost not yet recognized related to grants under the ESPP was $2.3 million, which is expected to be recognized over a weighted-average period of less than one year.
	Restricted Stock Units
	In 2014, we granted RSUs covering an equal number of our ordinary shares to employees with a weighted-average grant date fair value of $160.45. The fair value of RSUs is determined on the date of grant based on the market price of our ordinary shares as of that date. The fair value of the RSUs is recognized as expense ratably over the vesting period of four years. In 2014, 344,000 RSUs were released with 222,000 ordinary shares issued and 122,000 ordinary shares withheld for tax purposes. The total fair value of shares vested was $50.9 million, $16.1 million and none during 2014, 2013 and 2012, respectively.
	As of December 31, 2014, total compensation cost not yet recognized related to unvested RSUs was $74.1 million, which is expected to be recognized over a weighted-average period of 2.4 years.
	The following table summarizes information as of December 31, 2014 and activity during 2014 related to our RSUs:
		Number of RSUs (in thousands)			Weighted-				Weighted-		Aggregate
					Average				Average		Intrinsic
					Grant-Date				Remaining		Value
					Fair Value				Contractual		(In thousands)
									Term (Years)
	Outstanding at January 1, 2014	1,164			$	55.28
	RSUs granted	488			160.45
	RSUs released	(344	)		55.3
	RSUs forfeited	(120	)		75.43
	RSUs expired	—			—
Outstanding at December 31, 2014	1,188			96.41				1.3		$	194,546

Segment_and_Other_Information

Segment and Other Information	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment and Other Information	Segment and Other Information
	Our operating segment is reported in a manner consistent with the internal reporting provided to the chief operating decision maker or, CODM. Our CODM has been identified as our chief executive officer. We have determined that we operate in one business segment, which is the development and commercialization of meaningful products that address unmet medical needs. The following table presents a summary of total revenues (in thousands):
		Year Ended December 31,
		2014			2013				2012
	Xyrem	$	778,584		$	569,113			$	378,663
	Erwinaze/Erwinase	199,665			174,251				72,083
	Defitelio/defibrotide	70,537			—				—
	Prialt® (ziconotide) intrathecal infusion	26,421			27,103				26,360
	Psychiatry	40,879			49,226				76,489
	Other	46,630			45,705				26,932
	Product sales, net	1,162,716			865,398				580,527
	Royalties and contract revenues	10,159			7,025				5,452
	Total revenues	$	1,172,875		$	872,423			$	585,979
	The following table presents a summary of total revenues attributed to geographic sources (in thousands):
		Year Ended December 31,
		2014			2013				2012
	United States	$	1,007,396		$	792,518			$	538,219
	Europe	126,715			61,843				38,590
	All other	38,764			18,062				9,170
	Total revenues	$	1,172,875		$	872,423			$	585,979
	The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues:
		Year Ended December 31,
		2014		2013			2012
	Express Scripts	66	%	65	%		64	%
	Accredo	14	%	16	%		N/A
	The following table presents total long-lived assets by location (in thousands):
		December 31,
		2014			2013
	Ireland	$	37,775		$	5,799
	United States	9,795			7,734
	Italy	8,462			—
	Other	2,331			713
	Total long-lived assets	$	58,363		$	14,246
	_________________________
	-1	Long-lived assets consist of property and equipment.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	The components of income from continuing operations before the income tax provision (benefit) were as follows (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Republic of Ireland	$	238,351		$	186,903		$	(73,949	)
	United States	222,328			132,855			250,348
	Other	(309,122		)	(11,808		)	956
	Total	$	151,557		$	307,950		$	177,355
	The following table sets forth the details of the income tax provision (benefit) (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Current
	Republic of Ireland	$	23,506		$	17,089		$	(10,733	)
	United States	97,679			71,964			33,387
	Other	16,469			12,682			7,414
	Total current income tax	137,654			101,735			30,068
	Deferred
	Republic of Ireland	2,323			8,353			(315		)
	United States	(15,003		)	(3,513		)	(103,932		)
	Other	(30,743		)	(14,937		)	(9,615		)
	Total deferred income tax benefit	(43,423		)	(10,097		)	(113,862		)
	Total income tax provision (benefit)	$	94,231		$	91,638		$	(83,794	)
	During 2014, we recognized an income tax provision of $94.2 million related to tax arising on income in Ireland, the United States and certain other foreign jurisdictions, certain uncertain tax positions and various expenses not deductible for tax purposes. During 2013, we recognized an income tax provision of $91.6 million related to tax arising on income in Ireland, the United States and certain other foreign jurisdictions, certain uncertain tax positions and various expenses not deductible for tax purposes. During 2012, we recognized an income tax benefit of $83.8 million which resulted primarily from our reversal of a valuation allowance on most of our U.S. federal and state deferred tax assets as described below. As discussed in Note 1, in January 2012, the businesses of Jazz Pharmaceuticals, Inc. and Azur Pharma were combined in a merger transaction accounted for as a reverse acquisition and the combined company changed its domicile from the United States to Ireland.
	The effective tax rate for 2014 was 62.2%. After adjusting the income before income tax provision for the year ended December 31, 2014 by excluding a total of $202.0 million in upfront and milestone payments for rights to JZP-110 and to defibrotide in the Americas, which were acquired by our subsidiaries in a non-taxable jurisdiction, the effective tax rate on the resulting income before income tax provision for 2014 was 26.7%. The effective tax rate for 2014 was higher than the Irish statutory rate of 12.5%, primarily due to income taxable at a rate higher than the Irish statutory rate, uncertain tax positions, current year losses in some jurisdictions for which no tax benefit is available and various expenses not deductible for tax purposes, partially offset by changes in U.S. state valuation allowances and benefits from certain originating income tax credits. The effective tax rate for 2013 of 29.8% was higher than the Irish statutory rate of 12.5%, primarily due to income taxable at a rate higher than the Irish statutory rate, certain uncertain tax positions, current year losses in some jurisdictions for which no tax benefit is available, and various expenses not deductible for tax purposes, partially offset by benefits from certain originating income tax credits. In 2012, following the Azur Merger and the change in the combined company’s domicile, the statutory income tax rate changed from the U.S. rate of 35.0% to the Irish rate of 12.5%. In June 2012, we completed the EUSA Acquisition, which further expanded our global operations. The 2012 effective income tax rate on continuing activities before utilization of net operating losses, or NOLs, and tax credit carryforwards and release in valuation allowance in 2012 of 42.5% was higher than the Irish statutory rate of 12.5% due to a number of factors, including income taxable at a rate higher than the Irish statutory rate, losses in certain tax jurisdictions for which no tax benefit is available and various expenses not deductible for tax purposes. The decrease in the effective tax rate, after excluding the upfront and milestone payments, for 2014 compared to 2013 was primarily due to changes in income mix among the various jurisdictions in which we operate, changes in U.S. state valuation allowances and benefits from certain originating income tax credits.  The decrease in the effective tax rate in 2013 compared to 2012 was primarily due to changes in income mix among the various jurisdictions in which we operate as well as higher taxes in 2012 relating to acquisition restructuring. We are currently paying taxes in Ireland, the United States and certain other foreign jurisdictions where we have operations and either all NOLs have been utilized, or are restricted as a result of the Azur Merger.
	A reconciliation of income taxes at the statutory income tax rate to our effective income tax rate was as follows (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Statutory income tax rate	12.5		%	12.5		%	12.5		%
	Income tax provision at statutory rate	$	18,945		$	38,494		$	22,169
	Acquisition-related costs	4,703			—			763
	Research and other tax credits	(14,234		)	(5,957		)	(100		)
	Non-deductible share-based compensation	4,203			2,497			873
	Foreign income tax rate differential	75,780			31,651			52,066
	Change in unrecognized tax benefits	9,447			8,685			2,249
	Prior period adjustments	(5,522		)	3,375			(2,524		)
	Change in valuation allowance	9,006			3,220			(159,158		)
	Non-deductible contingent consideration	—			5,320			—
	Non-deductible financing costs	1,088			—			—
	Deduction on subsidiary equity	(11,403		)	—			—
	Non-deductible officers' compensation	2,715			1,528			—
	Other	(497		)	2,825			(132		)
	Income tax provision (benefit)	$	94,231		$	91,638		$	(83,794	)
	Effective income tax rate	62.2		%	29.8		%	(47.2		)%
	In 2014, the change in valuation allowance was $9.0 million. In 2013, the change in valuation allowance was $3.2 million. In 2012, the change in valuation allowance of $159.2 million was comprised of NOLs and tax credit carryforwards of $55.0 million and a release in valuation allowance of $104.2 million.
	Deferred income taxes reflect the tax effects of NOLs and tax credit carryforwards and the net temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes using currently enacted tax rates and regulations that are expected to be in effect when the differences are expected to be recovered or settled.
	Significant components of our net deferred tax assets/(liabilities) were as follows (in thousands):
		December 31,
		2014			2013
	Deferred tax assets:
	Net operating loss carryforwards	$	74,057		$	71,364
	Tax credit carryforwards	23,946			11,374
	Intangible assets	19,507			10,733
	Share-based compensation	14,033			8,116
	Accruals	36,157			30,730
	Deferred revenue and other	5,038			9,252
	Total deferred tax assets	172,738			141,569
	Valuation allowance	(29,697		)	(20,691		)
	Net deferred tax assets	143,041			120,878
	Deferred tax liabilities:
	Acquired intangible assets	(395,651		)	(176,576		)
	Other	(7,940		)	(10,848		)
	Total deferred tax liabilities	(403,591		)	(187,424		)
	Net deferred tax liabilities	$	(260,550	)	$	(66,546	)
	The following table presents the breakdown between current and non-current deferred tax assets/(liabilities) (in thousands):
	Year Ended December 31,
	2014			2013
Current deferred tax assets	$	48,440		$	33,613
Current deferred tax liabilities	(9,430		)	(6,259		)
Non-current deferred tax assets	75,494			74,597
Non-current deferred tax liabilities	(375,054		)	(168,497		)
Net deferred tax liabilities	$	(260,550	)	$	(66,546	)
As of December 31, 2014, we had NOL carryforwards and tax credit carryforwards for U.S. federal income tax purposes of approximately $264.9 million and $29.2 million, respectively, available to reduce future income subject to income taxes. The NOL carryforwards are inclusive of $117.2 million from the EUSA Acquisition in 2012. The federal NOL carryforwards will expire, if not utilized, in the tax years 2016 to 2034, and the federal tax credits will expire, if not utilized, in the tax years 2016 to 2034. In addition, we had approximately $267.4 million of NOL carryforwards and $4.2 million of tax credit carryforwards as of December 31, 2014 available to reduce future taxable income for state income tax purposes. The state NOL carryforwards will expire, if not utilized, in the tax years 2015 to 2033. The state tax credits have no expiration date. In addition, as of December 31, 2014, there were NOL carryforwards for income tax purposes of approximately $56.1 million and $74.2 million available to reduce future income subject to income taxes in the United Kingdom and Italy, respectively. The NOLs generated in the United Kingdom and Italy have no expiration period. We also had excess foreign tax credits, as of December 31, 2014, of $4.7 million, which may only be utilized against certain sources of income.  The excess foreign tax credits have no expiration period.
Utilization of certain of our NOL and tax credit carryforwards in the United States is subject to annual limitation due to the ownership change limitations provided by Sections 382 and 383 of the Internal Revenue Code and similar state provisions. Such an annual limitation may result in the expiration of certain NOLs and tax credits before future utilization. We currently estimate that we have an annual limitation on the utilization of certain acquired federal NOLs of $28.8 million for 2015, $28.9 million for 2016, $15.0 million for 2017, $1.4 million for 2018 and a combined total of $4.9 million for 2019 to 2026. In addition, as a result of the Azur Merger, until 2022 we are subject to certain limitations under the Internal Revenue Code in relation to the utilization of U.S. NOLs to offset U.S. taxable income resulting from certain transactions.
Approximately $191.7 million of both the U.S. federal and state NOL carryforwards as of December 31, 2014 resulted from exercises of employee share options and certain sales by employees of shares issued under other employee equity compensation plans. We have not recorded the tax benefit of the deduction related to these exercises and sales as deferred tax assets on our balance sheet. When we realize the tax benefit as a reduction to taxable income in our tax returns, we will account for the tax benefit as a credit to shareholders’ equity rather than as a reduction of our income tax provision in our financial statements.
Valuation allowances require an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction-by-jurisdiction basis. Our valuation allowance was $29.7 million and $20.7 million as of December 31, 2014 and 2013, respectively, for certain U.S. state and foreign deferred tax assets which we maintain until sufficient positive evidence exists to support reversal. During 2014, as part of the overall change in valuation allowance, we recognized an income tax benefit of $7.7 million relating to the net reversal of a valuation allowance against certain deferred tax assets associated with NOLs and tax credit carryforwards. During 2013, as part of the overall change in valuation allowance, we recognized an income tax expense of $2.3 million relating to the creation of a valuation allowance against certain U.S. state deferred tax assets associated with tax credit carryforwards. During the fourth quarter of 2012, we recognized an income tax benefit of $104.2 million relating to the reversal of a valuation allowance against substantially all of our U.S. federal and state deferred tax assets. Management determined that a valuation allowance was no longer needed on these deferred tax assets based on an assessment of the relative impact of all positive and negative evidence that existed at December 31, 2012, including an evaluation of cumulative income in recent years, future sources of taxable income exclusive of reversing temporary differences, and significant risks and uncertainties related to our business. We periodically evaluate the likelihood of the realization of deferred tax assets and will adjust such amounts in light of changing facts and circumstances including, but not limited to, future projections of taxable income, tax legislation, rulings by relevant tax authorities, the progress of tax audits and the regulatory approval of products currently under development. Realization of substantially all the deferred tax assets are dependent on future book income.
Temporary differences related to investments in foreign subsidiaries totaled approximately $736.9 million and $664.3 million as of December 31, 2014 and 2013, respectively. In the event of the distribution of those earnings in the form of dividends, a sale of the subsidiaries, or certain other transactions, we may be liable for income taxes, subject to an adjustment, if any, for foreign tax credits and foreign withholding taxes payable to certain foreign tax authorities. As of December 31, 2014, it was not practicable to determine the amount of the income tax liability related to these investments.
We are required to recognize the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. As a result, we have established a liability for certain tax benefits which we judge may not be sustained upon examination. A reconciliation of our unrecognized tax benefits follows (in thousands):
	December 31,
	2014			2013			2012
Balance at the beginning of the year	$	21,637		$	7,288		$	3,764
Increases related to current year tax positions	19,837			14,308			3,492
Increases related to prior year tax positions	—			183			40
Decreases related to prior year tax positions	(672		)	(142		)	(8		)
Balance at the end of the year	$	40,802		$	21,637		$	7,288
The unrecognized tax benefits were included in other non-current liabilities and deferred tax assets, net, non-current in our consolidated balance sheet. Interest related to our unrecognized tax benefits is recorded in income tax provision (benefit) in our consolidated statements of income. As of December 31, 2014 and 2013, our accrued interest and penalties related to uncertain tax positions were not significant. Included in the balance of unrecognized tax benefits were potential benefits of $29.7 million and $16.3 million at December 31, 2014 and 2013, respectively, that, if recognized, would affect the effective tax rate on income. We do not anticipate that the amount of existing unrecognized tax benefits will significantly increase or decrease within the next 12 months.
Our most significant tax jurisdictions are Ireland, the United States, Italy and France. Because of our NOL and tax credit carryforwards, substantially all of our tax positions remain open to federal and state examination in the United States. In France, tax periods open to examination include all periods from 2012. In Ireland, tax periods open to examination include all periods from 2010. As of December 31, 2014, certain of our subsidiaries were under examination by the U.S. Internal Revenue Service, or IRS, for 2010. However, we subsequently received written confirmation from the IRS that no adjustment would be made for that year and the audit is now closed. As of December 31, 2014, certain of our subsidiaries were under examination by the French tax authorities for 2012 and 2013. Subsequent to December 31, 2014, certain of our Italian subsidiaries were notified of the commencement of an examination by the Italian tax authorities for 2012.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions
	In 2014, certain holders of warrants to purchase 947,867 of our ordinary shares exercised the warrants in full for an aggregate cash purchase price payable to us of $3.8 million. The warrant holders are entities affiliated with one of our directors. In accordance with the terms of an existing investor rights agreement with the warrant holders, we registered the resale of the ordinary shares underlying the warrants and, pursuant to such agreement, we paid expenses of approximately $0.1 million in connection with the resale registration.
	In 2013, we entered into an underwriting agreement with an underwriter and certain selling shareholders, pursuant to which the selling shareholders sold to the underwriter 5.4 million of our ordinary shares, resulting in aggregate gross proceeds to the selling shareholders of approximately $314.4 million, before deducting underwriting discounts, commissions and other offering expenses. The selling shareholders included entities affiliated with certain members of our board of directors and one of our directors. We did not receive any proceeds from the sale of our ordinary shares by the selling shareholders in the offering and, consistent with our obligations under existing registration rights agreements with those shareholders, we paid expenses of approximately $0.5 million in connection with the offering.
	In 2012, in connection with the Azur Merger, we assumed a lease for office space in Dublin, Ireland. The lease agreement was with Seamus Mulligan, the former Chief Executive Officer of Azur Pharma, who is a member of our board of directors. Rentals paid on this lease amounted to $0.3 million in 2012. In November 2012, we terminated this lease at a cost of $1.2 million, which was the carrying value of our above market lease liability.  There was no resulting gain or loss on the lease termination.
	In 2012, we entered into an underwriting agreement with two underwriters and certain selling shareholders, pursuant to which the selling shareholders agreed to sell to the underwriters 7.9 million of our ordinary shares, resulting in aggregate gross proceeds to the selling shareholders of approximately $390.7 million. The selling shareholders included entities affiliated with certain members of our board of directors, four of our directors and four of our executive officers at the time of the agreement. We did not receive any proceeds from the sale of our ordinary shares by the selling shareholders in the offering, and we paid expenses of approximately $0.4 million in connection with this offering.

Assets_Held_for_Sale_Notes

Assets Held for Sale (Notes)	12 Months Ended
	Dec. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]
Assets Held for Sale	Assets Held for Sale
	In 2014, we reorganized our operations in Europe to focus our commercial efforts on our hematology/oncology therapeutic area following the Gentium Acquisition. As a result, we are selling certain products acquired as part of the EUSA Acquisition. In the fourth quarter of 2014, we entered into a definitive agreement to sell these products and the related business for approximately $34 million in cash, subject to certain working capital adjustments. The sale, subject to certain closing conditions, is expected to close in the first half of 2015. The related assets met the assets held for sale criteria and were reclassified to assets held for sale as of December 31, 2014. Goodwill was allocated to these assets using the relative fair value method.
	In the fourth quarter of 2014, we adjusted the carrying value of the held for sale assets to fair value less costs to sell which resulted in a $6.6 million impairment charge. The impairment charge was recorded in impairment charges on the consolidated statements of income. This charge was in addition to the $32.8 million intangible asset impairment charge recorded during the second quarter of 2014 related to the assets now classified as held for sale.
	We have determined that the expected disposition of these assets does not qualify for reporting as a discontinued operation since the expected sale does not represent a strategic shift that has or will have a major effect on our operations and financial results.
	The following assets were segregated and classified as assets held for sale in the consolidated balance sheet as of December 31, 2014 (in thousands):
		31-Dec-14
	Inventories	$	4,693
	Accounts receivable	4,880
	Intangible assets, net	27,479
	Goodwill	1,686
	Other	654
	Valuation allowance	(6,559		)
	Assets held for sale	$	32,833

Restructuring

Restructuring	12 Months Ended
	Dec. 31, 2014
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring
	In the fourth quarter of 2014, we incurred severance costs for terminated employees in connection with our decision to discontinue sales representative-led promotion of our psychiatry products starting in 2015. In addition, we initiated a restructuring plan related to the consolidation of our UK office locations and incurred costs of severance for terminated employees and facility closure costs in connection with this plan. The one-time termination benefits were recorded over the remaining service period where employees were required to stay through their termination date to receive the benefits. We recorded costs related to these one-time termination benefits of $1.8 million in the year ended December 31, 2014 within selling, general and administrative expenses in our consolidated statements of income. We expect to incur additional one-time termination benefit costs of $0.3 million in 2015. Facility closure costs of $0.1 million incurred in the year ended December 31, 2014 were recorded within selling, general and administrative expenses in our consolidated statements of income. We expect to incur additional facility closure costs of $0.1 million in 2015.
	In June 2012, we initiated a restructuring plan to re-align certain support functions across the company following the Azur Merger and the EUSA Acquisition. In connection with this restructuring plan, we incurred restructuring costs of $1.5 million and $2.8 million in the years ended December 31, 2013 and 2012 respectively, within selling, general and administrative expenses in our consolidated statements of income. We do not expect to incur any additional restructuring costs in connection with this plan.
	The following table summarizes the amounts related to restructuring through December 31, 2014 (in thousands):
		Termination Benefits			Facility Closure Costs			Total
	Balance at December 31, 2011	$	—		$	—		$	—
	Costs incurred during the period	2,789			—			2,789
	Cash payments	(1,562		)	—			(1,562		)
	Balance at December 31, 2012	1,227			—			1,227
	Costs incurred during the period	1,045			412			1,457
	Cash payments	(2,272		)	(160		)	(2,432		)
	Balance at December 31, 2013	—			252			252
	Costs incurred during the period	1,823			118			1,941
	Cash payments	—			(252		)	(252		)
	Balance at December 31, 2014	$	1,823		$	118		$	1,941
	The balances as of December 31, 2014, 2013 and 2012 were included within accrued liabilities in our consolidated balance sheets.

Discontinued_Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations
	In 2012, we sold the women’s health business, a component of the acquired Azur Pharma business, to Meda Pharmaceuticals Inc. and Meda Pharma, Sàrl, or collectively, Meda, for $97.6 million, including $2.6 million for certain inventory transferred to Meda upon the closing of the sale, less transaction costs of $3.7 million.  As part of the transaction, Meda purchased six women’s health products from us and offered positions to approximately 60 of our employees who directly supported the women’s health business.  In 2012, we recorded a non-recurring gain on the sale of $35.2 million.
	We decided to sell our women’s health business to concentrate our commercial efforts on our core products in our target therapeutic areas. The results of the women’s health business are included in income from discontinued operations in 2012. Goodwill was allocated to the divested women’s health business using the relative fair value method.
	Net revenue and income from discontinued operations were as follows (in thousands):
		Year Ended
		31-Dec-12
	Product sales, net	$	20,873
	Loss from discontinued operations before income taxes (1)	$	(5,787	)
	Income tax expense (1)	(2,020		)
	Loss from discontinued operations, net of taxes	(7,807		)
	Gain on sale of discontinued operations (2)	35,244
	Income from discontinued operations, net of taxes	$	27,437
	__________________________
	(1) The income tax expense related to profits generated by the women’s health business in 2012 which were attributable to the United States.
	(2) The gain on sale of discontinued operations was not impacted by income taxes as the value attributable to the women’s health business was held in a non-taxable jurisdiction.

Employee_Benefit_Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plans	Employee Benefit Plans
	We operate a number of defined contribution retirement plans. The costs of these plans are charged to the income statement in the period they are incurred. We recorded expense related to our defined contribution plans of $2.0 million, $1.1 million and $0.3 million in the years ended December 31, 2014, 2013 and 2012, respectively. In Ireland, we operate a defined contribution plan in which we contribute up to 8% of an employee’s eligible earnings. We recorded expense of $0.5 million and $0.3 million in the years ended December 31, 2014 and 2013, respectively, and none in 2012 in connection with the contributions we made under the Irish defined contribution plan. In the United States, we provide a qualified 401(k) savings plan for our U.S.-based employees. All U.S.-based employees are eligible to participate, provided they meet the requirements of the plan. In 2013, we elected to match employee contributions under the 401(k) savings plan and recorded expense of $1.0 million and $0.4 million in the years ended December 31, 2014 and 2013, respectively. No such matching contributions were made prior to 2013. In the United Kingdom, we operate a defined contribution plan in which we contribute up to 12% of an employee’s eligible earnings. We recorded expense of $0.5 million, $0.4 million and $0.2 million in the years ended December 31, 2014, 2013 and 2012, respectively, in connection with contributions we made under the U.K. defined contribution plan. In France, we accrue for a potential liability which is payable if an employee retires. The accrued liability for France was $0.4 million, $0.3 million and $0.3 million as of December 31, 2014, 2013 and 2012, respectively. In Italy, we accrue for a potential liability which is payable if an employee leaves employment. The accrued liability for Italy was $0.4 million as of December 31, 2014.

Quarterly_Financial_Data_Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data (Unaudited)	Quarterly Financial Data (Unaudited)
	The following interim financial information presents our 2014 and 2013 results of operations on a quarterly basis (in thousands, except per share amounts):
		2014
		31-Mar			30-Jun		30-Sep		31-Dec
	Revenues	$	246,919		$	291,230	$	306,584	$	328,142
	Gross margin (1)	214,062			258,408		277,413		295,415
	Net income (loss) attributable to Jazz Pharmaceuticals plc	(92,650		)	43,659		25,766		81,612
	Net income (loss) per ordinary share attributable to Jazz Pharmaceuticals plc, basic	(1.58		)	0.73		0.43		1.35
	Net income (loss) per ordinary share attributable to Jazz Pharmaceuticals plc, diluted	(1.58		)	0.7		0.41		1.3
		2013
		March 31			June 30		September 30		December 31
	Revenues	$	196,237		$	208,252	$	232,160	$	235,774
	Gross margin (1)	167,432			181,533		206,134		208,153
	Net income	43,425			42,185		75,409		55,293
	Net income per share, basic	0.74			0.72		1.3		0.96
	Net income per share, diluted	0.71			0.69		1.23		0.9
	__________________________
	-1	Gross margin excludes amortization of acquired developed technology of $30.3 million, $31.7 million, $29.6 million and $31.0 million in the first, second, third and fourth quarters of 2014, respectively, and $19.5 million, $19.3 million, $19.5 million and $20.5 million in the first, second, third and fourth quarters of 2013, respectively.
	The tables above include the following unusual or infrequently occurring items:
	•	Upfront and milestone payments of $127.0 million, $75.0 million and $0.6 million in the first, third and fourth quarters of 2014, respectively, and $4.0 million and $1.0 million in the first and third quarters of 2013, respectively.
	•	Impairment charges of $32.8 million and $6.6 million in the second and fourth quarters of 2014, respectively, associated with certain products and related assets acquired as part of the EUSA Acquisition.  We report sales of these products under “Other” products.  The second quarter impairment charge resulted from the reorganization of our operations in Europe to focus on our hematology/oncology therapeutic area following the Gentium Acquisition. The fourth quarter impairment charge represented the adjustment made to reduce the carrying value of the assets held for sale to fair value less cost to sell;
	•	Revenues of $13.5 million, $22.4 million, $21.1 million and $21.2 million in the first, second, third and fourth quarters of 2014, respectively, resulting from the Gentium Acquisition as measured from the date of acquisition of January 24, 2014. The portion of gross margin and net income associated with the acquired Gentium business was not separately identifiable due to the integration with our operations.
	•	Acquisition accounting inventory value step-up adjustments of $8.0 million and $2.5 million in the first and second quarters of 2014, respectively, and $1.5 million, $1.1 million, $0.5 million and $0.7 million in the first, second, third and fourth quarters of 2013, respectively;
	•	Transaction costs of $17.1 million, $4.4 million, $0.7 million and $5.2 million in the first, second, third and fourth quarters of 2014, respectively, and $0.4 million and $4.4 million in the second and fourth quarters of 2013, respectively;
	•	The change in fair value of the contingent consideration payable of $4.5 million, $3.4 million, $5.0 million and $2.3 million in the first, second, third and fourth quarters of 2013, respectively, for an additional contingent payment of $50.0 million in cash that we agreed to make as part of the EUSA Acquisition if Erwinaze achieved U.S. net sales of $124.5 million or greater in 2013. In 2013, Erwinaze U.S. net sales were greater than $124.5 million and as a result, we made the payment of $50.0 million in the first quarter of 2014; and
	•	A loss on extinguishment and modification of debt of $3.7 million in the second quarter of 2013.

Valuation_and_Qualifying_Accou

Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2014
Valuation and Qualifying Accounts [Abstract]
Valuation and Qualifying Accounts	Valuation and Qualifying Accounts
	(In thousands)
				Balance at		Additions			Other Additions		Deductions			Balance at
				beginning		charged to								end of
				of period		costs and								period
						expenses
	For the year ended December 31, 2014
	Allowance for doubtful accounts	(1	)	$	594	$	—		$	—	$	(64	)	$	530
	Allowance for sales discounts	(1	)	378		3,794			—		(3,934		)	238
	Allowance for chargebacks	(1	)	2,708		28,614			—		(28,607		)	2,715
	Deferred tax asset valuation allowance	(2)(4)		20,691		18,971			—		(9,965		)	29,697
	For the year ended December 31, 2013
	Allowance for doubtful accounts	(1	)	$	715	$	(4	)	$	—	$	(117	)	$	594
	Allowance for sales discounts	(1	)	528		5,267			—		(5,417		)	378
	Allowance for chargebacks	(1	)	2,536		21,047			—		(20,875		)	2,708
	Deferred tax asset valuation allowance	(2	)	17,471		3,220			—		—			20,691
	For the year ended December 31, 2012
	Allowance for doubtful accounts	(1	)	$	50	$	678		$	—	$	(13	)	$	715
	Allowance for sales discounts	(1	)	296		6,022			—		(5,790		)	528
	Allowance for chargebacks	(1	)	20		13,072			—		(10,556		)	2,536
	Deferred tax asset valuation allowance	(3)(4)		111,188		3,421			62,971		(160,109		)	17,471
	__________________________
	-1	Shown as a reduction of accounts receivable. Charges related to sales discounts and chargebacks are reflected as a reduction of revenue.
	-2	Additions to the deferred tax asset valuation allowance relate to movements on certain U.S. state and other foreign deferred tax assets where we continue to maintain a valuation allowance until sufficient positive evidence exists to support reversal.
	-3	Other additions to the deferred income tax asset valuation allowance resulted from the Azur Merger and the EUSA Acquisition.
	-4	Deductions to the deferred tax asset valuation allowance include movements relating to utilization of NOLs and tax credit carryforwards, release in valuation allowance and other movements including adjustments following finalization of tax returns.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policy)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Basis Of Presentation	Basis of Presentation
	The consolidated financial statements include the accounts of Jazz Pharmaceuticals plc and our subsidiaries and intercompany transactions and balances have been eliminated. We record noncontrolling interests in our consolidated financial statements which represent the ownership interest of minority shareholders in the equity of Gentium. The results of operations of the acquired Azur Pharma, EUSA Pharma and Gentium businesses, along with the estimated fair values of the assets acquired and liabilities assumed in each transaction, are included in our consolidated financial statements since the effective dates of the Azur Merger, the EUSA Acquisition and the Gentium Acquisition, respectively.
Significant Risks And Uncertainties	Significant Risks and Uncertainties
	Our financial results are significantly influenced by sales of Xyrem. In 2014, net product sales of Xyrem were $778.6 million, which represented 67.0% of total net product sales. Our ability to maintain or increase sales of Xyrem in its approved indications is subject to a number of risks and uncertainties, including the potential introduction of generic competition, changed or increased regulatory restrictions and continued acceptance of Xyrem as safe and effective by physicians and patients. Five abbreviated new drug applications, or ANDAs, have been filed with the U.S. Food and Drug Administration, or FDA, by third parties seeking to market generic versions of Xyrem, including the most recent in the fourth quarter of 2014. We have initiated lawsuits against all five third parties, and the litigation proceedings are ongoing. We cannot predict the timing or outcome of these proceedings. Although no trial date has been set in any of the ANDA suits, we anticipate that trial on some of the patents in the case against the first ANDA filer, Roxane Laboratories, Inc., or Roxane, could occur as early as the third quarter of 2015. In addition, certain of the ANDA filers have sought to challenge the validity of our patents covering the distribution system for Xyrem by filing petitions for covered business method, or CBM, post-grant patent review and/or inter partes review, or IPR, by the Patent Trial and Appeal Board, or PTAB, of the U.S. Patent and Trademark Office, or USPTO. The PTAB has issued decisions denying institution of CBM review for all of the CBM petitions and has not yet determined whether to institute proceedings with respect to the petitions for IPR. We cannot predict whether PTAB will institute any of the petitioned IPR proceedings, whether additional post-grant patent review challenges will be filed, the outcome of any IPR or other proceeding if instituted, or the impact any IPR or other proceeding might have on ongoing ANDA litigation proceedings. We expect that the approval of an ANDA that results in the launch of a generic version of Xyrem, or the approval and launch of other sodium oxybate products that compete with Xyrem, would have a material adverse effect on our business, financial condition, results of operations and growth prospects.
	In addition, we are continuing our efforts on various regulatory matters, including updating documents that we have submitted to the FDA on our risk management and controlled distribution system for Xyrem, which we refer to as the Xyrem Risk Management Program. We are engaged in ongoing communications with respect to our risk evaluation and mitigation strategies, or REMS, documents for Xyrem, but have not reached agreement with the FDA on certain significant terms. In late 2013, the FDA notified us that it would exercise its claimed authority to modify our REMS and that it would finalize the REMS as modified by the FDA unless we initiated dispute resolution procedures with respect to the modification of the Xyrem deemed REMS.  Among other things, we disagree with the FDA’s position in the late 2013 notice that, as part of the current REMS process, the Xyrem deemed REMS should be modified to enable the distribution of Xyrem through more than one pharmacy, or potentially through retail pharmacies and wholesalers, as well as with certain modifications proposed by the FDA that would, in the FDA’s view, be sufficient to ensure that the REMS includes only those elements necessary to ensure that the benefits of Xyrem outweigh its risks, and that would, in the FDA’s view, reduce the burden on the healthcare system. Given these circumstances, we initiated dispute resolution procedures with the FDA at the end of February 2014. We received the FDA’s denial of our initial dispute resolution submission in the second quarter of 2014, and our dispute is currently subject to further supervisory review at the next administrative level of the FDA. We have received interim responses from the FDA, but the FDA has not yet communicated a decision on our further appeal to us. We expect to receive the FDA’s decision in the first quarter of 2015. We cannot predict whether, or on what terms, we will reach agreement with the FDA on final REMS documents for Xyrem, the outcome or timing of the current dispute resolution procedure, whether we will initiate additional dispute resolution proceedings with the FDA or other legal proceedings prior to finalizing the REMS documents, or the outcome or timing of any such proceedings. We expect that final REMS documents for Xyrem will include modifications to, and/or requirements that are not currently implemented in, the Xyrem Risk Management Program. Any such modifications or additional requirements could potentially make it more difficult or expensive for us to distribute Xyrem, make it easier for future generic competitors, and/or negatively affect sales of Xyrem.
	We also expect to face pressure to license or share our Xyrem Risk Management Program, which is the subject of multiple issued patents, or elements of it, with generic competitors. In January 2014, the FDA held an initial meeting with us and the then-current Xyrem ANDA applicants to facilitate the development of a single shared system REMS for Xyrem (sodium oxybate). The parties have had numerous interactions with respect to a single shared system REMS since the initial meeting, and we expect the interactions to continue. In addition, if we do not develop a single shared system REMS or license or share our REMS with a generic competitor within a time frame or on terms that the FDA considers acceptable, the FDA may assert that its waiver authority permits it to allow the generic competitor to market a generic drug with a REMS that does not include the same elements that are in our deemed REMS or, when Xyrem REMS documents are approved, with a separate REMS that includes different, but comparable, elements to assure safe use. Similarly, it is possible that, consistent with the position that the FDA articulated in its December 2012 response denying a Citizen Petition we filed in July 2012, the FDA could approve an ANDA with a risk management plan that is separate from our Xyrem deemed REMS, rather than with a final REMS or a shared REMS for both the generic and Xyrem. We cannot predict the outcome or impact on our business of any future action that we may take with respect to the development of a single shared system REMS for Xyrem (sodium oxybate), licensing or sharing our REMS, or the FDA’s response to a certification that a third party had been unable to obtain a license.
	Sales of our second largest product, Erwinaze, continue to grow. In 2014, net product sales of Erwinaze/Erwinase were $199.7 million, which represented 17.2% of net product sales in 2014. We seek to maintain and increase sales of Erwinaze, as well as to make Erwinaze more widely available, through ongoing research and development activities. However, our ability to successfully and sustainably maintain or grow sales of Erwinaze is subject to a number of risks and uncertainties, including the limited population of patients with acute lymphoblastic leukemia, or ALL, and the incidence of hypersensitivity reactions to E. coli-derived asparaginase within that population, our ability to obtain clinical data on the use of Erwinaze in young adults age 18 to 39 with ALL who are hypersensitive to E. coli-derived asparaginase, as well as our need to apply for and receive marketing authorizations, through the European Union’s, or EU’s, mutual recognition procedure or otherwise, in certain additional countries so we can launch promotional efforts in those countries. Another significant challenge to our ability to maintain current sales levels and to increase sales is our need to avoid supply interruptions of Erwinaze due to capacity constraints, production delays, quality challenges or other manufacturing difficulties. We have limited inventory of Erwinaze, which puts us at significant risk of not being able to meet product demand. The current manufacturing capacity for Erwinaze is nearly completely absorbed by demand for the product. As a consequence of constrained manufacturing capacity, we have had an extremely limited ability to build an excess level of product inventory that could be used to absorb disruptions to supply resulting from any quality or other issues. If we continue to be subject to capacity constraints or experience quality or other manufacturing challenges in the future, we may be unable to build a desired excess level of product inventory, and our ability to supply the market may be compromised. Although we are taking steps to improve the Erwinaze manufacturing process, if our ongoing efforts are not successful, we could experience additional Erwinaze supply interruptions in the future, which could have a material adverse effect on our sales of and revenues from Erwinaze and limit our potential future maintenance and growth of the market for this product. In addition, while we continue to work with the manufacturer of Erwinaze to evaluate potential steps to expand production capacity to increase the supply of Erwinaze over the longer term to address worldwide demand, our ability to maintain or increase sales of Erwinaze may be limited by our ability to obtain a sufficient supply of the product.
	In furtherance of our growth strategy, we have made a significant investment in Defitelio. We added the product to our portfolio as a result of the Gentium Acquisition and secured worldwide rights to the product by acquiring rights to defibrotide in the Americas in August 2014. Our ability to realize the anticipated benefits from this investment is subject to a number of risks and uncertainties, including our ability to successfully maintain or grow sales of Defitelio in Europe, or obtain marketing approval in other countries, including the United States, so that we can launch promotional efforts in those countries. During 2014, Defitelio was launched in a number of European countries. We expect to continue to launch Defitelio in additional European countries on a rolling basis in 2015. A key challenge to our success in maintaining or growing sales of Defitelio in Europe is our ability to obtain appropriate pricing and reimbursement approvals in those European countries where Defitelio is not yet launched. If we experience delays or unforeseen difficulties in obtaining favorable pricing and reimbursement approvals, planned launches in the affected countries would be delayed, or, if we are unable to ultimately obtain favorable pricing and reimbursement approvals in countries that represent significant markets, especially where a country’s reimbursed price influences other countries, our growth prospects in Europe could be negatively affected.
	We are also engaged in activities related to the potential approval of defibrotide in the United States. We initiated a rolling submission of a new drug application, or NDA, to the FDA for defibrotide for the treatment of severe hepatic veno-occlusive disease, or VOD, in December 2014 and expect to complete the submission in mid-2015. We do not expect to be required to complete any additional clinical trials prior to completion of the NDA submission. However, we may be unable to acquire and remediate key information to be included in the data package for the NDA in a timely manner or our analysis of such information may not support submission, which would delay or preclude the completion of our NDA submission, and we may be unable to otherwise obtain regulatory approval of defibrotide in the United States in a timely manner, if at all. We also face other challenges that could impact the anticipated value of Defitelio/defibrotide, including the limited size of the population of patients who undergo hematopoietic stem cell transplantation, or HSCT, therapy and develop severe VOD, the need to establish U.S. pricing and reimbursement support for the product in the event we are able to obtain U.S. marketing approval for defibrotide, the possibility that we may be required to conduct time-consuming and costly clinical trials as a condition of any U.S. marketing approval for the product, the lack of experience of U.S. physicians in diagnosing and treating VOD, and challenges to our ability to develop the product for indications in addition to the treatment of severe VOD. If sales of Defitelio/defibrotide do not reach the levels we expect, our anticipated revenue from the product would be negatively affected, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
	In addition to risks specifically related to Xyrem, Erwinaze and Defitelio/defibrotide, we are subject to other challenges and risks specific to our business, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including: the challenges of protecting and enhancing our intellectual property rights; delays or problems in the supply or manufacture of our products, particularly with respect to certain products as to which we maintain limited inventories, including products for which our supply demands are growing, and our dependence on single source suppliers to continue to meet our ongoing commercial demand or our requirements for clinical trial supplies; the need to obtain and maintain appropriate pricing and reimbursement for our products in an increasingly challenging environment due to, among other things, the attention being paid to healthcare cost containment and other austerity measures in the United States and worldwide, including the need to obtain and maintain reimbursement for Xyrem in the United States in an environment in which we are subject to increasingly restrictive conditions for reimbursement required by third party payors; and the challenges of compliance with the requirements of the FDA, the U.S. Drug Enforcement Administration, or DEA, and non-U.S. regulatory agencies, including with respect to product labeling, requirements for distribution, obtaining sufficient DEA quotas where needed, marketing and promotional activities, adverse event reporting and product recalls or withdrawals.
	Other risks and uncertainties related to our ability to execute on our strategy include: the challenges of achieving and maintaining commercial success of our products, such as obtaining sustained acceptance of our products by patients, physicians and payors; the risks associated with business combination or product or product candidate acquisition transactions, such as the challenges inherent in the integration of acquired businesses with our historic business, the increase in geographic dispersion among our centers of operation, taking on the operation of a manufacturing plant as a result of the Gentium Acquisition, and the risks that we may acquire unanticipated liabilities along with acquired businesses or otherwise fail to realize the anticipated benefits (commercial or otherwise) from such transactions; the difficulty and uncertainty of pharmaceutical product development, including the timing thereof, and the uncertainty of clinical success, such as the risk that results from preclinical studies and/or early clinical trials may not be predictive of results obtained in later and larger clinical trials planned or anticipated to be conducted for our product candidates; the inherent uncertainty associated with the regulatory approval process, especially as we continue to undertake increased activities and make growing investment in our product pipeline development projects; our ability to identify and acquire, in-license or develop additional products or product candidates to grow our business; and possible restrictions on our ability and flexibility to pursue certain future opportunities as a result of our substantial outstanding debt obligations, which increased significantly in 2014.
Business Acquisitions	Business Acquisitions
	Our consolidated financial statements include the results of operations of an acquired business from the date of acquisition. We account for acquired businesses using the acquisition method of accounting. The acquisition method of accounting for acquired businesses requires, among other things, that assets acquired, liabilities assumed and any noncontrolling interests in the acquired business be recognized at their estimated fair values as of the acquisition date, with limited exceptions, and that the fair value of acquired IPR&D be recorded on the balance sheet. Also, transaction costs are expensed as incurred. Any excess of the acquisition consideration over the assigned values of the net assets acquired is recorded as goodwill. Contingent consideration is included within the acquisition cost and is recognized at its fair value on the acquisition date. A liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved and changes in fair value are recognized in earnings.
Concentrations Of Risk	Concentrations of Risk
	Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents and marketable securities. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities and issuers of investments to the extent recorded on the balance sheet.
	We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the United States, and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on our financial position, liquidity or results of operations. As of December 31, 2014, five customers accounted for 86% of gross accounts receivable including Express Scripts Specialty Distribution Services, Inc. and its affiliate CuraScript, Inc., or Express Scripts, which accounted for 66% of gross accounts receivable and IDIS Limited, which accounted for 11% of gross accounts receivable. As of December 31, 2013, five customers accounted for 85% of gross accounts receivable including Express Scripts which accounted for 69% of gross accounts receivable and Accredo Health Group, Inc. which accounted for 9% of gross accounts receivable.
	We depend on single source suppliers and manufacturers for each of our products, product candidates and their active pharmaceutical ingredients.
Cash Equivalents And Marketable Securities	Cash Equivalents and Marketable Securities
	We consider all highly liquid investments, readily convertible to cash, that mature within three months or less from date of purchase to be cash equivalents.
	Marketable securities are investments in debt securities with maturities of less than one year from the balance sheet date, or securities with maturities of greater than one year that are specifically identified to fund current operations. Collectively, cash equivalents and marketable securities are considered available-for-sale and are recorded at fair value. Unrealized gains and losses, net of tax, are recorded in accumulated other comprehensive income (loss) in shareholders’ equity. We use the specific-identification method for calculating realized gains and losses on securities sold. Realized gains and losses and declines in value judged to be other than temporary on marketable securities are included in interest expense, net in the consolidated statements of income. Realized gains and losses on sales of marketable securities have not been significant.
Inventories	Inventories
	Inventories are valued at the lower of cost or market. Cost is determined using the first-in, first-out method for all inventories. Our policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected requirements. The estimate of excess quantities is subjective and primarily dependent on our estimates of future demand for a particular product. If our estimate of future demand changes, we consider the impact on the reserve for excess inventory and adjust the reserve as required. Increases in the reserve are recorded as charges in cost of product sales. For product candidates that have not been approved by the FDA, inventory used in clinical trials is expensed at the time of production and recorded as research and development expense. For products that have been approved by the FDA, inventory used in clinical trials is expensed at the time the inventory is packaged for the clinical trial. Prior to receiving FDA approval, costs related to purchases of the active pharmaceutical ingredient and the manufacturing of the product candidate are recorded as research and development expense. All direct manufacturing costs incurred after approval are capitalized into inventory.
Property And Equipment	Property and Equipment
	Property and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from three to 10 years. Leasehold improvements are amortized over the shorter of the noncancelable term of our operating leases or their economic useful lives. Maintenance and repairs are expensed as incurred.
Goodwill, Acquired In-Process Research and Development, And Intangible Assets	Goodwill
	Goodwill represents the excess of the acquisition consideration over the fair value of assets acquired and liabilities assumed. We have determined that we operate in a single segment and have a single reporting unit associated with the development and commercialization of pharmaceutical products. The annual test for goodwill impairment is a two-step process. The first step is a comparison of the fair value of the reporting unit with its carrying amount, including goodwill. If this step indicates impairment, then, in the second step, the loss is measured as the excess of recorded goodwill over its implied fair value. Implied fair value is the excess of the fair value of the reporting unit over the fair value of all identified assets and liabilities. We test goodwill for impairment annually in October and when events or changes in circumstances indicate that the carrying value may not be recoverable.
	Acquired In-Process Research and Development
	The initial costs of rights to IPR&D projects acquired in an asset acquisition are expensed as IPR&D unless the project has an alternative future use. The fair value of IPR&D projects acquired in a business combination are capitalized and accounted for as indefinite-lived intangible assets until the underlying project receives regulatory approval, at which point the intangible asset will be accounted for as a finite-lived intangible asset, or discontinued, at which point the intangible asset will be written off. Development costs incurred after an acquisition are expensed as incurred.
	Intangible Assets
	Intangible assets with finite useful lives consist primarily of purchased developed technology and are amortized on a straight-line basis over their estimated useful lives, which range from two to 16 years. The estimated useful lives associated with finite-lived intangible assets are consistent with the estimated lives of the associated products and may be modified when circumstances warrant. Such assets are reviewed for impairment when events or circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset and its eventual disposition are less than its carrying amount. The amount of any impairment is measured as the difference between the carrying amount and the fair value of the impaired asset.
Revenue Recognition	Revenue Recognition
	Revenues are recognized when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed and determinable and collection is reasonably assured.
	Product Sales, Net
	Product sales revenue is recognized when title has transferred to the customer and the customer has assumed the risks and rewards of ownership, which is typically on delivery to the customer or, in the case of products that are subject to consignment agreements, when the customer removes product from our consigned inventory location for shipment directly to a patient.
	Revenue from sales transactions where the buyer has the right to return the product is recognized at the time of sale only if (i) the seller’s price to the buyer is substantially fixed or determinable at the date of sale, (ii) the buyer has paid the seller, or the buyer is obligated to pay the seller and the obligation is not contingent on resale of the product, (iii) the buyer’s obligation to the seller would not be changed in the event of theft or physical destruction or damage of the product, (iv) the buyer acquiring the product for resale has economic substance apart from that provided by the seller, (v) the seller does not have significant obligations for future performance to directly bring about resale of the product by the buyer, and (vi) the amount of future returns can be reasonably estimated.
	Revenues from sales of products are recorded net of estimated allowances for returns, specialty distributor fees, wholesaler fees, prompt payment discounts, government rebates, government chargebacks, coupon programs and rebates under managed care plans. Provisions for returns, specialty distributor fees, wholesaler fees, government rebates, coupon programs and rebates under managed care plans are included within current liabilities in our consolidated balance sheets. Provisions for government chargebacks and prompt payment discounts are generally shown as a reduction in accounts receivable. Calculating certain of these items involves estimates and judgments based on sales or invoice data, contractual terms, historical utilization rates, new information regarding changes in these programs’ regulations and guidelines that would impact the amount of the actual rebates, our expectations regarding future utilization rates for these programs and channel inventory data. Adjustments to estimates for these allowances have not been material.
	Royalties and Contract Revenues
	We receive royalties from third parties based on sales of our products under licensing and distribution arrangements. For those arrangements where royalties are reasonably estimable, we recognize revenues based on estimates of royalties earned during the applicable period, and adjust for differences between the estimated and actual royalties in the following quarter. Historically, these adjustments have not been significant.
	Our contract revenues consist of fees and milestone payments. Non-refundable fees where we have no continuing performance obligations are recognized as revenues when there is persuasive evidence of an arrangement and collection is reasonably assured. In situations where we have continuing performance obligations, non-refundable fees are deferred and are recognized ratably over our projected performance period. We recognize at-risk milestone payments, which are typically related to regulatory, commercial or other achievements by us or our licensees and distributors, as revenues when the milestone is accomplished and collection is reasonably assured. Sales-based milestone payments are typically payments made to us that are triggered when aggregate net sales of a product by a collaborator for a specified period (for example, an annual period) reach an agreed upon threshold amount. We recognize sales-based milestone payments from a collaborator when the event which triggers the obligation of payment has occurred, there is no further obligation on our part in connection with the payment, and collection is reasonably assured. Refundable fees are deferred and recognized as revenues upon the later of when they become nonrefundable or when our performance obligations are completed.
Cost Of Product Sales	Cost of Product Sales
	Cost of product sales includes third party manufacturing and distribution costs, the cost of drug substance, royalties due to third parties on product sales, product liability and cargo insurance, FDA user fees, freight, shipping, handling and storage costs and salaries and related costs of employees involved with production.
Research And Development	Research and Development
	Research and development expenses consist primarily of personnel expenses, costs related to clinical studies and outside services, and other research and development costs. Personnel expenses relate primarily to salaries, benefits and share-based compensation. Clinical study and outside services costs relate primarily to services performed by clinical research organizations, clinical studies performed at clinical sites, materials and supplies, and other third-party fees. Other research and development expenses primarily include overhead allocations consisting of various support and facilities-related costs. Research and development costs are expensed as incurred. For product candidates that have not been approved by the FDA, inventory used in clinical trials is expensed at the time of production and recorded as research and development expense. For products that have been approved by the FDA, inventory used in clinical trials is expensed at the time the inventory is packaged for the trial.
Advertising Expenses	Advertising Expenses
	We expense the costs of advertising, including promotional expenses, as incurred.
Income Taxes	Income Taxes
	We use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amount and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more-likely-than-not that some portion or all of a deferred tax asset will not be realized. We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. A recognized tax position is then measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon settlement. Interest and penalties related to uncertain tax positions are included in the income tax provision (benefit) and classified with the related liability on the consolidated balance sheets.
Foreign Currency	Foreign Currency
	Our functional and reporting currency is the U.S. dollar. The assets and liabilities of our subsidiaries that have a functional currency other than the U.S. dollar are translated into U.S. dollars at the exchange rate prevailing at the balance sheet date with the results of operations of subsidiaries translated at the average exchange rate for the reporting period. The cumulative foreign currency translation adjustment is recorded as a component of accumulated other comprehensive income (loss) in shareholders’ equity.
	Transactions in foreign currencies are translated into the functional currency of the relevant subsidiary at the rate of exchange prevailing at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the relevant functional currency at exchange rates prevailing at the balance sheet date or on settlement. Resulting gains and losses are recorded in foreign currency gain (loss) in our consolidated statements of income.
Financing Costs	Financing Costs
	Deferred financing costs are reported at cost, less accumulated amortization and the related amortization expense is included in interest expense, net in our consolidated statements of income. The carrying amount of debt includes any related unamortized original issue discount.
Contingencies	Contingencies
	From time to time, we may become involved in claims and other legal matters arising in the ordinary course of business. We record accruals for loss contingencies to the extent that we conclude that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. Legal fees and other expenses related to litigation are expensed as incurred and included in selling, general and administrative expenses.
Use Of Estimates	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.
Net Income per Ordinary Share	Net Income per Ordinary Share
	Basic net income per ordinary share attributable to Jazz Pharmaceuticals plc is based on the weighted-average number of ordinary shares outstanding. Diluted net income per ordinary share attributable to Jazz Pharmaceuticals plc is based on the weighted-average number of ordinary shares outstanding and potentially dilutive ordinary shares outstanding.
	Basic and diluted net income per ordinary share attributable to Jazz Pharmaceuticals plc were computed as follows (in thousands, except per share amounts):
		Year Ended December 31,
		2014				2013			2012
	Numerator:
	Income from continuing operations	$	57,326			$	216,312		$	261,149
	Loss from continuing operations attributable to noncontrolling interests, net of tax	(1,061		)		—			—
	Income from continuing operations attributable to Jazz Pharmaceuticals plc	58,387				216,312			261,149
	Income from discontinued operations	—				—			27,437
	Net income attributable to Jazz Pharmaceuticals plc	$	58,387			$	216,312		$	288,586
	Denominator:
	Weighted-average ordinary shares used in calculating net income per ordinary share attributable to Jazz Pharmaceuticals plc - basic	59,746				58,298			56,643
	Dilutive effect of employee equity incentive and purchase plans	2,402				1,772			1,536
	Dilutive effect of warrants	466				1,499			2,016
	Weighted-average ordinary shares used in calculating net income per ordinary share attributable to Jazz Pharmaceuticals plc - diluted	62,614				61,569			60,195
	Net income per ordinary share attributable to Jazz Pharmaceuticals plc:
	Basic:
	Income from continuing operations	$	0.98			$	3.71		$	4.61
	Income from discontinued operations	—				—			0.48
	Net income attributable to Jazz Pharmaceuticals plc	$	0.98			$	3.71		$	5.09
	Diluted:
	Income from continuing operations	$	0.93			$	3.51		$	4.34
	Income from discontinued operations	—				—			0.45
	Net income attributable to Jazz Pharmaceuticals plc	$	0.93			$	3.51		$	4.79
	Potentially dilutive ordinary shares from our employee equity incentive and purchase plans, warrants and exchangeable senior notes are determined by applying the treasury stock method to the assumed exercise of share options and warrants, the assumed vesting of outstanding restricted stock units, or RSUs, the assumed issuance of ordinary shares under our employee stock purchase plan, or ESPP, and the assumed issuance of ordinary shares upon exchange of our exchangeable senior notes. The approximately 2.9 million ordinary shares issuable upon exchange of our exchangeable senior notes had no effect on diluted net income per ordinary share attributable to Jazz Pharmaceuticals plc because the average price of our ordinary shares for the year ended December 31, 2014 did not exceed the effective exchange price of $199.77 per ordinary share. For additional information relating to our exchangeable senior notes, see Note 9.
	The following table represents the weighted-average ordinary shares that were excluded from the computation of diluted net income per ordinary share attributable to Jazz Pharmaceuticals plc for the periods presented because including them would have an anti-dilutive effect (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Options to purchase ordinary shares and RSUs	819			1,584			1,506
	1.875% exchangeable senior notes due 2021	1,112			—			—
Share-Based Compensation	Share-Based Compensation
	We account for compensation cost for all share-based awards at fair value on the date of grant. The fair value is recognized as expense over the service period, net of estimated forfeitures, using the straight-line method. The estimation of share-based awards that will ultimately vest requires judgment, and, to the extent actual results or updated estimates differ from current estimates, such amounts will be recorded as a cumulative adjustment in the period estimates are revised. We primarily consider historical experience when estimating expected forfeitures.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, No. 2014-09, “Revenue from Contracts with Customers”, or ASU No. 2014-09, which states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this, an entity will need to identify the contract with a customer; identify the separate performance obligations in the contract; determine the transaction price; allocate the transaction price to the separate performance obligations in the contract; and recognize revenue when (or as) the entity satisfies each performance obligation. ASU No. 2014-09 will be effective for us beginning January 1, 2017 and can be adopted on a full retrospective basis or on a modified retrospective basis. We are currently assessing our approach to the adoption of this standard and the impact on our results of operations and financial position.
	In April 2014, the FASB issued ASU No. 2014-08, “Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity”, or ASU 2014-08. Under ASU 2014-08, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Additionally, ASU 2014-08 requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. ASU 2014-08 is effective for fiscal and interim periods beginning on or after December 15, 2014, with early adoption permitted. We early adopted ASU 2014-08 in 2014. Please see Note 18 for additional information.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule Of Net Income per Ordinary Share	Basic and diluted net income per ordinary share attributable to Jazz Pharmaceuticals plc were computed as follows (in thousands, except per share amounts):
		Year Ended December 31,
		2014				2013			2012
	Numerator:
	Income from continuing operations	$	57,326			$	216,312		$	261,149
	Loss from continuing operations attributable to noncontrolling interests, net of tax	(1,061		)		—			—
	Income from continuing operations attributable to Jazz Pharmaceuticals plc	58,387				216,312			261,149
	Income from discontinued operations	—				—			27,437
	Net income attributable to Jazz Pharmaceuticals plc	$	58,387			$	216,312		$	288,586
	Denominator:
	Weighted-average ordinary shares used in calculating net income per ordinary share attributable to Jazz Pharmaceuticals plc - basic	59,746				58,298			56,643
	Dilutive effect of employee equity incentive and purchase plans	2,402				1,772			1,536
	Dilutive effect of warrants	466				1,499			2,016
	Weighted-average ordinary shares used in calculating net income per ordinary share attributable to Jazz Pharmaceuticals plc - diluted	62,614				61,569			60,195
	Net income per ordinary share attributable to Jazz Pharmaceuticals plc:
	Basic:
	Income from continuing operations	$	0.98			$	3.71		$	4.61
	Income from discontinued operations	—				—			0.48
	Net income attributable to Jazz Pharmaceuticals plc	$	0.98			$	3.71		$	5.09
	Diluted:
	Income from continuing operations	$	0.93			$	3.51		$	4.34
	Income from discontinued operations	—				—			0.45
	Net income attributable to Jazz Pharmaceuticals plc	$	0.93			$	3.51		$	4.79
Schedule Of Computation Of Diluted Net Income (Loss) Per Share Having Anti-Dilutive Effect	The following table represents the weighted-average ordinary shares that were excluded from the computation of diluted net income per ordinary share attributable to Jazz Pharmaceuticals plc for the periods presented because including them would have an anti-dilutive effect (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Options to purchase ordinary shares and RSUs	819			1,584			1,506
	1.875% exchangeable senior notes due 2021	1,112			—			—

Business_Combination_and_Asset1

Business Combination and Asset Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Summary of acquisition consideration given	The acquisition consideration (not including the acquisition cost of $119.2 million to acquire the 12% noncontrolling interests in the subsequent offering period of the tender offer and the acquisition cost of $17.8 million to acquire the 1.8% noncontrolling interests later in 2014) was comprised of (in thousands):
	Cash consideration for shares acquired in initial tender offer period	$	697,917
	Liability for shares committed under guaranteed delivery procedures	76,666
	Liability for options committed for exercise	82,503
	Total acquisition consideration	$	857,086
Summary of assets and liabilities assumed in acquisition	The fair values of assets acquired and liabilities assumed at the closing date of the Gentium Acquisition, and the fair value of the noncontrolling interests in Gentium at the dates they were acquired, are summarized below (in thousands):
	Cash and cash equivalents	$	28,410
	Short-term deposit	5,418
	Accounts receivable (1)	13,855
	Inventories	13,525
	Prepaid and other current assets	1,383
	Intangible assets	960,350
	Goodwill	308,642
	Deferred tax assets	22,999
	Property, plant and equipment	10,201
	Other long-term assets	431
	Accounts payable	(11,778		)
	Accrued expenses	(51,477		)
	Income taxes payable	(502		)
	Other long-term liabilities	(654		)
	Debt (current and long-term)	(2,351		)
	Deferred tax liabilities	(304,788		)
	Noncontrolling interests	(136,578		)
	Total acquisition consideration	$	857,086
	___________________
	-1	The estimated fair value of trade receivables acquired was $13.9 million and the gross contractual amount was $14.9 million, of which we expect that $1.0 million will be uncollectible.
Summary of intangible assets acquired	The intangible assets as of the closing date of the Gentium Acquisition included (in thousands):
	Finite-lived intangible assets:
	Currently marketed product:
	Defibrotide VOD (Non Americas)	$	719,500
	Manufacturing contracts	14,500
	Tradename	350
	Total finite-lived intangible assets	734,350
	IPR&D:
	Defibrotide VOD Prophylaxis	168,000
	Defibrotide VOD (Americas)	58,000
	Total IPR&D	226,000
	Total intangible assets	$	960,350
Summary of pro forma information	The unaudited pro forma results do not assume any operating efficiencies as a result of the consolidation of operations and are as follows (in thousands, except per share data):
		Year Ended
		December 31,
		2014			2013
	Revenues	$	1,176,178		$	925,185
	Net income attributable to Jazz Pharmaceuticals plc	$	82,802		$	181,318
	Net income per ordinary share attributable to Jazz Pharmaceuticals plc - basic	$	1.39		$	3.11
	Net income per ordinary share attributable to Jazz Pharmaceuticals plc - diluted	$	1.32		$	2.94

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Schedule Of Available-For-Sale Securities	Cash and cash equivalents consisted of the following (in thousands):
		31-Dec-14
		Amortized		Gross		Gross		Estimated		Cash and Cash Equivalents
		Cost		Unrealized		Unrealized		Fair Value
				Gains		Losses
	Cash	$	338,262	$	—	$	—	$	338,262	$	338,262
	Time deposits	345,780		—		—		345,780		345,780
	Totals	$	684,042	$	—	$	—	$	684,042	$	684,042
		31-Dec-13
		Amortized		Gross		Gross		Estimated		Cash and
		Cost		Unrealized		Unrealized		Fair Value		Cash
				Gains		Losses				Equivalents
	Cash	$	495,990	$	—	$	—	$	495,990	$	495,990
	Time deposits	140,514		—		—		140,514		140,514
	Totals	$	636,504	$	—	$	—	$	636,504	$	636,504
Schedule Of Available-For-Sale Investments Measured At Fair Value On Recurring Basis	The following table summarizes, by major security type, our available-for-sale securities and liabilities that were measured at fair value on a recurring basis and were categorized using the fair value hierarchy (in thousands):
		31-Dec-14				31-Dec-13
		Significant		Total		Significant		Total
		Other		Estimated		Other		Estimated
		Observable		Fair Value		Observable		Fair Value
		Inputs				Inputs
		(Level 2)				(Level 2)
	Assets:
	Available-for-sale securities
	Time deposits	$	345,780	$	345,780	$	140,514	$	140,514
	Liabilities:
	Contingent consideration	$	—	$	—	$	50,000	$	50,000

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Components of Inventories	Inventories consisted of the following (in thousands):
		December 31,
		2014		2013
	Raw materials	$	3,570	$	3,506
	Work in process	9,870		10,301
	Finished goods	16,597		14,862
	Total inventories	$	30,037	$	28,669

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Schedule Of Property And Equipment	Property and equipment consisted of the following (in thousands):
		December 31,
		2014			2013
	Construction-in-progress	$	37,145		$	4,388
	Computer software	10,634			7,960
	Leasehold improvements	7,931			4,587
	Computer equipment	7,670			5,610
	Machinery and equipment	6,408			417
	Furniture and fixtures	2,220			1,897
	Land and buildings	1,547			—
	Subtotal	73,555			24,859
	Less accumulated depreciation and amortization	(15,192		)	(10,613		)
	Property and equipment, net	$	58,363		$	14,246

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consisted of the following (in thousands):
		December 31,
		2014		2013
	Rebates and other sales deductions	$	51,899	$	38,772
	Employee compensation and benefits	46,143		31,829
	Sales returns reserve	14,039		21,110
	Accrued interest	10,327		4,150
	Royalties	7,964		6,082
	Accrued construction-in-progress	4,931		450
	Professional fees	3,295		5,225
	Other	25,493		12,100
	Total accrued liabilities	$	164,091	$	119,718

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule Of Gross Carrying Amount Of Goodwill	The gross carrying amount of goodwill was as follows (in thousands):
	Balance at December 31, 2013	$	450,456
	Goodwill arising from the Gentium Acquisition	308,642
	Goodwill allocated to assets held for sale (1)	(1,686		)
	Foreign exchange	(54,699		)
	Balance at December 31, 2014	$	702,713
	_________________________
	-1	In December 2014, we entered into a definitive agreement to sell certain products and related assets. See Note 18 for information regarding assets held for sale.
Schedule Of Gross Carrying Amounts And Net Book Values Of Intangible Assets	The gross carrying amounts and net book values of our intangible assets were as follows (in thousands):
		December 31, 2014									December 31, 2013
		Remaining		Gross		Accumulated			Net Book		Gross		Accumulated			Net Book
		Weighted-		Carrying		Amortization			Value		Carrying		Amortization			Value
		Average Useful		Amount							Amount
		Life
		(In years)
	Acquired developed technologies	12.9		$	1,450,606	$	(259,889	)	$	1,190,717	$	957,089	$	(179,225	)	$	777,864
	Manufacturing contracts	3.1		13,012		(3,060		)	9,952		—		—			—
	Trademarks	0.1		2,914		(2,896		)	18		2,600		(2,327		)	273
	Total finite-lived intangible assets			1,466,532		(265,845		)	1,200,687		959,689		(181,552		)	778,137
	Acquired IPR&D assets			236,748		—			236,748		34,259		—			34,259
	Total intangible assets			$	1,703,280	$	(265,845	)	$	1,437,435	$	993,948	$	(181,552	)	$	812,396
Schedule Of Estimated Future Amortization Costs	Based on finite-lived intangible assets recorded as of December 31, 2014, and assuming the underlying assets will not be further impaired and that we will not change the expected lives of the assets, future amortization expenses were estimated as follows (in thousands):
	Year Ending December 31,	Estimated Amortization Expense
	2015	$	102,508
	2016	99,167
	2017	99,167
	2018	95,313
	2019	95,071
	Thereafter	709,461
	Total	$	1,200,687

Debt_Tables

Debt (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Schedule of long-term debt	The following table summarizes the carrying amount of our indebtedness (in thousands):
		December 31,
		2014			2013
	1.875% exchangeable senior notes due 2021	$	575,000		$	—
	Unamortized discount on 1.875% exchangeable senior notes due 2021	(124,735		)	—
	1.875% exchangeable senior notes due 2021, net	450,265			—
	Term loans	890,479			549,976
	Other borrowings	1,684			—
	Total debt	1,342,428			549,976
	Less current portion	9,428			5,572
	Total long-term debt	$	1,333,000		$	544,404
Schedule of maturities of long-term debt	Scheduled maturities with respect to our long-term debt are as follows (in thousands):
	Year Ending December 31,	Scheduled Long-Term Debt Maturities
	2015	$	9,428
	2016	9,433
	2017	9,438
	2018	868,479
	2019	114
	Thereafter	575,150
	Total	$	1,472,042

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule Of Lease Expense Under Operating Leases	Lease expense under our operating leases was as follows (in thousands):
		Year Ended December 31,
		2014		2013		2012
	Lease expense	$	10,678	$	9,114	$	5,303
Schedule Of Future Minimum Lease Payments Under Noncancelable Operating Leases	Future minimum lease payments under our noncancelable operating leases at December 31, 2014, were as follows (in thousands):
	Year ending December 31,	Lease
		Payments
	2015	$	10,165
	2016	7,852
	2017	4,915
	2018	1,443
	2019	671
	Thereafter	—
	Total	$	25,046

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Schedule of Authorized But Unissued Ordinary Shares	We had reserved the following shares of authorized but unissued ordinary shares (in thousands):
		December 31, 2014
	2011 Equity Incentive Plan	10,143
	2007 Equity Incentive Plan	962
	2007 Employee Stock Purchase Plan	587
	Amended and Restated 2007 Non-Employee Directors Stock Option Plan	419
	Amended and Restated Directors Deferred Compensation Plan	178
	Total	12,289

Comprehensive_Income_Loss_Tabl

Comprehensive Income (Loss) (Tables)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Components of Accumulated Other Comprehensive Income/(Loss)	The components of accumulated other comprehensive income (loss) attributable to Jazz Pharmaceuticals plc at December 31, 2014 and December 31, 2013 were as follows (in thousands):
		Foreign Currency Translation Adjustments			Total Accumulated Other Comprehensive Income (Loss)
	Balance at December 31, 2013	$	56,153		$	56,153
	Other comprehensive loss	(178,250		)	(178,250		)
	Balance at December 31, 2014	$	(122,097	)	$	(122,097	)

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model and Resulting Weighted-Average Grant Date Fair Value of Share Options Granted	The table below shows, for all share option grants, the weighted-average assumptions used in the Black-Scholes option pricing model and the resulting weighted-average grant date fair value of share options granted in each of the past three years:
		Year Ended December 31,
		2014				2013				2012
	Grant date fair value	$	60.29			$	29.09			$	25.28
	Volatility	45		%		58		%		64		%
	Expected term (years)	4.3				4.4				4.6
	Range of risk-free rates	1.1-1.4%				0.5-1.4%				0.5-1.1%
	Expected dividend yield	—		%		—		%		—		%
Schedule of Share-Based Compensation Expense Related to Share Options, RSUs, and Grants under ESPP	Share-based compensation expense in continuing operations related to share options, RSUs and grants under our ESPP was as follows (in thousands):
		Year Ended December 31,
		2014				2013				2012
	Selling, general and administrative	$	55,083			$	35,674			$	18,950
	Research and development	12,179				6,673				2,640
	Cost of product sales	2,376				2,204				1,416
	Total share-based compensation expense, pre-tax	69,638				44,551				23,006
	Tax benefit from share-based compensation expense	(20,795		)		(13,822		)		(7,499		)
	Total share-based compensation expense, net of tax	$	48,843			$	30,729			$	15,507
Schedule of Information and Activity Related to Share Option Plans Activity	The following table summarizes information as of December 31, 2014 and activity during 2014 related to our share option plans:
		Shares			Weighted-				Weighted-		Aggregate
		Subject to			Average				Average		Intrinsic
		Outstanding			Exercise				Remaining		Value
		Options			Price				Contractual		(In thousands)
		(In thousands)							Term (Years)
	Outstanding at January 1, 2014	4,306			$	42.54
	Options granted	1,000			160.4
	Options exercised	(1,185	)		36.33
	Options forfeited	(251	)		75.08
	Options expired	—			—
	Outstanding at December 31, 2014	3,870			72.77				7.6		$	354,050
	Vested and expected to vest at December 31, 2014	3,632			70.29				7.5		341,118
	Exercisable at December 31, 2014	1,639			36.61				6.5		208,339
Schedule of Information and Activity Related to RSUs Activity	The following table summarizes information as of December 31, 2014 and activity during 2014 related to our RSUs:
		Number of RSUs (in thousands)			Weighted-				Weighted-		Aggregate
					Average				Average		Intrinsic
					Grant-Date				Remaining		Value
					Fair Value				Contractual		(In thousands)
									Term (Years)
	Outstanding at January 1, 2014	1,164			$	55.28
	RSUs granted	488			160.45
	RSUs released	(344	)		55.3
	RSUs forfeited	(120	)		75.43
	RSUs expired	—			—
	Outstanding at December 31, 2014	1,188			96.41				1.3		$	194,546

Segment_and_Other_Information_

Segment and Other Information (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Summary Of Total Revenues	The following table presents a summary of total revenues (in thousands):
		Year Ended December 31,
		2014			2013				2012
	Xyrem	$	778,584		$	569,113			$	378,663
	Erwinaze/Erwinase	199,665			174,251				72,083
	Defitelio/defibrotide	70,537			—				—
	Prialt® (ziconotide) intrathecal infusion	26,421			27,103				26,360
	Psychiatry	40,879			49,226				76,489
	Other	46,630			45,705				26,932
	Product sales, net	1,162,716			865,398				580,527
	Royalties and contract revenues	10,159			7,025				5,452
	Total revenues	$	1,172,875		$	872,423			$	585,979
Summary Of Total Revenues Attributed To Geographic Sources	The following table presents a summary of total revenues attributed to geographic sources (in thousands):
		Year Ended December 31,
		2014			2013				2012
	United States	$	1,007,396		$	792,518			$	538,219
	Europe	126,715			61,843				38,590
	All other	38,764			18,062				9,170
	Total revenues	$	1,172,875		$	872,423			$	585,979
Summary Of Revenues From Customers Representing More Then 10% Of Total Revenues	The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues:
		Year Ended December 31,
		2014		2013			2012
	Express Scripts	66	%	65	%		64	%
	Accredo	14	%	16	%		N/A
Total Long-Lived Assets by Location	The following table presents total long-lived assets by location (in thousands):
		December 31,
		2014			2013
	Ireland	$	37,775		$	5,799
	United States	9,795			7,734
	Italy	8,462			—
	Other	2,331			713
	Total long-lived assets	$	58,363		$	14,246
	_________________________
	-1	Long-lived assets consist of property and equipment.

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Components of Income from Continuing Operations before Income Tax Provision (Benefit)	The components of income from continuing operations before the income tax provision (benefit) were as follows (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Republic of Ireland	$	238,351		$	186,903		$	(73,949	)
	United States	222,328			132,855			250,348
	Other	(309,122		)	(11,808		)	956
	Total	$	151,557		$	307,950		$	177,355
Details of Income Tax Provision (Benefit)	The following table sets forth the details of the income tax provision (benefit) (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Current
	Republic of Ireland	$	23,506		$	17,089		$	(10,733	)
	United States	97,679			71,964			33,387
	Other	16,469			12,682			7,414
	Total current income tax	137,654			101,735			30,068
	Deferred
	Republic of Ireland	2,323			8,353			(315		)
	United States	(15,003		)	(3,513		)	(103,932		)
	Other	(30,743		)	(14,937		)	(9,615		)
	Total deferred income tax benefit	(43,423		)	(10,097		)	(113,862		)
	Total income tax provision (benefit)	$	94,231		$	91,638		$	(83,794	)
Reconciliation of Income Taxes at the Statutory Income Tax Rate to Effective Income Tax Rate	A reconciliation of income taxes at the statutory income tax rate to our effective income tax rate was as follows (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Statutory income tax rate	12.5		%	12.5		%	12.5		%
	Income tax provision at statutory rate	$	18,945		$	38,494		$	22,169
	Acquisition-related costs	4,703			—			763
	Research and other tax credits	(14,234		)	(5,957		)	(100		)
	Non-deductible share-based compensation	4,203			2,497			873
	Foreign income tax rate differential	75,780			31,651			52,066
	Change in unrecognized tax benefits	9,447			8,685			2,249
	Prior period adjustments	(5,522		)	3,375			(2,524		)
	Change in valuation allowance	9,006			3,220			(159,158		)
	Non-deductible contingent consideration	—			5,320			—
	Non-deductible financing costs	1,088			—			—
	Deduction on subsidiary equity	(11,403		)	—			—
	Non-deductible officers' compensation	2,715			1,528			—
	Other	(497		)	2,825			(132		)
	Income tax provision (benefit)	$	94,231		$	91,638		$	(83,794	)
	Effective income tax rate	62.2		%	29.8		%	(47.2		)%
Schedule of Net Deferred Tax Assets/(Liabilities)	Significant components of our net deferred tax assets/(liabilities) were as follows (in thousands):
		December 31,
		2014			2013
	Deferred tax assets:
	Net operating loss carryforwards	$	74,057		$	71,364
	Tax credit carryforwards	23,946			11,374
	Intangible assets	19,507			10,733
	Share-based compensation	14,033			8,116
	Accruals	36,157			30,730
	Deferred revenue and other	5,038			9,252
	Total deferred tax assets	172,738			141,569
	Valuation allowance	(29,697		)	(20,691		)
	Net deferred tax assets	143,041			120,878
	Deferred tax liabilities:
	Acquired intangible assets	(395,651		)	(176,576		)
	Other	(7,940		)	(10,848		)
	Total deferred tax liabilities	(403,591		)	(187,424		)
	Net deferred tax liabilities	$	(260,550	)	$	(66,546	)
	The following table presents the breakdown between current and non-current deferred tax assets/(liabilities) (in thousands):
		Year Ended December 31,
		2014			2013
	Current deferred tax assets	$	48,440		$	33,613
	Current deferred tax liabilities	(9,430		)	(6,259		)
	Non-current deferred tax assets	75,494			74,597
	Non-current deferred tax liabilities	(375,054		)	(168,497		)
	Net deferred tax liabilities	$	(260,550	)	$	(66,546	)
Reconciliation of Unrecognized Tax Benefits	A reconciliation of our unrecognized tax benefits follows (in thousands):
		December 31,
		2014			2013			2012
	Balance at the beginning of the year	$	21,637		$	7,288		$	3,764
	Increases related to current year tax positions	19,837			14,308			3,492
	Increases related to prior year tax positions	—			183			40
	Decreases related to prior year tax positions	(672		)	(142		)	(8		)
	Balance at the end of the year	$	40,802		$	21,637		$	7,288

Assets_Held_for_Sale_Tables

Assets Held for Sale (Tables)	12 Months Ended
	Dec. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]
Summary of assets held for sale	The following assets were segregated and classified as assets held for sale in the consolidated balance sheet as of December 31, 2014 (in thousands):
		31-Dec-14
	Inventories	$	4,693
	Accounts receivable	4,880
	Intangible assets, net	27,479
	Goodwill	1,686
	Other	654
	Valuation allowance	(6,559		)
	Assets held for sale	$	32,833
	Net revenue and income from discontinued operations were as follows (in thousands):
		Year Ended
		31-Dec-12
	Product sales, net	$	20,873
	Loss from discontinued operations before income taxes (1)	$	(5,787	)
	Income tax expense (1)	(2,020		)
	Loss from discontinued operations, net of taxes	(7,807		)
	Gain on sale of discontinued operations (2)	35,244
	Income from discontinued operations, net of taxes	$	27,437
	__________________________
	(1) The income tax expense related to profits generated by the women’s health business in 2012 which were attributable to the United States.
	(2) The gain on sale of discontinued operations was not impacted by income taxes as the value attributable to the women’s health business was held in a non-taxable jurisdiction.

Restructuring_Tables

Restructuring (Tables)	12 Months Ended
	Dec. 31, 2014
Restructuring and Related Activities [Abstract]
Schedule of restructuring amounts	The following table summarizes the amounts related to restructuring through December 31, 2014 (in thousands):
		Termination Benefits			Facility Closure Costs			Total
	Balance at December 31, 2011	$	—		$	—		$	—
	Costs incurred during the period	2,789			—			2,789
	Cash payments	(1,562		)	—			(1,562		)
	Balance at December 31, 2012	1,227			—			1,227
	Costs incurred during the period	1,045			412			1,457
	Cash payments	(2,272		)	(160		)	(2,432		)
	Balance at December 31, 2013	—			252			252
	Costs incurred during the period	1,823			118			1,941
	Cash payments	—			(252		)	(252		)
	Balance at December 31, 2014	$	1,823		$	118		$	1,941

Discontinued_Operations_Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]
Net revenue and income from discontinued operations	The following assets were segregated and classified as assets held for sale in the consolidated balance sheet as of December 31, 2014 (in thousands):
		31-Dec-14
	Inventories	$	4,693
	Accounts receivable	4,880
	Intangible assets, net	27,479
	Goodwill	1,686
	Other	654
	Valuation allowance	(6,559		)
	Assets held for sale	$	32,833
	Net revenue and income from discontinued operations were as follows (in thousands):
		Year Ended
		31-Dec-12
	Product sales, net	$	20,873
	Loss from discontinued operations before income taxes (1)	$	(5,787	)
	Income tax expense (1)	(2,020		)
	Loss from discontinued operations, net of taxes	(7,807		)
	Gain on sale of discontinued operations (2)	35,244
	Income from discontinued operations, net of taxes	$	27,437
	__________________________
	(1) The income tax expense related to profits generated by the women’s health business in 2012 which were attributable to the United States.
	(2) The gain on sale of discontinued operations was not impacted by income taxes as the value attributable to the women’s health business was held in a non-taxable jurisdiction.

Quarterly_Financial_Data_Unaud1

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Schedule Of Interim Financial Information Of Results Of Operations On Quarterly Basis	The following interim financial information presents our 2014 and 2013 results of operations on a quarterly basis (in thousands, except per share amounts):
		2014
		31-Mar			30-Jun		30-Sep		31-Dec
	Revenues	$	246,919		$	291,230	$	306,584	$	328,142
	Gross margin (1)	214,062			258,408		277,413		295,415
	Net income (loss) attributable to Jazz Pharmaceuticals plc	(92,650		)	43,659		25,766		81,612
	Net income (loss) per ordinary share attributable to Jazz Pharmaceuticals plc, basic	(1.58		)	0.73		0.43		1.35
	Net income (loss) per ordinary share attributable to Jazz Pharmaceuticals plc, diluted	(1.58		)	0.7		0.41		1.3
		2013
		March 31			June 30		September 30		December 31
	Revenues	$	196,237		$	208,252	$	232,160	$	235,774
	Gross margin (1)	167,432			181,533		206,134		208,153
	Net income	43,425			42,185		75,409		55,293
	Net income per share, basic	0.74			0.72		1.3		0.96
	Net income per share, diluted	0.71			0.69		1.23		0.9
	__________________________
	-1	Gross margin excludes amortization of acquired developed technology of $30.3 million, $31.7 million, $29.6 million and $31.0 million in the first, second, third and fourth quarters of 2014, respectively, and $19.5 million, $19.3 million, $19.5 million and $20.5 million in the first, second, third and fourth quarters of 2013, respectively.

Organization_and_Description_o1

Organization and Description of Business (Details) (USD $)	12 Months Ended			10 Months Ended	0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Feb. 20, 2014
Business Acquisition [Line Items]
Acquisition cost of noncontrolling interest	$136,969,000	$0	$0
Gentium [Member]
Business Acquisition [Line Items]
Additional ownership interest acquired, percentage				1.80%
Acquisition cost of noncontrolling interest				17,800,000
Net acquisition consideration	994,100,000
Total acquisition consideration, including subsequent acquisition	1,011,200,000
Proceeds from exercise of acquired share options	$17,100,000
Gentium [Member] | Ordinary Shares and American Depositary Shares [Member]
Business Acquisition [Line Items]
Total ownership interest acquired, percentage					98.00%
Additional ownership interest acquired, percentage					12.00%

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Narrative) (Details) (USD $)	12 Months Ended			3 Months Ended
Share data in Millions, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Aug. 31, 2014
	Customer	Customer
Summary Of Significant Accounting Policies [Line Items]
Product sales, net	$1,162,716,000	$865,398,000	$580,527,000
Number of customer with significant accounts receivable	5	5		5				5
Percentage of gross accounts receivable	86.00%	85.00%		86.00%				85.00%
Inventory, step-up value	0	200,000		0				200,000
Acquisition accounting inventory fair value step-up adjustments	10,477,000	3,826,000	19,939,000
Amortization of intangible assets	126,584,000	79,042,000	72,922,000
Advertising expenses	1,000,000	1,000,000	700,000
Convertible Debt [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of shares issuable from exchangeable senior notes	2.9
Debt conversion price (in dollars per share)												$199.77
Acquired Developed Technologies [Member]
Summary Of Significant Accounting Policies [Line Items]
Intangible assets, useful life	12 years 11 months
Amortization of intangible assets	122,600,000	78,800,000	65,100,000	31,000,000	29,600,000	31,700,000	30,300,000	20,500,000	19,500,000	19,300,000	19,500,000
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of property and equipment	3 years
Intangible assets, useful life	2 years
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of property and equipment	10 years
Intangible assets, useful life	16 years
Express Scripts [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of gross accounts receivable	66.00%	69.00%		66.00%				69.00%
Accredo Health Group, Inc. [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of gross accounts receivable		9.00%						9.00%
Idis Limited [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of gross accounts receivable	11.00%			11.00%
Xyrem [Member]
Summary Of Significant Accounting Policies [Line Items]
Product sales, net	778,584,000	569,113,000	378,663,000
Number of ANDAs filed by third parties	5			5
Xyrem [Member] | Product Concentration Risk [Member] | Sales Revenue, Product Line [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of total revenues	67.00%
Xyrem [Member] | Pending Litigation [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of lawsuits filed	5
Number of patents named in CBM petitions	6
Erwinaze And Erwinase [Member]
Summary Of Significant Accounting Policies [Line Items]
Product sales, net	199,665,000	174,251,000	72,083,000
Erwinaze And Erwinase [Member] | Product Concentration Risk [Member] | Sales Revenue, Product Line [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of total revenues	17.20%
Reclassification of Inventories [Member]
Summary Of Significant Accounting Policies [Line Items]
Amount reclassified		$1,400,000

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Schedule of Net Income (Loss) Per Ordinary Share) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Numerator:
Income from continuing operations									$57,326	$216,312	$261,149
Loss from continuing operations attributable to noncontrolling interests, net of tax									-1,061	0	0
Income from continuing operations attributable to Jazz Pharmaceuticals plc									58,387	216,312	261,149
Income from discontinued operations									0	0	27,437
Net income attributable to Jazz Pharmaceuticals plc	$81,612	$25,766	$43,659	($92,650)	$55,293	$75,409	$42,185	$43,425	$58,387	$216,312	$288,586
Denominator:
Weighted-average ordinary shares used in calculating net income per ordinary share attributable to Jazz Pharmaceuticals plc - basic (in shares)									59,746	58,298	56,643
Dilutive effect of employee equity incentive and purchase plans (in shares)									2,402	1,772	1,536
Dilutive effect of warrants (in shares)									466	1,499	2,016
Weighted-average ordinary shares used in calculating net income per ordinary share attributable to Jazz Pharmaceuticals plc - diluted (in shares)									62,614	61,569	60,195
Basic:
Income from continuing operations (in dollars per share)									$0.98	$3.71	$4.61
Income from discontinued operations (in dollars per share)									$0	$0	$0.48
Net income (in dollars per share)	$1.35	$0.43	$0.73	($1.58)	$0.96	$1.30	$0.72	$0.74	$0.98	$3.71	$5.09
Diluted:
Income from continuing operations (in dollars per share)									$0.93	$3.51	$4.34
Income from discontinued operations (in dollars per share)									$0	$0	$0.45
Net income (in dollars per share)	$1.30	$0.41	$0.70	($1.58)	$0.90	$1.23	$0.69	$0.71	$0.93	$3.51	$4.79

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Schedule Of Computation Of Diluted Net Income (Loss) Per Share Having Anti-Dilutive Effect) (Details)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Aug. 31, 2014
Ordinary Shares and RSUs [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	819	1,584	1,506
Convertible Debt Securities [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	1,112	0	0
Convertible Debt [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Interest rate	1.88%			1.88%

Business_Combination_and_Asset2

Business Combination and Asset Acquisitions (Consideration Transferred) (Details) (USD $)	12 Months Ended			0 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jan. 23, 2014
Business Acquisition [Line Items]
Total acquisition consideration	$0	$0	$576,464
Gentium [Member]
Business Acquisition [Line Items]
Cash consideration for shares acquired in initial tender offer period				697,917
Total acquisition consideration				857,086
Gentium [Member] | American Depositary Shares [Member]
Business Acquisition [Line Items]
Liability for shares committed under guaranteed delivery procedures and options committed for exercise				76,666
Gentium [Member] | Ordinary Options [Member]
Business Acquisition [Line Items]
Liability for shares committed under guaranteed delivery procedures and options committed for exercise				$82,503

Business_Combination_and_Asset3

Business Combination and Asset Acquisitions (Assets and Liabilities Assumed) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Jan. 23, 2014
In Thousands, unless otherwise specified
Business Acquisition [Line Items]
Goodwill	$702,713	$450,456
Gentium [Member]
Business Acquisition [Line Items]
Cash and cash equivalents			28,410
Short-term deposit			5,418
Accounts receivable			13,855	[1]
Inventories			13,525
Prepaid and other current assets			1,383
Intangible assets			960,350
Goodwill			308,642
Deferred tax assets			22,999
Property, plant and equipment			10,201
Other long-term assets			431
Accounts payable			-11,778
Accrued expenses			-51,477
Income taxes payable			-502
Other long-term liabilities			-654
Debt (current and long-term)			-2,351
Deferred tax liabilities			-304,788
Noncontrolling interests			-136,578
Total acquisition consideration			$857,086
[1]	The estimated fair value of trade receivables acquired was $13.9 million and the gross contractual amount was $14.9 million, of which we expect that $1.0 million will be uncollectible.

Business_Combination_and_Asset4

Business Combination and Asset Acquisitions (Intangible Assets Acquired) (Details) (USD $)	0 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jan. 23, 2014	Dec. 31, 2014	Dec. 31, 2013
Gentium [Member]
Acquired Intangible Assets [Line Items]
Total intangible assets	$960,350
Gentium [Member] | Manufacturing Contracts [Member]
Acquired Intangible Assets [Line Items]
Total finite-lived intangible assets	14,500
Gentium [Member] | Trade Names [Member]
Acquired Intangible Assets [Line Items]
Total finite-lived intangible assets	350
Gentium [Member] | Acquired Intangible Assets Excluding In-process Research and Development [Member]
Acquired Intangible Assets [Line Items]
Total finite-lived intangible assets	734,350
Gentium [Member] | Defibrotide VOD TX (Non-US) [Member] | Acquired developed technologies [Member]
Acquired Intangible Assets [Line Items]
Total finite-lived intangible assets	719,500
In Process Research and Development [Member]
Acquired Intangible Assets [Line Items]
Total IPR&D		236,748	34,259
In Process Research and Development [Member] | Gentium [Member]
Acquired Intangible Assets [Line Items]
Total IPR&D	226,000
In Process Research and Development [Member] | Gentium [Member] | Defibrotide VOD Prophalaxis [Member]
Acquired Intangible Assets [Line Items]
Total IPR&D	168,000
In Process Research and Development [Member] | Gentium [Member] | Defibrotide VOD Tx (US) [Member]
Acquired Intangible Assets [Line Items]
Total IPR&D	$58,000

Business_Combination_and_Asset5

Business Combination and Asset Acquisitions (Pro Forma Information) (Details) (Gentium [Member], USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Gentium [Member]
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Revenues	$1,176,178	$925,185
Net income attributable to Jazz Pharmaceuticals plc	$82,802	$181,318
Net income (loss) per ordinary share - basic (in dollars per share)	$1.39	$3.11
Net income (loss) per ordinary share - diluted (in dollars per share)	$1.32	$2.94

Business_Combination_and_Asset6

Business Combination and Asset Acquisitions (Additional Information) (Details) (USD $)	3 Months Ended								12 Months Ended			0 Months Ended		10 Months Ended	0 Months Ended	11 Months Ended	1 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jan. 13, 2014	Jan. 23, 2014	Dec. 31, 2014	Feb. 20, 2014	Dec. 31, 2014	Aug. 31, 2014	Dec. 19, 2013
Business Acquisition [Line Items]
Acquisition cost of noncontrolling interest									$136,969,000	$0	$0
Acquisition consideration									0	0	576,464,000
Transaction costs	5,200,000	700,000	4,400,000	17,100,000	4,400,000		400,000
Revenues	328,142,000	306,584,000	291,230,000	246,919,000	235,774,000	232,160,000	208,252,000	196,237,000	1,172,875,000	872,423,000	585,979,000
Acquired in-process research and development	600,000	75,000,000		127,000,000		1,000,000		4,000,000	202,626,000	4,988,000	0
Upfront Payment [Member] | Aerial [Member]
Business Acquisition [Line Items]
Acquired in-process research and development												125,000,000
Milestone Payment [Member] | Aerial [Member]
Business Acquisition [Line Items]
Acquired in-process research and development									2,000,000
Maximum potential milestones payments (up to $270.0 million)									270,000,000
Gentium [Member]
Business Acquisition [Line Items]
Share price of cash tender offer (in dollars per share)																		$57
Additional ownership interest acquired, percentage														1.80%
Acquisition cost of noncontrolling interest														17,800,000
Net acquisition consideration									994,100,000
Total acquisition consideration, including subsequent acquisition									1,011,200,000
Proceeds from exercise of acquired share options									17,100,000
Acquisition consideration													857,086,000
Transaction costs									11,900,000
Revenues									78,200,000
Estimated fair value of trade receivables acquired													13,900,000
Gross contractual amount of trade receivables acquired													14,900,000
Estimated uncollectible amount of trade accounts receivables acquired													1,000,000
Pro forma adjustment, amortization expense									2,700,000	48,900,000
Pro forma adjustment, transaction-related expense									43,000,000	4,800,000
Pro forma adjustment, interest expense									1,300,000	22,500,000
Pro forma adjustment, non-recurring expenses									-40,700,000	18,600,000
Gentium [Member] | Product [Member]
Business Acquisition [Line Items]
Estimated remaining life													16 years
Gentium [Member] | Manufacturing Contracts [Member]
Business Acquisition [Line Items]
Estimated remaining life													4 years
Gentium [Member] | Selling, General and Administrative [Member]
Business Acquisition [Line Items]
Change in control obligation expenses									5,400,000
Gentium [Member] | Ordinary Options and American Depositary Shares [Member]
Business Acquisition [Line Items]
Shares tendered													12,244,156
Issued and outstanding shares acquired, percentage													79.00%
Fully diluted shares acquired, percentage													69.00%
Total ownership interest acquired, percentage															98.00%
Additional ownership interest acquired, percentage															12.00%
Ownership percentage													86.00%
Acquisition cost of a noncontrolling interest															119,200,000
Gentium [Member] | Noncontrolling Interest [Member]
Business Acquisition [Line Items]
Acquisition cost of noncontrolling interest																137,000,000
Issued and outstanding shares held by noncontrolling interests													2,007,452
Options not subject to support agreements held by noncontrolling interests													484,097
Tender Offer Agreement [Member] | American Depositary Shares [Member]
Business Acquisition [Line Items]
Shares committed to tender offering													1,345,023
Tender Offer Agreement [Member] | Ordinary Options [Member]
Business Acquisition [Line Items]
Options subject to support agreements													1,666,608
Sigma Tau [Member]
Business Acquisition [Line Items]
Potential milestone payments under agreement																	25,000,000
Potential milestone payments for FDA approval of defibrotide (up to $150.0 million)																	150,000,000
Sigma Tau [Member] | Upfront Payment [Member]
Business Acquisition [Line Items]
Acquired in-process research and development																	$75,000,000

Fair_Value_Measurement_Narrati

Fair Value Measurement (Narrative) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying amount of long term debt	$1,472,042,000
Assets held for sale	32,833,000	0
Convertible Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying amount of long term debt	575,000,000	0
Convertible debt fair value	653,800,000
Term Loan [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principle amount of long term debt	881,900,000
Carrying amount of long term debt	890,500,000
Term Loans [Member] | Term Loan [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principle amount of long term debt	895,400,000
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Target sales of Erwinaze in 2013			124,500,000
Cash Distribution [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Additional contingent payment to be made			50,000,000
Certain EUSA Products [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets held for sale	$32,833,000

Fair_Value_Measurement_Schedul

Fair Value Measurement (Schedule of Available-For-Sale Securities) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$684,042	$636,504
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	684,042	636,504
Amounts classified as cash and cash equivalents	684,042	636,504	387,196	82,076
Cash [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	338,262	495,990
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	338,262	495,990
Amounts classified as cash and cash equivalents	338,262	495,990
Time Deposits [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	345,780	140,514
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	345,780	140,514
Amounts classified as cash and cash equivalents	$345,780	$140,514

Fair_Value_Measurement_Schedul1

Fair Value Measurement (Schedule of Available-For-Sale Investments Measured at Fair Value on Recurring Basis) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	$684,042	$636,504
Time Deposits [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	345,780	140,514
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member] | Time Deposits [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	345,780	140,514
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member] | Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0	50,000
Estimate of Fair Value, Fair Value Disclosure [Member] | Fair Value, Measurements, Recurring [Member] | Time Deposits [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	345,780	140,514
Estimate of Fair Value, Fair Value Disclosure [Member] | Fair Value, Measurements, Recurring [Member] | Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	$0	$50,000

Inventories_Details

Inventories (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Components of Inventories
Raw materials	$3,570,000	$3,506,000
Work in process	9,870,000	10,301,000
Finished goods	16,597,000	14,862,000
Total inventories	30,037,000	28,669,000
Inventory, step-up value	$0	$200,000

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Abstract]
Construction-in-progress	$37,145	$4,388
Computer software	10,634	7,960
Leasehold improvements	7,931	4,587
Computer equipment	7,670	5,610
Machinery and equipment	6,408	417
Furniture and fixtures	2,220	1,897
Land and buildings	1,547	0
Subtotal	73,555	24,859
Less accumulated depreciation and amortization	-15,192	-10,613
Property and equipment, net	$58,363	$14,246

Accrued_Liabilities_Details

Accrued Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]
Rebates and other sales deductions	$51,899	$38,772
Employee compensation and benefits	46,143	31,829
Sales returns reserve	14,039	21,110
Accrued interest	10,327	4,150
Royalties	7,964	6,082
Accrued construction-in-progress	4,931	450
Professional fees	3,295	5,225
Other	25,493	12,100
Total accrued liabilities	$164,091	$119,718

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets (Schedule Of Gross Carrying Amount Of Goodwill) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Goodwill [Roll Forward]
Balance at December 31, 2013	$450,456
Goodwill arising from the Gentium Acquisition	308,642
Goodwill allocated to assets held for sale	-1,686	[1]
Foreign exchange	-54,699
Balance at December 31, 2014	$702,713
[1]	In December 2014, we entered into a definitive agreement to sell certain products and related assets. See Note 18 for information regarding assets held for sale.

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets (Schedule Of Gross Carrying Amounts And Net Book Values Of Intangible Assets) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived and Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$1,466,532	$959,689
Accumulated Amortization	-265,845	-181,552
Total	1,200,687	778,137
Intangible assets, gross	1,703,280	993,948
Intangible assets, net	1,437,435	812,396
In Process Research and Development [Member]
Finite-Lived and Indefinite Lived Intangible Assets [Line Items]
Acquired IPR&D assets	236,748	34,259
Acquired Developed Technologies [Member]
Finite-Lived and Indefinite Lived Intangible Assets [Line Items]
Remaining Weighted- Average Useful Life (In years)	12 years 11 months
Gross Carrying Amount	1,450,606	957,089
Accumulated Amortization	-259,889	-179,225
Total	1,190,717	777,864
Manufacturing Contracts [Member]
Finite-Lived and Indefinite Lived Intangible Assets [Line Items]
Remaining Weighted- Average Useful Life (In years)	3 years 1 month
Gross Carrying Amount	13,012	0
Accumulated Amortization	-3,060	0
Total	9,952	0
Trademarks [Member]
Finite-Lived and Indefinite Lived Intangible Assets [Line Items]
Remaining Weighted- Average Useful Life (In years)	0 years 1 month
Gross Carrying Amount	2,914	2,600
Accumulated Amortization	-2,896	-2,327
Total	$18	$273

Goodwill_and_Intangible_Assets4

Goodwill and Intangible Assets (Schedule Of Estimated Future Amortization Costs) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]
2015	$102,508
2016	99,167
2017	99,167
2018	95,313
2019	95,071
Thereafter	709,461
Total	$1,200,687	$778,137

Goodwill_and_Intangible_Assets5

Goodwill and Intangible Assets (Additional Information) (Details) (USD $)	3 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived and Indefinite Lived Intangible Assets [Line Items]
Impairment charges	$32,800,000	$39,365,000	$0	$0
Certain EUSA Products [Member]
Finite-Lived and Indefinite Lived Intangible Assets [Line Items]
Current intangible assets, net		27,479,000
Women's Health Business [Member]
Finite-Lived and Indefinite Lived Intangible Assets [Line Items]
Intangible assets, net				$41,400,000

Debt_Additional_Information_De

Debt (Additional Information) (Details) (USD $)	12 Months Ended			0 Months Ended	1 Months Ended	0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jan. 23, 2014	Aug. 31, 2014	Jun. 13, 2013	Jun. 30, 2012	Jun. 30, 2013
					D
Debt Instrument [Line Items]
Interest expense, net	$52,713,000	$26,916,000	$16,869,000
Amount outstanding under revolving credit facility	0
Carrying amount of long-term debt	1,342,428,000	549,976,000
Repayments of debt	9,524,000	465,910,000	11,875,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maximum amount available under revolving credit facility							100,000,000
Revolving Credit Facility [Member] | Credit Agreement [Member]
Debt Instrument [Line Items]
Maximum amount available under revolving credit facility						200,000,000
Interest rate reduction basis points								1.50%
Revolving Credit Facility [Member] | Second Credit Amendment [Member]
Debt Instrument [Line Items]
Maximum amount available under revolving credit facility				425,000,000
Interest rate reduction basis points				0.25%
Maturity date				12-Jun-17
Revolving Credit Facility [Member] | Second Credit Amendment [Member] | Rate Option [Member]
Debt Instrument [Line Items]
Interest rate reduction basis points				0.25%
Commitment fee percentage				0.25%
Revolving Credit Facility [Member] | Second Credit Amendment [Member] | Rate Option Two [Member]
Debt Instrument [Line Items]
Interest rate reduction basis points				0.50%
Commitment fee percentage				0.50%
Revolving Credit Facility [Member] | Second Credit Amendment [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate				1.50%
Convertible Debt [Member]
Debt Instrument [Line Items]
Principle amount of long term debt					575,000,000
Long term debt interest rate	1.88%				1.88%
Net proceeds from issuance exchangeable senior notes					558,900,000
Frequency of periodic payment					payable semi-annually in cash in arrears on February 15 and August 15 of each year
Percentage of conversion price					130.00%
Number of trading days					20
Number of consecutive days in trading period					30 days
Conversion rate of shares					5.0057
Conversion denominator					1,000
Debt conversion price (in dollars per share)					$199.77
Effective interest rate	6.40%
Debt term					7 years
Debt issuance cost					16,100,000
Interest expense, net	9,900,000
Carrying value of the equity component	126,900,000
Carrying amount of long-term debt	450,265,000	0
Unamortized discount	124,735,000	0
Term Loan [Member]
Debt Instrument [Line Items]
Principle amount of long term debt				554,400,000			475,000,000
Long term debt interest rate	3.25%
Effective interest rate	4.10%
Carrying amount of long-term debt	890,479,000	549,976,000
Deferred Finance Costs, Gross				21,700,000
Unamortized discount				6,100,000
Term Loan [Member] | Credit Agreement [Member]
Debt Instrument [Line Items]
Principle amount of long term debt						557,200,000
Repayments of debt						457,200,000
Interest rate reduction basis points								1.50%
Term Loan [Member] | Second Credit Amendment [Member]
Debt Instrument [Line Items]
Principle amount of long term debt				904,400,000
Frequency of periodic payment				quarterly
Maturity date				12-Jun-18
Percentage of principal amount for repayment				1.00%
Term Loan [Member] | Second Credit Amendment [Member] | Rate Option [Member]
Debt Instrument [Line Items]
Mandatory prepayments as percentage of excess cash flow				50.00%
Term Loan [Member] | Second Credit Amendment [Member] | Rate Option Two [Member]
Debt Instrument [Line Items]
Mandatory prepayments as percentage of excess cash flow				25.00%
Term Loan [Member] | Second Credit Amendment [Member] | Rate Option Two [Member] | Maximum [Member]
Debt Instrument [Line Items]
Mandatory prepayments total leverage ratio				2.25
Term Loan [Member] | Second Credit Amendment [Member] | Rate Option Two [Member] | Minimum [Member]
Debt Instrument [Line Items]
Mandatory prepayments total leverage ratio				1.25
Term Loan [Member] | Second Credit Amendment [Member] | Rate Option Three [Member]
Debt Instrument [Line Items]
Mandatory prepayments as percentage of excess cash flow				0.00%
Term Loan [Member] | Second Credit Amendment [Member] | Rate Option Three [Member] | Maximum [Member]
Debt Instrument [Line Items]
Mandatory prepayments total leverage ratio				1.25
Term Loan [Member] | Second Credit Amendment [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Secured debt interest rate minimum percentage				0.75%
Term Loan [Member] | Second Credit Amendment [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate				1.50%
Secured debt interest rate minimum percentage				1.75%
Term Loan [Member] | Revolving Credit Facility [Member] | Second Credit Amendment [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate				2.50%
Additional Term Loan [Member] | Second Credit Amendment [Member]
Debt Instrument [Line Items]
Principle amount of long term debt				350,000,000
Line of Credit [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Amount outstanding under revolving credit facility				300,000,000
Deferred Finance Costs, Gross				$5,400,000

Debt_Schedule_of_Debt_Details

Debt (Schedule of Debt) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Aug. 31, 2014	Jan. 23, 2014
In Thousands, unless otherwise specified
Debt Instrument [Line Items]
Principal amount	$1,472,042
Total debt	1,342,428	549,976
Less current portion	9,428	5,572
Total long-term debt	1,333,000	544,404
Convertible Debt 2021 Notes [Member]
Debt Instrument [Line Items]
Interest rate	1.88%		1.88%
Principal amount	575,000	0
Unamortized discount	-124,735	0
Total debt	450,265	0
Term Loan [Member]
Debt Instrument [Line Items]
Interest rate	3.25%
Unamortized discount				-6,100
Total debt	890,479	549,976
Other borrowings [Member]
Debt Instrument [Line Items]
Total debt	$1,684	$0

Debt_Debt_Maturities_Details

Debt (Debt Maturities) (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Long-term Debt, Fiscal Year Maturity [Abstract]
2015	$9,428
2016	9,433
2017	9,438
2018	868,479
2019	114
Thereafter	575,150
Total debt	$1,472,042

Deferred_Revenue_Details

Deferred Revenue (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2006
				payment
Other Long Term Liabilities [Line Items]
Deferred revenue, current	$1,138,000	$1,138,000
UCB Pharma Limited [Member]
Other Long Term Liabilities [Line Items]
Contract revenues	1,100,000	1,100,000	1,100,000
Payments received upfront from UCB				2
Deferred contract revenues upfront payment received				15,000,000
Deferred revenues, total	5,600,000
Deferred revenue, current	$1,100,000

Commitments_and_Contingencies_1

Commitments and Contingencies (Narrative) (Details) (USD $)

12 Months Ended

0 Months Ended

26 Months Ended

23 Months Ended

0 Months Ended

1 Months Ended

Dec. 31, 2014

Dec. 11, 2014

Jul. 15, 2014

Dec. 27, 2013

Nov. 21, 2013

Dec. 10, 2012

Oct. 18, 2010

Dec. 05, 2012

Jul. 23, 2010

Feb. 20, 2015

Jan. 19, 2015

Jan. 09, 2015

Jan. 08, 2015

Jan. 31, 2015

Oct. 19, 2011

Jan. 31, 2014

product

patent

patent

patent

patent

patent

patent

patent

patent

patent

patent

patent

renewal_term

sqft

Other Commitments [Abstract]

Total future lease payments

$25,046,000

Noncancelable purchase commitments due within one year

34,600,000

Number of radiopharmaceutical products

2

Pending Litigation [Member]

Other Commitments [Abstract]

Amounts sought in alleged breach of contractual obligation - minimum

10,500,000

Estimate of a possible additional contingent payment

25,000,000

Pending Litigation [Member] | Xyrem ANDA Matters [Member]

Other Commitments [Abstract]

Gain Contingency, Patents Allegedly Infringed upon, Number

15

14

13

9

5

10

Term of court ordered stay

30 months

30 months

Pending Litigation [Member] | FazaClo ANDA Matters [Member]

Other Commitments [Abstract]

Number of generic manufacturers that certifications were received from

3

Number of ANDAs outstanding

2

Pending Litigation [Member] | Gentium [Member]

Other Commitments [Abstract]

Share price (in dollars per share)

$57

Subsequent Event [Member] | Pending Litigation [Member] | Xyrem ANDA Matters [Member]

Other Commitments [Abstract]

Gain Contingency, Patents Allegedly Infringed upon, Number

3

4

2

3

Office Building [Member] | Subsequent Event [Member] | Lease Agreements [Member] | Palo Alto

Other Commitments [Abstract]

Leased area (square footage)

100,000

Operating lease, term (in years)

12 years

Number of renewal option terms

2

Operating lease, extended term option (in years)

5 years

Total future lease payments

96,000,000

Estimated total operating expenses

$25,000,000

Termination period after lease commencement

10 years

Lease termination notice period

1 year

Xyrem [Member]

Other Commitments [Abstract]

Number of ANDAs outstanding

5

Xyrem [Member] | Pending Litigation [Member]

Other Commitments [Abstract]

Number of patents named in CBM petitions

6

Commitments_and_Contingencies_2

Commitments and Contingencies (Schedule Of Rent Expense Under Operating Leases) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Other Commitments [Line Items]
Lease expense	$10,678	$9,114	$5,303

Commitments_and_Contingencies_3

Commitments and Contingencies (Schedule Of Future Minimum Lease Payments Under Noncancelable Operating Leases) (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2015	$10,165
2016	7,852
2017	4,915
2018	1,443
2019	671
Thereafter	0
Total	$25,046

Shareholders_Equity_Narrative_

Shareholders' Equity (Narrative) (Details) (Ordinary Shares [Member], USD $)	12 Months Ended
Share data in Millions, except Per Share data, unless otherwise specified	Dec. 31, 2014	31-May-13
Ordinary Shares [Member]
Stockholders' Equity Note [Line Items]
Total amount authorized for repurchase of shares under share repurchase program (up to $200 million)		$200,000,000
Share repurchases	42,200,000
Stock repurchased, shares	0.3
Treasury stock acquired, average cost per share (in dollars per share)	$138.64
Remaining amount authorized for repurchase of shares	$21,300,000

Shareholders_Equity_Schedule_o

Shareholders' Equity (Schedule of Authorized But Unissued Ordinary Shares) (Details)	Dec. 31, 2014
In Thousands, unless otherwise specified
Class of Stock [Line Items]
Authorized but unissued ordinary shares reserved (in shares)	12,289
2011 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Authorized but unissued ordinary shares reserved (in shares)	10,143
2007 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Authorized but unissued ordinary shares reserved (in shares)	962
2007 Employee Stock Purchase Plan [Member]
Class of Stock [Line Items]
Authorized but unissued ordinary shares reserved (in shares)	587
Amended and Restated 2007 Non-Employee Directors Stock Option Plan [Member]
Class of Stock [Line Items]
Authorized but unissued ordinary shares reserved (in shares)	419
Amended and Restated Directors Deferred Compensation Plan [Member]
Class of Stock [Line Items]
Authorized but unissued ordinary shares reserved (in shares)	178

Comprehensive_Income_Loss_Deta

Comprehensive Income (Loss) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at December 31, 2013	$56,153
Other comprehensive loss	-178,264	25,107	31,077
Balance at December 31, 2014	-122,097	56,153
Foreign Currency Translation Adjustments [Member]
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at December 31, 2013	56,153
Other comprehensive loss	-178,250
Balance at December 31, 2014	-122,097
Parent [Member]
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at December 31, 2013	56,153
Other comprehensive loss	-178,250	25,107	31,077
Balance at December 31, 2014	($122,097)	$56,153

ShareBased_Compensation_Narrat

Share-Based Compensation (Narrative) (Details) (USD $)	12 Months Ended			1 Months Ended	0 Months Ended		12 Months Ended	9 Months Ended	0 Months Ended	1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jan. 01, 2015	Jan. 18, 2012	Jan. 17, 2012	Sep. 30, 2011	Oct. 24, 2011	Aug. 31, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recognized tax benefits related to share options exercised	$11,800,000	$6,700,000	$18,300,000
Aggregate intrinsic value of share options exercised	138,200,000	46,000,000	106,500,000
Share Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to unvested share options and RSUs	68,800,000
Unrecognized compensation cost, weighted-average period of recognition (in years)	2 years 3 months 0 days
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)	4 years
Unrecognized compensation cost related to unvested share options and RSUs	74,100,000
Unrecognized compensation cost, weighted-average period of recognition (in years)	2 years 5 months 0 days
RSUs weighted-average grant date fair value (in dollars per share)	$160.45
Number of RSUs released (in shares)	344,000
Shares issued (in shares)	222,000
Shares withheld for tax purposes (in shares)	122,000
Total fair value of shares vested	50,900,000	16,100,000	0
2011 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service periods (in years)				4 years
Shares authorized for issuance (in shares)	13,549,336
2011 Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants expiration period (in years)				10 years
2011 Equity Incentive Plan [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in shares reserved under plan (in shares)					2,728,927
2011 Equity Incentive Plan, Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance, annual automatic increase, maximum percentage of outstanding shares				4.50%
2011 Equity Incentive Plan, Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in shares reserved under plan (in shares)				5,000,000
2007 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance (in shares)						1,000,000
2007 Equity Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service periods (in years)						1 year	3 years
2007 Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service periods (in years)						3 years	5 years
Grants expiration period (in years)						10 years	10 years
2007 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance (in shares)	2,660,000			1,000,000
ESPP discount rate				15.00%
ESPP offering period (in months)				24 months
Number of purchase periods within each ESPP offering period				4
Number of shares available for issuance (in shares)				175,000
Unrecognized compensation cost related to unvested share options and RSUs	2,300,000
2007 Employee Stock Purchase Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost, weighted-average period of recognition (in years)	1 year
Two Thousand Seven Employee Stock Purchase Plan Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares outstanding on December 31				1.50%
2007 Directors Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance under deferred compensation plan (in shares)	837,713
2007 Directors Option Plan [Member] | Initial Grant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)								3 years
2007 Directors Option Plan [Member] | Annual Automatic Grant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)								1 year
2007 Directors Option Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service periods (in years)									1 year
2007 Directors Option Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service periods (in years)									3 years
Grants expiration period (in years)									10 years
Shares authorized for issuance under deferred compensation plan (in shares)	200,000
2007 Directors Option Plan [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance under deferred compensation plan (in shares)					32,075
Directors Deferred Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in shares reserved under plan (in shares)										200,000
Recorded expense related to retainer fees earned and deferred	$0	$0	$0
Deferred Compensation Arrangement With Individual Shares Unissued	14,499

ShareBased_Compensation_Schedu

Share-Based Compensation (Schedule of Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model and Resulting Weighted-Average Grant Date Fair Value of Share Options Granted) (Details) (Share Options [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value (in dollars per share)	$60.29	$29.09	$25.28
Volatility	45.00%	58.00%	64.00%
Expected term (in years)	4 years 3 months 24 days	4 years 4 months 24 days	4 years 7 months 6 days
Range of risk-free rates, minimum	1.10%	0.50%	0.50%
Range of risk-free rates, maximum	1.40%	1.40%	1.10%
Expected dividend yield	0.00%	0.00%	0.00%

ShareBased_Compensation_Schedu1

Share-Based Compensation (Schedule of Stock-Based Compensation Expense Related to Stock Options, RSUs, Ordinary Shares Credited to Directors' Phantom Share Accounts and Grants under ESPP) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense, pre-tax	$69,638	$44,551	$23,006
Tax benefit from share-based compensation expense	-20,795	-13,822	-7,499
Total share-based compensation expense, net of tax	48,843	30,729	15,507
Selling, General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense, pre-tax	55,083	35,674	18,950
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense, pre-tax	12,179	6,673	2,640
Cost of Product Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense, pre-tax	$2,376	$2,204	$1,416

ShareBased_Compensation_Schedu2

Share-Based Compensation (Schedule of Share Option Plans Activity) (Details) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014
Shares Subject to Outstanding Options [Roll Forward]
Outstanding at January 1, 2014	4,306
Options granted	1,000
Options exercised	-1,185
Options forfeited	-251
Options expired	0
Outstanding at December 31, 2014	3,870
Vested and expected to vest at December 31, 2014	3,632
Exercisable at December 31, 2014	1,639
Weighted Average Exercise Price (in dollars per share) [Roll Forward]
Outstanding at January 1, 2014	$42.54
Options granted	$160.40
Options exercised	$36.33
Options forfeited	$75.08
Options expired	$0
Outstanding at December 31, 2014	$72.77
Vested and expected to vest at December 31, 2014	$70.29
Exercisable at December 31, 2014	$36.61
Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value
Weighted-average remaining contractual term, outstanding at December 31, 2014 (in years)	7 years 7 months 14 days
Weighted-average remaining contractual term, vested and expected to vest, exercisable at December 31, 2014 (in years)	7 years 6 months 0 days
Weighted-average remaining contractual term, exercisable at December 31, 2014 (in years)	6 years 6 months 0 days
Aggregate intrinsic value, outstanding at December 31, 2014	$354,050
Aggregate intrinsic value, vested and expected to vest at December 31, 2014	341,118
Aggregate intrinsic value, exercisable at December 31, 2014	$208,339

ShareBased_Compensation_Schedu3

Share-Based Compensation (Schedule of RSUs Activity) (Details) (Restricted Stock Units (RSUs) [Member], USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014
Restricted Stock Units (RSUs) [Member]
Number of RSUs [Roll Forward]
Number of RSUs, outstanding at January 1, 2014 (in shares)	1,164
Number of RSUs granted (in shares)	488
Number of RSUs released (in shares)	-344
Number of RSUs forfeited (in shares)	-120
Number of RSUs expired (in shares)	0
Number of RSUs, outstanding at December 31, 2014 (in shares)	1,188
Weighted-Average Grant-Date Fair Value [Roll Forward]
Weighted-average grant-date fair value, outstanding at January 1, 2014 (in dollars per share)	$55.28
Weighted-average grant-date fair value, RSUs granted (in dollars per share)	$160.45
Weighted-average grant-date fair value, RSUs released (in dollars per share)	$55.30
Weighted-average grant-date fair value, RSUs forfeited (in dollars per share)	$75.43
Weighted-average grant-date fair value, RSUs expired (in dollars per share)	$0
Weighted-average grant-date fair value, outstanding at December 31, 2014 (in dollars per share)	$96.41
Weighted-average remaining contractual term, outstanding at December 31, 2014 (in years)	1 year 3 months 0 days
Aggregate intrinsic value, outstanding at December 31, 2014	$194,546

Segment_and_Other_Information_1

Segment and Other Information (Additional Information) (Details)	12 Months Ended
	Dec. 31, 2014
	Segment
Segment Reporting [Abstract]
Number of operating business segment	1

Segment_and_Other_Information_2

Segment and Other Information (Summary of Total Revenues) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Product sales, net									$1,162,716	$865,398	$580,527
Royalties and contract revenues									10,159	7,025	5,452
Total revenues	328,142	306,584	291,230	246,919	235,774	232,160	208,252	196,237	1,172,875	872,423	585,979
Xyrem [Member]
Segment Reporting Information [Line Items]
Product sales, net									778,584	569,113	378,663
Erwinaze And Erwinase [Member]
Segment Reporting Information [Line Items]
Product sales, net									199,665	174,251	72,083
Defitelio/defibrotide [Member]
Segment Reporting Information [Line Items]
Product sales, net									70,537	0	0
Prialt® (ziconotide) intrathecal infusion [Member]
Segment Reporting Information [Line Items]
Product sales, net									26,421	27,103	26,360
Psychiatry [Member]
Segment Reporting Information [Line Items]
Product sales, net									40,879	49,226	76,489
Other [Member]
Segment Reporting Information [Line Items]
Product sales, net									$46,630	$45,705	$26,932

Segment_and_Other_Information_3

Segment and Other Information (Summary of Total Revenues Attributed to Geographic Sources) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Total revenues	$328,142	$306,584	$291,230	$246,919	$235,774	$232,160	$208,252	$196,237	$1,172,875	$872,423	$585,979
United States [Member]
Segment Reporting Information [Line Items]
Total revenues									1,007,396	792,518	538,219
Europe [Member]
Segment Reporting Information [Line Items]
Total revenues									126,715	61,843	38,590
All other [Member]
Segment Reporting Information [Line Items]
Total revenues									$38,764	$18,062	$9,170

Segment_and_Other_Information_4

Segment and Other Information (Summary of Revenues from Customers Representing at Least 10% of Total Revenues) (Details) (Sales Revenue, Goods, Net [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Express Scripts [Member]
Concentration Risk [Line Items]
Percentage of total revenues	66.00%	65.00%	64.00%
Accredo Health Group, Inc. [Member]
Concentration Risk [Line Items]
Percentage of total revenues	14.00%	16.00%

Segment_and_Other_Information_5

Segment and Other Information (Total Long-Lived Assets by Location) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$58,363	$14,246
Ireland [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	37,775	5,799
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	9,795	7,734
Italy [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	8,462	0
Other [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$2,331	$713

Income_Taxes_Components_of_Inc

Income Taxes (Components of Income from Continuing Operations before Income Tax Provision (Benefit)) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Components of Income from Continuing Operations before Income Tax Provision (Benefit)
Republic of Ireland	$222,328	$132,855	$250,348
United States	238,351	186,903	-73,949
Other	-309,122	-11,808	956
Total	$151,557	$307,950	$177,355

Income_Taxes_Details_of_Income

Income Taxes (Details of Income Tax Provision (Benefit)) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current
Republic of Ireland	$97,679	$71,964	$33,387
United States	23,506	17,089	-10,733
Other	16,469	12,682	7,414
Total current income tax	137,654	101,735	30,068
Deferred
Republic of Ireland	-15,003	-3,513	-103,932
United States	2,323	8,353	-315
Other	-30,743	-14,937	-9,615
Total deferred income tax benefit	-43,423	-10,097	-113,862
Total income tax provision (benefit)	$94,231	$91,638	($83,794)

Income_Taxes_Effective_Income_

Income Taxes (Effective Income Tax Rate Reconciliation) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Effective Income Tax Rate Reconciliation [Abstract]
Income tax provision at statutory rate	$18,945	$38,494	$22,169
Acquisition-related costs	4,703	0	763
Research and other tax credits	-14,234	-5,957	-100
Non-deductible share-based compensation	4,203	2,497	873
Foreign income tax rate differential	75,780	31,651	52,066
Change in unrecognized tax benefits	9,447	8,685	2,249
Prior period adjustments	-5,522	3,375	-2,524
Change in valuation allowance	9,006	3,220	-159,158
Non-deductible contingent consideration	0	5,320	0
Non-deductible financing costs	1,088	0	0
Deduction on subsidiary equity	-11,403	0	0
Non-deductible officers' compensation	2,715	1,528	0
Other	-497	2,825	-132
Total income tax provision (benefit)	$94,231	$91,638	($83,794)
Effective income tax rate	62.20%	29.80%	-47.20%
Ireland [Member]
Effective Income Tax Rate Reconciliation [Abstract]
Statutory income tax rate	12.50%	12.50%	12.50%

Income_Taxes_Schedule_of_Net_D

Income Taxes (Schedule of Net Deferred Tax Assets/(Liabilities)) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred tax assets:
Net operating loss carryforwards	$74,057	$71,364
Tax credit carryforwards	23,946	11,374
Intangible assets	19,507	10,733
Share-based compensation	14,033	8,116
Accruals	36,157	30,730
Deferred Tax Assets, Deferred Income	5,038	9,252
Total deferred tax assets	172,738	141,569
Valuation allowance	-29,697	-20,691
Net deferred tax assets	143,041	120,878
Deferred tax liabilities:
Acquired intangible assets	-395,651	-176,576
Other	-7,940	-10,848
Total deferred tax liabilities	-403,591	-187,424
Net deferred tax liabilities	($260,550)	($66,546)

Income_Taxes_Current_and_Noncu

Income Taxes (Current and Non-current Deferred Assets/(Liabilities) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current and Non-current Deferred Tax Assets (Liabilities) [Abstract]
Current deferred tax assets	$48,440	$33,613
Current deferred tax liabilities	-9,430	-6,259
Non-current deferred tax assets	75,494	74,597
Non-current deferred tax liabilities	-375,054	-168,497
Net deferred tax liabilities	($260,550)	($66,546)

Income_Taxes_Reconciliation_of

Income Taxes (Reconciliation of Unrecognized Tax Benefits) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits
Balance at the beginning of the year	$21,637	$7,288	$3,764
Increases related to current year tax positions	19,837	14,308	3,492
Increases related to prior year tax positions	0	183	40
Decreases related to prior year tax positions	-672	-142	-8
Balance at the end of the year	$40,802	$21,637	$7,288

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	3 Months Ended						12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating Loss Carryforwards [Line Items]
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	$29,700,000						$29,700,000	$16,300,000
Income tax provision (benefit)							94,231,000	91,638,000	-83,794,000
Effective income tax rate							62.20%	29.80%	-47.20%
Acquired in-process research and development	600,000	75,000,000	127,000,000	1,000,000	4,000,000		202,626,000	4,988,000	0
Change in valuation allowance							9,006,000	3,220,000	-159,158,000
NOLs and tax credit carryforwards						55,000,000			55,000,000
Non-recurring income tax benefit						104,200,000	7,700,000	-2,300,000
Deferred tax assets, valuation allowance	29,697,000						29,697,000	20,691,000
Cumulated unremitted earnings of overseas subsidiaries	736,900,000						736,900,000	664,300,000
Employee Share Options [Member]
Operating Loss Carryforwards [Line Items]
NOL carryforwards	191,700,000						191,700,000
Non-Taxable Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Tax rate excluding certain milestone payments							26.70%
Non-Taxable Jurisdiction [Member] | Aerial and Defibrotide in Americas [Member]
Operating Loss Carryforwards [Line Items]
Acquired in-process research and development							202,000,000
Ireland [Member]
Operating Loss Carryforwards [Line Items]
Statutory income tax rate							12.50%	12.50%	12.50%
U.S. Federal [Member]
Operating Loss Carryforwards [Line Items]
NOL carryforwards	264,900,000						264,900,000
Tax credit carryforwards	29,200,000						29,200,000
U.S. Federal [Member] | Year 2015 [Member]
Operating Loss Carryforwards [Line Items]
Annual limitation on utilization of certain acquired federal NOLs	28,800,000						28,800,000
U.S. Federal [Member] | Year 2016 [Member]
Operating Loss Carryforwards [Line Items]
Annual limitation on utilization of certain acquired federal NOLs	28,900,000						28,900,000
U.S. Federal [Member] | Year 2017 [Member]
Operating Loss Carryforwards [Line Items]
Annual limitation on utilization of certain acquired federal NOLs	15,000,000						15,000,000
U.S. Federal [Member] | Year 2018 [Member]
Operating Loss Carryforwards [Line Items]
Annual limitation on utilization of certain acquired federal NOLs	1,400,000						1,400,000
U.S. Federal [Member] | Year 2019 to 2026 [Member]
Operating Loss Carryforwards [Line Items]
Annual limitation on utilization of certain acquired federal NOLs	4,900,000						4,900,000
U.S. Federal [Member] | EUSA Pharma Acquisition [Member]
Operating Loss Carryforwards [Line Items]
NOL carryforwards						117,200,000			117,200,000
U.S. State [Member]
Operating Loss Carryforwards [Line Items]
NOL carryforwards	267,400,000						267,400,000
Tax credit carryforwards	4,200,000						4,200,000
Foreign Tax Authorities [Member]
Operating Loss Carryforwards [Line Items]
Tax rate before utilization of net operating losses, net credit carryforwards and valuation allowances									42.50%
Tax credit carryforwards	4,700,000						4,700,000
Foreign Tax Authorities [Member] | United Kingdom [Member]
Operating Loss Carryforwards [Line Items]
NOL carryforwards	56,100,000						56,100,000
Foreign Tax Authorities [Member] | Italy [Member]
Operating Loss Carryforwards [Line Items]
NOL carryforwards	$74,200,000						$74,200,000

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	12 Months Ended			1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Nov. 30, 2012	Feb. 28, 2014
			underwriter
			director
			executive_officer
Related Party Transaction [Line Items]
Shares sold in secondary offering		5,400,000	7,900,000
Proceeds from secondary offering		$314,400,000	$390,700,000
Expenses from transactions with related party		500,000	400,000
Rent expense	10,678,000	9,114,000	5,303,000
Number of underwriters buying shares in secondary offering			2
Number of directors selling shares in secondary offering			4
Number of executive officers selling shares in secondary offering			4
Related Party Mulligan [Member]
Related Party Transaction [Line Items]
Rent expense			300,000
Lease termination expense				1,200,000
Gain (Loss) on Contract Termination				0
Exercise of Warrant [Member] | Affiliated Entity [Member]
Related Party Transaction [Line Items]
Issuance of ordinary shares in conjunction with exercise of warrants, shares					947,867
Proceeds from Warrant Exercises					3,800,000
Payments of Stock Issuance Costs					$100,000

Assets_Held_for_Sale_Details

Assets Held for Sale (Details) (USD $)	3 Months Ended		12 Months Ended
	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Jun. 30, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment charges	$6,600,000	$32,800,000	$39,365,000
Assets held for sale	32,833,000		32,833,000	0
Certain EUSA Products [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Inventories	4,693,000		4,693,000
Accounts receivable	4,880,000		4,880,000
Intangible assets, net	27,479,000		27,479,000
Goodwill	1,686,000		1,686,000
Other	654,000		654,000
Valuation allowance	-6,559,000		-6,559,000
Assets held for sale	32,833,000		32,833,000
Scenario, Forecast [Member] | Certain EUSA Products [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Consideration					$34,000,000

Restructuring_Details

Restructuring (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2015
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	$252	$1,227	$0
Cash payments	-252	-2,432	-1,562
Restructuring Reserve, Ending Balance		252	1,227
Accrued Liabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Ending Balance	1,941
Selling, General and Administrative Expenses [Member]
Restructuring Reserve [Roll Forward]
Costs incurred during the period	1,941	1,457	2,789
One-time Termination Benefits
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	0	1,227	0
Cash payments	0	-2,272	-1,562
Restructuring Reserve, Ending Balance		0	1,227
One-time Termination Benefits | Accrued Liabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Ending Balance	1,823
One-time Termination Benefits | Selling, General and Administrative Expenses [Member]
Restructuring Reserve [Roll Forward]
Costs incurred during the period	1,823	1,045	2,789
One-time Termination Benefits | Selling, General and Administrative Expenses [Member] | Scenario, Forecast [Member]
Restructuring Reserve [Roll Forward]
Costs incurred during the period				300
Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	252	0	0
Cash payments	-252	-160	0
Restructuring Reserve, Ending Balance		252	0
Facility Closing [Member] | Accrued Liabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Ending Balance	118
Facility Closing [Member] | Selling, General and Administrative Expenses [Member]
Restructuring Reserve [Roll Forward]
Costs incurred during the period	118	412	0
Facility Closing [Member] | Selling, General and Administrative Expenses [Member] | Scenario, Forecast [Member]
Restructuring Reserve [Roll Forward]
Costs incurred during the period				$100

Discontinued_Operations_Detail

Discontinued Operations (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]
Income (loss) from discontinued operations	$0	$0	$27,437,000
Women's Health Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales price of business sold			97,600,000
Inventory transferred to Meda upon close of the sale			2,600,000
Transactions costs incurred on sale			3,700,000
Women's health products purchased by Meda			6
Employee positions offered by acquirer			60
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]
Product sales, net			20,873,000
Loss from discontinued operations before income taxes			-5,787,000	[1]
Income tax expense			-2,020,000	[1]
Loss from discontinued operations, net of taxes			-7,807,000
Gain on sale of discontinued operations			35,244,000	[2]
Income (loss) from discontinued operations			$27,437,000
[1]	The income tax expense related to profits generated by the women’s health business in 2012 which were attributable to the United States.
[2]	The gain on sale of discontinued operations was not impacted by income taxes as the value attributable to the women’s health business was held in a non-taxable jurisdiction.

Employee_Benefit_Plans_Details

Employee Benefit Plans (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Defined Contribution Plan Disclosure [Line Items]
Expenses related to defined contribution plans	$2,000,000	$1,100,000	$300,000
Ireland [Member]
Defined Contribution Plan Disclosure [Line Items]
Expenses related to defined contribution plans	500,000	300,000	0
Defined contribution plans, employer matching percentage of employee's eligible contributions	8.00%
United States [Member]
Defined Contribution Plan Disclosure [Line Items]
Expenses related to defined contribution plans	1,000,000	400,000	0
United Kingdom [Member]
Defined Contribution Plan Disclosure [Line Items]
Expenses related to defined contribution plans	500,000	400,000	200,000
Defined contribution plans, employer matching percentage of employee's eligible contributions	12.00%
France [Member]
Defined Contribution Plan Disclosure [Line Items]
Accrued Retirement Liability	400,000	300,000	300,000
Italy [Member]
Defined Contribution Plan Disclosure [Line Items]
Accrued Retirement Liability	$400,000

Quarterly_Financial_Data_Unaud2

Quarterly Financial Data (Unaudited) (Schedule Of Interim Financial Information Presents Results Of Operations On Quarterly Basis) (Details) (USD $)	3 Months Ended																12 Months Ended
	Dec. 31, 2014		Sep. 30, 2014		Jun. 30, 2014		Mar. 31, 2014		Dec. 31, 2013		Sep. 30, 2013		Jun. 30, 2013		Mar. 31, 2013		Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Data [Line Items]
Revenues	$328,142,000		$306,584,000		$291,230,000		$246,919,000		$235,774,000		$232,160,000		$208,252,000		$196,237,000		$1,172,875,000	$872,423,000	$585,979,000
Gross margin	295,415,000	[1]	277,413,000	[1]	258,408,000	[1]	214,062,000	[1]	208,153,000	[1]	206,134,000	[1]	181,533,000	[1]	167,432,000	[1]
Net income (loss)	81,612,000		25,766,000		43,659,000		-92,650,000		55,293,000		75,409,000		42,185,000		43,425,000		58,387,000	216,312,000	288,586,000
Net income (in dollars per share), basic	$1.35		$0.43		$0.73		($1.58)		$0.96		$1.30		$0.72		$0.74		$0.98	$3.71	$5.09
Net income (in dollars per share), diluted	$1.30		$0.41		$0.70		($1.58)		$0.90		$1.23		$0.69		$0.71		$0.93	$3.51	$4.79
Amortization of intangible assets																	126,584,000	79,042,000	72,922,000
Acquired in-process research and development	600,000		75,000,000				127,000,000				1,000,000				4,000,000		202,626,000	4,988,000	0
Asset impairment charges	6,600,000				32,800,000												39,365,000
Fair value step-up adjustments, purchase accounting inventory					2,500,000		8,000,000		700,000		500,000		1,100,000		1,500,000
Transaction costs	5,200,000		700,000		4,400,000		17,100,000		4,400,000				400,000
Change in fair value of contingent consideration									2,300,000		5,000,000		3,400,000		4,500,000
Loss on extinguishment and modification of debt													3,700,000				0	3,749,000	0
Fair Value, Inputs, Level 3 [Member]
Quarterly Financial Data [Line Items]
Target sales																			124,500,000
Cash Distribution [Member] | Maximum [Member]
Quarterly Financial Data [Line Items]
Contingent consideration																			50,000,000
Gentium [Member]
Quarterly Financial Data [Line Items]
Revenues																	78,200,000
Revenue of acquiree since acquisition date	21,200,000		21,100,000		22,400,000		13,500,000
Transaction costs																	11,900,000
EUSA Pharma Acquisition [Member] | Cash Distribution [Member]
Quarterly Financial Data [Line Items]
Change in fair value of contingent consideration							50,000,000
Acquired Developed Technologies [Member]
Quarterly Financial Data [Line Items]
Amortization of intangible assets	$31,000,000		$29,600,000		$31,700,000		$30,300,000		$20,500,000		$19,500,000		$19,300,000		$19,500,000		$122,600,000	$78,800,000	$65,100,000
[1]	Gross margin excludes amortization of acquired developed technology of $30.3 million, $31.7 million, $29.6 million and $31.0 million in the first, second, third and fourth quarters of 2014, respectively, and $19.5 million, $19.3 million, $19.5 million and $20.5 million in the first, second, third and fourth quarters of 2013, respectively.

Valuation_and_Qualifying_Accou1

Valuation and Qualifying Accounts (Schedule of Valuation and Qualifying Accounts) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Allowance for Doubtful Accounts [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	$594	[1]	$715	[1]	$50	[1]
Additions charged to costs and expenses	0	[1]	-4	[1]	678	[1]
Other Additions	0	[1]	0	[1]	0	[1]
Deductions	-64	[1]	-117	[1]	-13	[1]
Balance at end of period	530	[1]	594	[1]	715	[1]
Allowance for Sales Discounts [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	378	[1]	528	[1]	296	[1]
Additions charged to costs and expenses	3,794	[1]	5,267	[1]	6,022	[1]
Other Additions	0	[1]	0	[1]	0	[1]
Deductions	-3,934	[1]	-5,417	[1]	-5,790	[1]
Balance at end of period	238	[1]	378	[1]	528	[1]
Allowance for Chargebacks [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	2,708	[1]	2,536	[1]	20	[1]
Additions charged to costs and expenses	28,614	[1]	21,047	[1]	13,072	[1]
Other Additions	0	[1]	0	[1]	0	[1]
Deductions	-28,607	[1]	-20,875	[1]	-10,556	[1]
Balance at end of period	2,715	[1]	2,708	[1]	2,536	[1]
Deferred Tax Asset Valuation Allowance [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	20,691	[2]	17,471	[2],[3],[4]	111,188	[3],[4]
Additions charged to costs and expenses	18,971	[2]	3,220	[2]	3,421	[3],[4]
Other Additions	0	[2]	0	[2]	62,971	[3],[4]
Deductions	-9,965	[2]	0	[2]	-160,109	[3],[4]
Balance at end of period	$29,697	[2]	$20,691	[2]	$17,471	[2],[3],[4]
[1]	Shown as a reduction of accounts receivable. Charges related to sales discounts and chargebacks are reflected as a reduction of revenue.
[2]	Additions to the deferred tax asset valuation allowance relate to movements on certain U.S. state and other foreign deferred tax assets where we continue to maintain a valuation allowance until sufficient positive evidence exists to support reversal.
[3]	Deductions to the deferred tax asset valuation allowance include movements relating to utilization of NOLs and tax credit carryforwards, release in valuation allowance and other movements including adjustments following finalization of tax returns.
[4]	Other additions to the deferred income tax asset valuation allowance resulted from the Azur Merger and the EUSA Acquisition.